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Abstract 
A new dry powder inhaler (DPI) for respiratory drug delivery was developed. This novel 
device is characterized by a micro-dose, passive delivery and multiple doses individually 
sealed in one replaceable disk. The micro-dose delivery system uses only a small amount of 
excipient, such as 2-3mg lactose, thereby improving the drug delivery efficiency. The passive 
delivery method eliminates the need for coordination between breath and device actuation 
such as the pressure metered dose inhaler (pMDI). Finally, 14 doses on a disk reduce the 
need to frequently change dosage disks. In addition, each dose is effectively protected by a 
blister package to minimize damage from moisture and oxygen. 
A comprehensive evaluation on key parameters, including dosage emittion, air flow 
resistance and fine particle fraction, has been conducted. The air resistance of our device is 
about 0.06 kPa0.5·min/liter, slightly higher than several marketed products but close to 
Inhalator®. The in vtiro performance results show that this new dry powder inhaler is able to 
achieve a high efficiency for drug delivery, with 10% of drug remaining in the device. This 
device can also effectively disperse drug particles to acquire a high fine particle fraction (FPF) 
as 50%. A primary stability research demonstrates that the FPF of a formulation containing 
5%-fine additive would stay at 40% when being accelerated for 3 months. Furthermore, 
comparative studies between this novel inhaler and typical marketed products –such as 
Diskus®, Turbuhaler® and Aerolizer®, show that when combined with suitable formulations, 
the FPF of our device could be about 25% as Diskus® and Aerolizer®, or above 40% as 
Turbuhaler® and Clickhaler®. When using the same powder, our device shows a FPF of 
50%, similar as Clickhaler® and Aerolizer® and higher than Twister®, indicating similar or 
better performance of our inhaler device to disperse drug particles.  
Because no existing powder filling system could satisfy the filling requirements of this new 
inhaler, a new powder dispensing and packaging system was developed. The new powder 
filling system designed and implemented in our lab was evaluated and optimized to improve 
the uniformity of filling weight and drug content among disks/blisters. The relative standard 
deviation (RSD) of filling weight among disks and blisters is 1~3% and 6~8% respectively. 
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The uniformity of drug content among disks, with a RSD from 2~5%, demonstrate the filling 
system could completely meet the requirements of the inhaler development.  
Suitable drug formulations for this new DPI were also developed, including research and 
optimization of powder composition and processing. The preparation of a uniform drug-
lactose blend was investigated, including the mixing method, mixing time & speed, and 
mixing sequence. The composition studies are conducted to better understand the effect of 
the drug particle and excipient on the drug delivery. Experiments show that the powder 
composition and processing have a significant influence on the in vitro performance, which 
can be controlled and adjusted to obtain the desired results. For example, when increasing the 
ratio of fine additive from 0% to 20%, the FPF is increased from 20% to 45%. Meanwhile, if 
the mixing time is extended from 2min to 10min, the FPF experiences a drop from 35% to 
22%. 
With the optimization of powder composition and processing, development of the powder 
filling system and implement of the new inhaler device, this novel inhaler can deliver 2-3mg 
powder per dose with an adjustable fine particle fraction from 25%-50%. 
Keywords 
Respiratory drug delivery, dry powder inhaler, active pharmaceutical ingredient, lactose, 
carrier, powder filling, powder formulation, in vitro evaluation, delivered drug content 
uniformity, fine particle fraction, laser diffraction size measurement, air flow resistance, 
blend content uniformity, powder mixing. 
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Chapter 1  
1 General Introduction 
1.1 Objectives 
Respiratory drug delivery is a novel and promising method to treat local and systemic 
disease, which has attracted increasing attention from pharmaceutical scientists and 
clinical experts. Among those inhalation drug delivery methods, the dry powder inhaler is 
particularly attractive. The dry powder inhaler is more and more welcome by patients and 
clinical experts as a result of its unique advantages. Nevertheless, the welcomed dry 
powder inhaler products on the market still have some inherent shortcomings from the 
perspectives of pharmaceutical scientists or patients. Consequently, a novel dry powder 
inhaler product is designed, manufactured and evaluated in this project. The 
corresponding powder filling & packaging system and formulation research are also 
established and carried out to demonstrate the performance of the inhaler and the 
feasibility of industrialization. 
The core targets of this work are listed as follows:  
To develop a novel dry powder inhaler device. It is characterized by a micro-dose, 
passive delivery, using an individual blister package and multi-unit doses on one 
replaceable disk. This device should realize the following targets: high efficiency of drug 
delivery, effective dispersion of particles, stable performance, convenient and easy to use, 
and feasible to industrialize. 
To develop a novel powder filling and packaging system. This system should realize 
the targets of metering and filling powder accurately, avoiding contamination, feasible to 
industrialize. 
To develop formulations with similar performance as marketed products. The 
influence of formulation process and composition on the inhaler performance should be 
studied. Furthermore, the influence of packaging and formulation on performance 
stability should be investigated. 
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1.2 Thesis Overview 
This thesis contains eight chapters and follows the “Monograph” format as outlined in the 
Thesis Regulation Guide by the School of Graduate and Postdoctoral Studies of The 
Western University. It is organized as follows:  
l Chapter 1 gives a brief introduction of the background of this research and 
demonstrates the need for this study. Research objectives and thesis structure as well 
as major contributions of the present work are stated. 
l Chapter 2 reviews the literature related to respiratory drug delivery, dry powder 
inhaler devices, and powder filling technologies for dry powder inhalers, powder 
formulation and in vitro evaluation of inhalers. 
l Chapter 3 summarizes materials and methods used in this research in four 
sections: the 1st section includes common chemical & physical analysis and special 
evaluation of inhaler performance; the 2nd section covers the powder filling and 
packaging system; the 3rd section focuses on the novel drug powder inhaler device, 
where both design and working principle of which are described in details; the 4th 
section includes the formulation work like composition and processing of the powder. 
l Chapter 4 provides the validation results of the analytical method, which 
indicates that the HPLC method for drug content analysis is accurate, durable and 
reproducible. Furthermore, in vitro evaluation methods of inhaler performance are 
validated. 
l Chapter 5 reports the evaluation results of common marketed dry powder 
inhalers, modification of the novel dry powder inhaler design and the corresponding 
improvement. The comparison of the novel inhaler and other commercial products is 
also presented, demonstrating that the novel inhaler has similar or better in vitro 
performance than others. 
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l Chapter 6 introduces the uniformity results of the powder filling system and its 
optimization, including uniformity of filling weight and drug content among disks 
and blisters. The results demonstrate that this novel filling and packaging system can 
meet uniformity requirements and is suitable for the novel inhaler device.  
l Chapter 7 describes the research on formulation composition, powder treatment, 
and their influence on inhaler performance. After a series of sing-factor experiment, 
a comprehensive orthogonal experiment was designed and carried out to study the 
influence of formulation factors and their corresponding significance. The stability of 
formulations is also investigated and presented. 
l Chapter 8 serves as a conclusion to the entire project. It also recommends future 
research focus and problems to resolve in the future.  
1.3 Major Contributions 
l A novel dry powder inhaler device is designed and implemented. Based on in vitro 
evaluation and improvement work, a better understanding of its critical parameters 
and working principles has been acquired. This not only lays a solid foundation for 
future commercialization, but is also helpful for the development of other dry powder 
inhaler products. 
l A novel powder filling and packaging system is designed and made in our lab and 
Shanghai Institute of Pharmaceutical Industry. A set of quality control criteria and 
methods are established to ensure inhaler performance. These criteria and test 
methods can also be used as important intermediate quality controls in large-scale 
production. 
l A comprehensive formulation work has been carried out to study the influence of 
lactose and drug powder, mixing process on the performance of this inhaler. The 
innovation of the formulation work is reflected by the small quantity of delivered 
dose. Specifically, the influence of formulation factors is studied on a scale of 2-3mg 
rather than 20-30mg commonly studied before. 
4 
 
Chapter 2  
2 Literature Review 
This chapter reviews the literatures related to the respiratory drug delivery, dry powder 
inhaler devices, powder filling technologies, powder formulation for dry powder inhaler 
and in vitro evaluation of inhalers. 
2.1 Respiratory Drug Delivery 
2.1.1 The advantages and application of respiratory drug delivery 
The advantage of respiratory drug delivery is determined by the unique physical 
characteristics of respiratory tract and lung: There are less digestive enzyme in the lung 
than in the digestive tract and the hydrolytic enzymes show less activities, both of which 
are helpful to enhance bioavailability of the Active Pharmaceutical Ingredient (API); 
Second, the respiratory tract and lung have a huge surface area where plenty of capillary 
vessels exist and carry huge blood flow. Additionally, alveolar epithelial cells are 
arranged by a monolayer structure which would greatly improve the rate and extent of the 
API absorption. Third, the API is absorbed into systemic circulation directly, avoiding  
the hepatic first-pass effect[1]. For respiratory disease, besides the advantages mentioned 
above, inhalation drug delivery could decrease the drug quantity by enhancing therapy 
efficiency, and decreases systemic side effect by direct action on target cells. As a result, 
the respiratory drug delivery has been widely used treat respiratory disease by topical 
therapy and other disease by systemic therapy.[2] 
Asthma and chronic obstructive pulmonary disease (COPD) are the most common 
respiratory diseases, and respiratory drug delivery is the first choice to treat both diseases. 
Asthma is a chronic airway inflammation characterized by reversible airflow limitation. 
Hence its therapeutic drug could be divided into two categories as anti-inflammatory and 
relieving symptoms. Glucocorticoids are the most effective anti-inflammatory drugs. 
When these APIs are administered by inhalation, the therapy amount and systemic side 
effect are decreased by direct action on the respiratory tract. Therefore, inhaled 
glucocorticoids are the first choice for treatment of persisting asthma. The contraction of 
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airway smooth muscle is the primary mechanism of reversible airway narrowing and β2 
agonists could prevent and reverse the contraction of airway smooth muscle to relieve 
symptoms. Consequently, the short-acting β2 agonists (SABA) are the first choice for 
relieving mild to moderate acute asthma, and long-acting β2 agonists (LABA) are able to 
maintain their bronchodilator effect more than 12 hours[3; 4]. COPD is a preventable and 
treatable disease characterized by airflow limitation. Inhaled β2 agonists and other 
bronchodilators are the primary choice to relieve the symptoms of COPD. Meanwhile, 
long-term and regular corticosteroids administration by inhalation could reduce the 
incidence of acute exacerbation of COPD, and improve life quality[5]. Inhalation therapy 
is the first recommendation to treat asthma and COPD according to Global Initiative for 
Asthma (GINA) and Global initiative for chronic Obstructive Lung Disease (GOLD). 
In addition to asthma and COPD, the respiratory drug delivery is also used to treat cystic 
fibrosis. The pathological features of cystic fibrosis include thick secretion, damaged 
mucociliary and lung infection. Hence, the main treatment is antibiotic therapy, plus 
bronchodilators and others to alleviate symptoms. Clinical trials demonstrated that 
inhaled tobramycin could greatly improve lung function, reduce hospitalization and 
intravenous antibiotic injection[6]. By inhalation of hypertonic saline, the hydration of 
surface liquid of the airway could be enhanced and the clearance of mucosal surface 
would be increased[7]. Because cystic fibrosis is a recessive genetic disease caused by 
mutations of cystic fibrosis transmembrane conductance regulator (CFTR), the 
pulmonary delivery of gene therapy has become a hot spot for cystic fibrosis treatment.[8; 
9]  
Other respiratory drug delivery for local treatment include: treatment of neonatal 
respiratory distress syndrome through inhalation of surfactant[10], avoid acute lung injury 
caused by hypoxemia through inhalation of prostaglandin E1. 
Due to development of modern life science and biotechnology, more and more protein, 
peptide drugs are widely used in clinical practices. Yet, the easily hydrolysis of protein 
and peptides would inactive these macromolecular drugs in the digestive tract. Their 
large molecular weight would limit their absorption rate and extent in the gastrointestinal 
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tract. Consequently, most protein, peptide drugs can only be administered by injection, 
which may cause compliance and convenience problems. Thanks to absorption 
enhancement, avoiding first-pass effect, bioavailability improvement of inhalation drug 
delivery, its application in systemic drug delivery, especially for protein and peptides is 
increasingly attracting attention.[11; 12] 
Insulin is able to lower blood sugar level, serving as an effective treatment for the type I 
and type II diabetes. Nevertheless, since insulin is easily digested in the digestive tract, it 
is usually administered by subcutaneous injection which would bring great inconvenience 
and pain to patients and result in compliance problems. Therefore, non-invasive 
administration of insulin, such as respiratory delivery and transdermal delivery has been a 
hot research field for many years. In 2006, Exubera® became the first FDA-approved 
inhaled insulin products, developed by Pfizer and Nektar jointly for treatment of type I 
and type II diabetes. Clinical trials showed that the glycemic control effect of the inhaled 
product was comparable to injection and superior to oral hypoglycemic drugs[13; 14]. Just a 
year later, Pfizer announced that no production and sales of the inhaled insulin any more 
for market and safety reasons. Hopefully, other companies are still developing inhaled 
insulin products, such as Mankind submitting its new drug application to the FDA in 
2009. In addition to insulin, other inhaled biological macromolecules like luteinizing 
hormone-releasing hormone, interferon A, growth hormone had already been in the 
clinical stages[15]. 
Respiratory drug delivery is also applied to vaccination. Firstly, immune cells of 
pulmonary, nasal and oral system account for about 80% of systemic immune cells. 
Secondly, plenty of macrophages and dendritic cells in respiratory tract could swallow, 
present antigen to stimulate T cell, induce mucosal and systemic immunity. Finally, the 
inhaled vaccine could greatly enhance the vaccination speed and reduce the need for 
health professionals, avoid cross-infection and blood borne diseases. Clinical trials have 
shown that children vaccinated against measles after inhalation can produce a good 
immune effect in Mexico.[16; 17] 
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Inhalation drug delivery has become the most popular research topics in the global drug 
R&D (Research and Development). About 25% of global formulation work is focused on 
inhalation drug, which is second only to oral preparation. 
2.1.2 Deposition of drug particles in respiratory tract 
There are three primary mechanisms for drug particle depositing on the respiratory tract 
and lung: inertial impaction, gravitational settling and Brownian diffusion, all of which 
are closely related to the particle size. When the particle is above a certain size, it is 
difficult to immediately change particle motion with airflow and particles would impact 
on airway wall. Consequently, the main deposition mechanism for those particles is 
inertial impaction mostly in the oropharynx, bronchus and conducting airways. The 
increasement of particles size and velocity would increase the possibility of inertial 
impaction. [18] 
The deposition manner for smaller particles is gravitational settling, which requires 
longer residence time of particles in airflow. At the first few levels of lung airways, the 
total cross-section area is small and result in higher flow rate resulting less residence time 
of particles. Consequently, gravity sedimentation mainly occurs in the small airways and 
alveolar. This phenomenon also has practical significance for clinical application. When 
using an inhaler product, enhancing the intake air amount (deep breathing) or holding the 
breath after administration would increase the particle residence time and deposition in 
the lung. When particles are smaller than a certain size, the Brownian diffusion would 
determine the particle precipitation. According to Task Model, when particles are above 
10µm, they would deposit on the oropharynx; for particles between 1~5µm, they 
would deposit in the bronchi, bronchioles and alveoli. If particles diameter is less 
than 1µm, they would mainly deposit in alveoli.[19] 
As mentioned above, drug particles of different sizes would deposit in different positions 
of the respiratory tract, which provides a basis for targeting delivery. Bronchodilators - 
β2 agonists are mainly used for relaxation of bronchial smooth muscle cells mainly 
distributing in the large bronchi and smaller bronchi; β2 receptors are mainly distributed 
in the smaller airways. Therefore, the ideal deposition site of β2 agonists is from 
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bronchial to bronchioles. The targets of anti-inflammatory drugs are eosinophils or 
glucocorticoid receptors, locating mainly in the large airway and alveolar wall 
respectively. For drugs with systemic effect, its ideal deposition targets should be alveoli, 
since the surface area of the alveoli is the largest, in addition to thinnest cell barrier and 
lowest mucosal clearance rate. [20-22] 
2.1.3  Common respiratory drug delivery methods 
The sufficiently small size (<5µm) is the key to respiratory drug delivery. Consequently, 
the dispersion of drug droplets or powder from bulk liquid or agglomerates is the core 
part for all respiratory drug delivery methods. Since the surface energy is increased 
significantly during the dispersion, additional energy should be provided in a short time. 
According to the energy source and devices, the respiratory drug delivery can be divided 
into nebulizer, pressure metered dose inhaler (pMDI) and dry powder inhaler (DPI). 
Nebulizers apply compressed air, ultrasonic or vibrating sieve to disperse solutions or 
suspensions into drug droplets of suitable size. The compressed air speed through the 
nozzle and disperse liquid into droplets by high shear and turbulence, and large droplets 
would impact on a baffle and return to a liquid reservoir[23]. Ultrasonic nebulizers utilize 
high-frequency vibration of a dielectric unit to atomize the drug solution, which exhibited 
better atomization efficiency than compressed air nebulizer but may lead to a 
degeneration of heat-sensitive protein and compound[24]. The vibrating-sieve nebulizer is 
a novel device which uses a sieve with a certain aperture to atomize the drug solution[25]. 
The advantages of the nebulizer are listed as follows: it could be applied for a wide range 
of drugs; solution, suspension or emulsion can be atomized; widely used in hospitals, for 
infants and other patients; compared to pMDI and DPI, patients might feel the 
administration skills easier. Nevertheless, there are some drawbacks: For the compressed 
air and ultrasonic atomizer, a large dead volume would remain in the reservoir chamber 
and the pipe, which may be more than 1ml; longer delivery time decrease patient 
compliance; devices are too large to carry; vibrating-sieve nebulizer overcome some of 
above shortcomings, but the price is expensive because of intricate structure. 
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Pressure Metered Dose Inhalers (pMDI) utilize a propellant with a low boiling point and 
high vapor pressure to provide droplet dispersion force. All pMDIs are comprised of two 
parts: device and formulation. The device is comprised of a quantitative valve, pressure 
containers and an actuator. The formulation includes propellant, latent solvents, drug and 
surfactant. Based on the dispersed state of drug in the solvent, it can be divided into 
solution and suspension pMDI. The propellant used to be chlorofluoroalkane (CFC) 
which has been replaced by hydrofluoroalkane (HFA) in past 20 years because of CFC’s 
destruction effects on the atmosphere ozone. 
The DPI will be reviewed in detail in the following sections. Hence, here is a summary 
table (Table 2.1) to compare the advantage and disadvantage of pMDI and DPI. 
Table 2.1: A comparison of pMDI and DPI 
 Advantages Disadvantages 
DPI 
Easy to use, convenient; 
Compact and portable; 
No need for “actuation and breath ” 
coordination; 
Chemically stable for powder state; 
Larger delivered dose; 
Environment friendly; 
Complicated use for single unit dose DPI; 
Higher price; 
Sensitive to moisture; 
Different usage of different devices; 
Depending on the inspiratory flow; 
pMDI 
Easy to use, convenient; 
Compact and portable; 
Lower price; 
Almost the same procedure for different 
products; 
Require the coordination of actuation and 
breath; 
Depending on using techniques; 
Delivered dose is limited; 
Influence on environment even if HFA is 
used;  
2.2 Devices for Dry Powder Inhalation 
Unlike oral preparation and injection, the performance of inhaler product is dependent on 
drug delivery device, which provide energy to overcome the interaction force between 
particles and make it possible that the fine particle would deposit in the lung. Since the 
DPI devices are usually used by patients themselves without a doctor’s guidance most of 
the time, the convenience plus excellent aerodynamic performance is important to DPI 
device design. 
 After decades of development on DPI device, there a
market. As Fig.2.1, these devices may be 
unit dose DPI and multiple dose DPI (also known as
dosing principles. Or, DPI devices may also be div
in terms of driving force to disperse 
Figure 2.1: Illustration of three kind
2.2.1 Single unit dose DPI
For a single unit dose DPI,
dispensing to patients. When patients use that kind of device, they must take
capsule or blister from package
for administration. Aerolizer
deliver fumarate formoterol 
a capsule is inserted into the bottom, patient
to drive needles to pierce the capsule
from the mouthpiece. The inspiratory flow would vibrate the capsule and bring the 
powder out into the patients
prevent large capsule fragment
re already lots of device
categorized as single unit dose DPI, multiple 
 reservoir DPI) according to their 
ided into the passive or active device 
the powder. 
s of dry powder inhaler devices
adapted from Daniher[26] 
 
 the drug powder is metered into a capsule or blister before 
s and insert it into the device, and then the 
® (Fig.2.2a) is a famous device marketed in U
(Foradil®, Novartis). Its working principle is 
s push the buttons on both sides of the device 
. Then the buttons are released, and 
’ respiratory tract. Meanwhile, a grid above the capsule could 
s and assist the deagglomeration of particles
10 
s on the 
 
,  
 out a 
device is ready 
SA market to 
like that: when 
patients inhale 
[27; 28].  
 Single unit dose DPI is the first DPI device on 
design and formulation, which is still used to 
2002, the Boehringer Ingehein introduced Handihaler
to treat COPD[29]. In 2011, 
which also use a single unit dose device
dose devices are often employed 
as a model to study computer fluid dy
Figure 2.2: Common dry powder inhaler product
Handihaler®; c, Diskhaler
However, the disadvantages
of the capsule-device is complicated and time
inserted into the device before 
[34]. Secondly, the capsule may become fragile
pieces during piercing which may be inhaled into 
uncomfortable. To overcome 
devices and multiple dose device
2.2.2 Multiple unit dose DPI
Diskhaler® (Fig.2.2c) is the first multiple unit dose device, marketed in
4-8 dose on one disk. The most commercial
Diskus® (Fig.2.2d), marketed by 
the market due to its simplicity both on 
develop new DPI products. For example, in 
® (Fig.2.2b) to deliver 
Novartis brings a new compound as Indacaterol
[30]. Due to their simple design, the single unit 
to study the hydrodynamic of device design
namics[28; 32; 33]. 
 
s on market. a, Aerolizer
®; d, Diskus®; e, Turbuhaler®; f, Clickhaler
 of the single unit dose device are also obvious. 
-consuming, because a capsule 
using and then discarded after administration
 under too dry environment[35]
the respiratory tract causing cough or 
the weakness of single unit dose device, multiple unit dose 
s are developed. 
 
 1988, which has
ly successful multiple unit dose 
GlaxoSmithKline in 1995 to deliver fluticasone and 
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salmeterol at the same time for asthma and COPD. There are up to 60 blisters on a long 
foil strip which curls tightly in the device, and each blister contains the active ingredient 
for one administration. When a patient use it, they only have to push a lever on one side 
of the device to open a blister and then push the lever back to make next blister ready for 
administration. What is better, a counter on the surface of the device would clearly show 
remaining doses, and remind patients to have a new one before it runs out.[34; 36] 
Because this kind of device could bring dozens of blisters, it is convenient for usage and 
carry, making it popular among patients[37]. Due to its individual package for each dosage, 
the powder could be protected rather well against moisture and oxygen[38]. Similar as 
single unit dose inhaler, the dose precision is better than multiple dose DPI, since the 
drug is pre-metered into individual packages in factories[39].Yet, the metering principle is 
similar as a single unit dose device, making it necessary to utilize lactose as carrier and 
result in API and carrier detachment problem. 
2.2.3 Multiple dose DPI 
Multiple dose device, also named as reservoir device, store the drug powder in a reservoir 
without pre-metering. When it is used, the device could meter a dose accurately and 
deliver it to patients. Turbuhaler® (Fig.2.2e) is the first device containing more than 100 
doses, as convenient as pMDI. By rotating the device bottom, powder flow into a series 
of very small holes on the metering disk from a reservoir. Simultaneously, a batch of 
scrapes ripe off excess powder. Since the dose quantity is determined by the volume of 
the holes on the metering disk, there is no need to employ lactose as carrier as long as the 
API particles show good flowability. Consequently, the Turbuhaler® could deliver pure 
API particles with or without carrier, which is a big step forward in the DPI 
development[40]. Clickhaler® (Fig.2.2f) is another example of reservoir device, which is 
believed as most similar device to the pMDI in terms of shape and operation method. By 
clicking the top button, the cone rotates to place a dimple filled with powder in 
respiratory airflow pathway[41].  
As a result of less or no carrier, the multiple dose device could achieve a very high drug 
delivery efficiency than Diskus® at the expense of lower delivery uniformity[42; 43]. Yet, 
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this kind device is more complicated than the other two kinds, and its moisture resistance 
and delivery uniformity are usually the primary concern for regulatory agencies[42]. For 
example, due to worries on delivered dose content uniformity, the FDA postponed the 
marketing of Turbuhaler® on the USA market. However, the variance of lung deposition 
is smaller than pMDI[44]. Long-term clinical trials showed that even under hot and humid 
environment, Turbuhaler® showed good clinical records in adult and child asthma 
therapy[45]. 
2.2.4 Active devices 
All devices mentioned above would be classified as passive device, which rely on patient 
inspiratory flow to dispense and detach powder. Dependence on users’ airflow is 
advantageous but also disadvantage of this kind of device at the same time, since persons 
with different airflow attributes may have different drug delivery results[46-48]. As a result, 
active devices independent of a patient’s airflow are developed, which are able to 
dispense powder by compressed air or vibration produced by the devices themselves. 
The most famous active DPI device is Exubera® from Nektar as Fig.2.3a, marketed by 
Pfizer as the first inhaled insulin product. It has a manual air pump which may produce a 
compressed air to dispense powder into a transparent chamber, and then patients may 
inhale drug powder from the chamber[49]. Although this device is withdrawn from the 
market only 1 year after its launch, it greatly expands the potential of the DPI on 
therapeutic range and device design. After withdraw of the Exubera®-inhaled insulin, 
there appeared some reluctance to consider the pulmonary delivery for systemically 
acting agents, as most companies gave up their insulin inhalation product. However, 
recent R&D and market activities suggest that inhalation for systemic delivery is 
recovering from the blow[50]. Microdose® device (Fig.2.3c) from Microdose Technology 
utilize vibration (piezoelectric) energy to disaggregate the particles and deliver them into 
the patient inspiratory flow[51]. Corcoran et al utilized this technology for atropine 
systemic delivery, which obtained rapid and consistent systemic concentrations of 
atropine[52]. 
 Figure 2.3: Active dry powder inhalers. a, Exubera®; 
2.3 Filling Device for 
A combination and interaction of formulation/inhaler device/powder filling will 
determine the final product performance,
the high efficiency of inhalation drug delivery and high potency of 
amount of API is usually on milligram or microgram scale. Meanwhile, to deliver drug
to bronchi, bronchioles or alveoli
1~5µm. When the particle size
a big challenge for precise filling by volume. 
tendency to form tight agglomerate
delivery. Although problems 
like lactose, the quantity of total 
system for dry powder inhaler is a critical part 
2.3.1 Powder filling by volume
2.3.1.1 Standard dosator technology
The principle of Standard dosa
measure and transfer a certain amount of powder.
dependant on the volume and compaction extent of powder (density).
that a quite large amount of 
 
b, principle of Micro
device; c, Microdose® device 
Dry Powder Inhaler  
 especially for dry powder inhaler
the API, the delivered 
, particle size of the API should be in the range of 
 is so small, the flowability decreases dramatically, 
Besides, the extra fine particle
s and prevent particles disaggregation
mentioned above may be solved partly by add
powder is still very small. Therefore, the powder filling
of whole product development.
 
 
tor technology is to utilize a hollow quantitative
 Accordingly, powder weight is 
 Its advantage lies in 
powder could be measured precisely, and the 
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. As a result of 
s 
making 
s show strong 
 during drug 
ing a carrier, 
 
  
 tube to 
amount can be 
 adjusted in a wide range. The 
dry powder inhaler. As shown in Fig.
piston in it. During the dosing process, the hollow tube is i
taken out with a certain powder in the tube, 
right above a capsule or reservoir
be used to prevent powder falling out
powder out and the filling is completed. 
height of the piston in the tube and diameter of the tube
powder density as a result of 
Consequently, the powder compaction extent
constant during filling process
powder bed height and tube st
be detached for clean, to avoid 
Figure 2.4: Schematic of working principle of
The common parameters for standard dosator technology
quantity is usually between 
2%. The production capacity may be 3000~200000 capsule
equipment size. This production capacity can
commercial production [54]. 
filling and closing machine (German, Harro Hofliger) and G
MG2). 
standard dosator technology is most widely used for filling 
2.4, the dosing part comprises a hollow tube with a 
nserted into powder bed and 
and then the tube is transferred to 
. During the transfer process, a negative pressure may 
. Following that, the piston in the tube push
The powder volume is determined by both the 
. The volume
powder compaction extent, determine the 
 is a critical parameter which 
. The unchanged compaction extent is achieved by keeping 
roke constant. After filling process, the entire system can 
contamination among different powder[53]. 
 
 the standard dosator technology
 are listed as follows
10 ~ 500 mg and relative standard deviation (RSD) is about 
s per hour dependant on the 
 meet requirement of clinical stage
Successful marketed equipments include Mod UC Capsule 
250 Capsule Filling (
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es 
 together with 
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The biggest disadvantage lies in that the lower limit is up to 10mg, implying that lactose 
must be added as a bulking agent for API to increase filling precision and repeatability. It 
is commonly believed that lactose would exert a negative influence on delivery efficiency. 
Besides, an ideal powder state should be free flow, non-agglomerate, but the compaction 
during the dosing may cause powder agglomeration. At last, most standard dosator units 
are too large to achieve modular operation, making it impossible to add temperature and 
humidity control unit[54].  
2.3.1.2 Vacuum drum filler 
The principle of the vacuum drum filler is to utilize a pocket on drum to measure powder. 
The most impressive advantage is the decreased requirement for powder flowability and 
much smaller metering quantity. For example, the typical vacuum drum filler as 
Omnidose® from Harro Hofliger is capable to meter and fill 1mg powder. When it is 
working, the drum sleeve is rotating under the powder bed and powder would enter the 
metering hole on the surface of the drum with the assistance of mechanical agitation and 
vacuum and excess powder would be wiped by a blade. When the metering pocket is 
rotated to an underneath position, a stream of compressed air come out from air channel 
instead of vacuum to push powder out (Fig.2.5a). Fadi et al[55] evaluated the performance 
of Omnidose® in tiny dose filling in DPIs by lactose, suggesting that this equipment 
could be used to meter 1~5mg powder.  
  
 Figure 2.5: Schematic of 
2.3.2 Powder filling by weight
The most advanced precise & micro metering system is 
Capsugle (Fig.2.5b). Its working principle is like
powder flow out from the hopper
stop the vibration by a feedback 
would form micro-bridges between holes on the tip of 
flow stop. The metering quantity is dependan
on the dispensing unit and shaking strength and time.
This system can dispense 0.1mg to several hundred milligram powder
RSD, which is applicable to all kinds of capsule
600 capsules per hour, suitable for stage
attribute is able to meter extremely
salbutamol, its RSD is about 2.6%. 
expensive drug and high potent compound
cohesive starch with 13 micron average volume median diameter (VMD) showed that the 
RSD is 2.2% when metering
for each capsule is 2 second[57]
the working principle of Vacuum drum 
 and Xcelodose 600[56] 
 
the Xcelodose 600
 a “pepper shaker”: vibration help 
, and a balance connected to a computer system would 
system. When the vibration is suspended, the powder 
dispensing unit, then the powder 
t on powder flowability, diameter of holes 
 
 with about 2% 
 (5#-000#). The production cap
 I and stage II clinical trial[56]. Its most attractive 
 tiny powder, for example when metering 1mg sulfate 
Consequently, it also can be used to meter very 
[54]. Additionally, the suitability test by using 
 0.5 mg per capsule and 900 capsules, and the metering time 
. 
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filler 
® from 
acity is 
 Another filling by weight technology is
company used this system to meter mixture of 
is between 5~25mg, the RSD
metering process is rather slow, for instance 50mg powder required 20
restrict its application in large
2.3.3 Other novel meteri
Chen et al. reported a vibrating capillary tube to meter powder. 
capillary was between 0.5~2mm
in it quantively with 0.1-10mg/s 
that the metered weight is 
powder flow by mechanical blocking or vacuum. Results showed that this system could 
meter 3mg powder as low limit with 2.5% RSD
Zhu et al utilized rotation fluidized bed to meter tiny and ex
Firstly, their patented technology 
the particle will be absorbed into metering holes by vacuum. This device could be used to 
dispense and meter particles under 3
with 2.9% and 3.3% RSD[61]
Figure 2.6: Schematic of 
 Quantos® system by Mettler Toledo
micronized API and lactose, when quantity 
 is less than 1% and 2.5% for 1~2.5mg.
-30 second, w
 scale[58]. 
ng device 
The diameter of 
, and lactose particle with 100~200µm VMD would flow 
flow rate. When online weight feedback system 
achieved, the feedback system would send signal
[59; 60]. 
tra-fine particle
achieved the uniform fluidization of particles, and then 
µm, and quantity could range from 25 to 2000
. 
the working principle of Rotation 
Fluidized bed for filling[62] 
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2.4 Formulation and Process for Dry Powder Inhaler 
2.4.1 Inter-particle forces in DPI formulation 
To better understand the composition and processing of DPI formulation, it is necessary 
to recognize the major inter-particle forces determining the formulation performance and 
stability. There are mainly four forces between particles. 
Van der Waal force is often ignored when we consider large particles. Nevertheless, 
when particles go down to several microns, the Van der Waal should not be neglected 
anymore as a result of large specific surface area and small distance between particles[63]. 
If the Van der Waal attraction forces are too strong to impair flowability and 
dispersibility, it is a wise choice to add large particles into extra-fine ones or make the 
surface of particle more corrugated since the Van der Waal force of attraction is inversely 
related to square of inter-particle distance. Then, the Van der Waal forces decrease 
dramatically and aerosol performance is improved [64; 65].  
Capillary force is very important when pharmaceutical scientists consider the stability of 
DPI formulation. When particles are on micron scale, the pores among particles make 
water vapor easier to condensate as a result of decreasing saturated vapor pressure. Then, 
the capillary force would play a dominant role in the adhesion between particles, and 
significantly reduce the disaggregation and dispersion of a dry powder formulation[66; 67]. 
Once a liquid bridge forms among particles as Fig.2.7, local dissolution and 
recrystallization of surface material would make a irreversible aggregation through solid 
bridge between particles, which definitely would decrease the powder dispersibility[68]. 
Consequently, it is very critical to control the humidity of production environment and 
moisture in the formulation.  
 Figure 2.7: Schematic of liquid bridge and mechanical interlocking
Electrostatic forces rise mainly from 
wall, during production and transportation
generate much electrostatic
uniform API-lactose blend. 
content uniformity of blend
that uncontrolled electrostatic charge
meanwhile elimination or minim
negative impact on powder blend uniformity
would decrease the electrostatic
moisture is above a certain value, 
would become dominate factor for 
Mechanical interlocking as Fig.2.7
particulate interaction and prevent particle dispersion
particle surface determined by the particle preparation method would influence the 
mechanical interlocking. For example, Raula et al 
L-Leucine to get powder with decreased surface roug
aerosol performance compared common micronized particle, as a result of decreasing 
mechanical interlocking[74]. 
impaction between particles, particles with container 
[69]. Especially, production process would 
 charge since a vigorous agitation is often used to obtain 
Electrostatic force not only has significant influence on drug 
[70; 71], but also on aerosol performance. Pu et al
 has an adverse effect on powder blend uniformity
ization of electrostatic charge also appears to have a 
. Increasing moisture to a critical 
 and hence improve aerosol performance
stability problems such as formation of 
aerosol performance [72; 73].  
 due to surface features or roughness would increase 
[68]. The smooth/rough
coated sulfate salbutamol particles by 
hness, which greatly improve 
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2.4.2 Carrier for DPI formulation 
DPI formulation is required to exhibit some flowability, which is critical to the 
production process, e.g. accurately dosing and delivered dose content uniformity 
(DDCU). Usually, drug particles are micronized by a jet-mill to several microns when 
high specific surface make particles tend to form agglomerates. Those tight agglomerates 
are difficult to meter accurately or dispense. The other larger sized particles used to 
separate those cohesive drug particles are applied into the formulation. Additionally, 
because of a high efficiency of inhalation drug delivery, the delivered dose is usually 
dozens to hundred micrograms, as shown in Table 2.2. This makes a big challenge for the 
pharmaceutical industry, since it is very difficult to meter such a small amount of particle 
with acceptable speed and accuracy. Consequently, a bulk excipient is required. A 
common solution is to blend the micronized particle with larger carriers to form 
interactive mixture. When a patient uses a DPI, the fine drug particles would detach from 
carriers and penetrate the deep airway. This method is still widely used for DPI 
development, although it may be somewhat unfavorable for efficient drug delivery. [75-79] 
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Table 2.2: Types of DPIs, formulation and dose system[80] 
GSK denote GlaxoSmithKline, fluticasone and mometasone contain acid group 
respectively. 
The most common carrier for DPI is α-lactose monohydrate for its established safety 
profile, stable physical and chemical property[81]. During the formulation R&D process, 
the size distribution and surface property of lactose , ratio between lactose and API are 
important parameters, exerting a great influence on the final product performance[82-84]. 
Alternative carriers like mannitol, glucose, sorbitol, maltitol and xylitol have been studied 
for their potential use in DPI formulation[85; 86]. 
DPI drug drug: 
lactose 
Total dose 
weight 
Dose 
system 
Spinhlaer(Aventis) 20mg sodium 
cromoglycate 
1:1 40mg Capsule 
Rotahahler(GSK) 200µg 
salbutamol 
1:125 25mg Capsule 
Inhalator(Boehringer-
Ingelheim) 
200µg fenoterol 1:24 5.0mg Capsule 
Diskhaler(GSK) 100µg 
fluticasone  
1:250 25mg Blister 
Diskus(GSK) 50µg salmeterol 
100-500µg 
fluticasone 
1:250 12.5mg Blister 
Turbuhaler® 
(Astrazeneca) 
200µg 
budesonide 
No lactose 200µg Reservoir 
Easyhaler(Orion) 100µg 
salbutamol 
1:99 10mg Reservoir 
Twisthaler(Schering-
Ploug) 
200µg 
mometasone  
1:5.8 1.36mg Reservoir 
Novolizer (ASTA 
Medica) 
200µg 
budesonide 
1:56.5 11.5mg Reservoir 
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To avoid the decline of delivery efficiency, sphere agglomerates formed by fine particles 
are fabricated purposely with or without carrier[87; 88]. Those sphere agglomerates exhibit 
good flowability as a result of larger size and regular shape. The stability against 
humidity and mechanical vibration is also improved, since those agglomerates would be 
treated under specific humidity condition[89; 90]. The most important thing for those 
agglomerates is to remain stable during storage and transportation, but easy to 
disaggregate during administration[91; 92].  
2.4.3 Additives  
Besides of carrier selection, the fine particles excipient which usually are also lactose 
with much smaller size, play a key role to enhance the delivery efficiency. One common 
theory suggests that there are some “high energy” or “active” sites on coarse carriers, 
especially for carriers with rough surface, and fine drug particles tend to adhere to those 
sites tightly[93]. Those active sites may locate at pores, cracks of carrier and may be 
caused by amorphous part or powder processing[94]. Then, when additive fine particles 
are introduced into a formulation as competitors for those active sites, it definitely would 
help drug particle to detach from carrier surface[95-97]. 
Magnesium stearate is widely studied to improve inhaler performance. Magnesium 
stearate could not merely increase powder flowability, but also serve to occupy active site 
on lactose as fine lactose and could stabilize the formulation[98-100]. Another additive, 
leucine could be used in powder processing, serving to decrease the density but enhance 
flowability and aerosol performance subsequently[74; 101].  
2.4.4 Powder preparation  
In the past, the extra-fine particles are mostly micronized by a jet mill. The particles were 
produced with sufficiently small size but irregular and fragmented pieces, as Fig.2.8a 
Recently, particle engineering like spray drying and super critical fluid (SCF) are used to 
produce particle with regular shape and favorable size distribution[102; 103]. The particles 
produced by spray drying are usually regularly hollow sphere as Fig.2.8b/c, which not 
only decrease particles interaction to exhibit better flowability but also decrease particle 
density to get smaller aerodynamic diameter even if geometric diameter is the same as 
 micronized flakes[104-106]. As is 
amorphous component which may 
problem. Fortunately, when the 
the glass transition temperature, 
under ambient temperature
marketed by Nektar (Fig.2.8d)
products, e.g. the first marketed inhaled insulin product
buffered sugar based matrix
fluorocarbon may be used to keep particles in
resulting in a better performance
Figure 2.8: Prepared particles. a, particles micronized by 
prepared by spray dr
2.5 In vitro Evaluation for Dry Powder Inhaler
The ultimate and perfect assessment of DPI would definitely be 
provide a definitive result of safety and efficacy, 
evidence to get regulatory approval
quite difficult to carry out a clinical trial for inhaler product
is challenging and results may be confusing 
Another point is that the clinical trial is so expensive that 
phase or routine quality control and quality analysis
known, the particles produced by spray drying
transform to crystal after some time, causing stability 
API is spray dried with carbohydrate, it would enhance 
indicating that spray-dried powder would remain stable 
. A famous example is the Pulmoshpere® 
. This technology has already been applied in 
 where the insulin is dispersed 
[107; 108]. In a spray drying process, a blowing agent like 
flated and creating pores in their structure
[109]. 
 
a jet mill; b,c 
y[110]; d, Pulmosphere® particles[111]
 
a clinical trial. 
and be employed as the most powerful 
. Unfortunately, unlike oral dose or injection, it is 
s, since the detection
due to different airway attribute
it is not suitable for early R&D 
[112].  
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 2.5.1  Inertial impaction method to characterize particle size
The primary deposition pattern of drug pa
which could be well reflected by an
not be too surprising that the impaction method 
evaluate inhaler products. A
major countries[113].  
The principle of the inertial impaction method 
with stronger inertial would impact the surface of collecting 
similarly as larger particles
particles with less inertial are ab
particles with different size
representing respirable part could be calculated to evaluate the delivery efficiency.
is worthy of attention, the diameter mentioned here is 
correlated with particles’ aerodynamic behavior. Aerodynamic diameter is defined as the 
diameter of a sphere with unit density, settling in 
delivered particles. [114] 
Figure 2.9: A schematic diagram
There are several equipment
Generation Impactor (NGI) 
rticle in human airway is an inertial impaction, 
 in vitro inertial impaction method. Hence
is considered as a “Gold standard
dditionally, this method is included in pharmacopoeias of 
is shown in Fig.2.9. The larger particles 
stage earlier
 impacting on primary bronchi. As a contrast, the smaller 
le to change their direction with airflow. Therefore
s could be divided into several sections and the section 
an aerodynamic diameter 
the air with the same velocity as the 
 
 of particle deposition in lung and
 cascade impactors[114] 
s for inertial impaction tests, like Twin impinger
and Anderson Cascade Impactor (ACI), and the former two 
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would be used frequently in this research. Although those equipment outlooks are 
different, the main information that we get from the experiment is the same, such as the 
percentage of drug particles under a certain diameter in total drug particles.  
As is known, the inertial impaction method is a preferable choice when compared with 
the clinical trial for inhaler product. Nevertheless, there are still lots of disadvantages for 
impaction test for in vitro evaluation. Firstly, impaction test is a labor-intensive work 
since analysts should collect and analyze the drug on each plate of the impactors. What is 
worse, because the quantity of drug collected on each stage is very tiny, high 
performance liquid chromatography (HPLC) is essential for inhaler analysis. When we 
consider a cascade impactor, the situation becomes even worse since there are about 10 
separate parts requiring rinse and analysis, like NGI or ACI. Therefore, the impaction test 
is a labor- and time-intensive work. As a solution to this challenge, in the early R&D 
phase, an impactor with fewer stages like TI are applied to do lots of screen work and 
then carry out NGI or ACI tests for final quality evaluation. Secondly, impaction tests 
neglect the size change during flight by only considering particles deposited on stages. 
Luckily, this drawback is more serious for pMDI rather than DPI.[115-117] At last, unlike 
many other analytical instruments, it is almost impossible to carry out routine calibrations 
in a pharmaceutical laboratory. As a result, it is hard to distinguish the error from 
operation or instrument, and it is difficult to train new comers[118-120].  
2.5.2 Other particle sizing technologies 
Thanks to technology progress, other particle sizing techniques have been increasingly 
used to characterize the aerosol emitted from inhalers. The most exciting one is laser 
diffraction method as Fig.2.10b, e.g. Sympatec Rodos® & Inhaler®. This technique 
utilizes a diffraction angle and shape produced when particles fly through a laser beam to 
calculate the particle size. A laser diffraction method could analyze lots of samples in a 
short time to accelerate inhalers R&D, and get a full profile of size distribution rather 
than particle size in a certain range. A laser diffraction method has been recommended by 
European pharmacopeia as a powerful supplement to test a nebulizer[121]. Yet, this 
method would not replace the impaction tests, since there are some inherent limitations 
for a laser method. Most important of all, the laser diffraction method could not 
 distinguish drug from excipient
pure drug particles. Another challenge i
calculation and transformation, particle properties
significantly affect the final 
diameter, which further decrease its p
Figure 2.10: Principle of Time of flight sizing
Another famous particles sizing
(Fig.2.10a), e.g. TSI technology,
adjacent laser beam and then trans
124]. Similarly, this method could 
Hence, to sum up, those laser sizing techniques may provide useful size information on 
particles, but could not provide critical data on drug
as a powerful supplement for impaction test rather than a substitution.
Other techniques, like microscope and 
frequently. Those image results 
particle interaction, like agglomeration and fine particle a
again, people could not tell drug particles from excipient
particles observed are in static state and only represent
 particles; hence it could not provide size 
s that laser diffraction result require
 like true density and shape factor 
results. At last, this technique could only get volumetric 
racticality[115]. 
[122] and laser diffraction
 method for inhalers is Time of Flight 
 which detect the time of a particle going through 2 
form the time value to a size by a calibration curve
not get information of the API size distribution either. 
 size distribution, so it may 
[125] 
scanning electron microscope, are also used 
could reflect the size and shape of steady particles, 
ttaching to large carrier. Once 
s according to images
 a portion of the whole formulation.
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2.5.3 Delivered dose content uniformity tests 
Besides the delivery efficiency, another remarkable parameter of the inhaler product is 
delivered dose content uniformity. A constant and stable dose emitted from the inhaler 
device is a prerequisite of delivery efficiency. Only when a uniform delivery is achieved, 
then we move forward to the respirable fraction of API particle. The inhaler R&D and 
clinical application allow some drug particles to remain in a blister or capsule after one 
administration (usually not more than 20%), but the emitted dose should be constant 
during the whole test and usage.  
For pre-metered inhaler devices, like single unit dose inhalers or multiple unit dose 
inhalers mentioned above, it is relatively simple to achieve the delivery uniformity, since 
an accurate amount of drugs has been filled into an independent unit package, e.g. a 
blister or capsule. As long as the powder in a unit package stays physically and 
chemically stable, the emitted dose would not change significantly. Meanwhile, for a 
multiple dose inhaler, like Turbuhaler® or Clickhaler®, the delivered dose content 
uniformity is greatly dependent on the powder metering and filling mechanism of the 
device, which could be influenced by lots of factors, like patients’ operation, the powder 
remaining in the reservoir and mechanics condition of devices. Another point is that, drug 
powder stored in a reservoir is more likely influenced by environment moisture than 
inhaler with independent package.  
Therefore, for a pre-metered inhaler device, sometimes regulatory agencies may be 
satisfied if a supplier proves that the drug content among capsules or blisters is uniform. 
Nevertheless, for a multiple dose inhaler, the manufacture first need to prove the emitted 
doses from the same batch or different batches are the same, implying a stable production 
process. Then, they are required to confirm that the emitted doses are uniform for a 
product through life, indicating the performance stability at the beginning, middle and 
end of usage. 
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Chapter 3  
3 Materials and Methods 
3.1 Brief Introduction  
This chapter describes all methods, devices and equipment used in this project, including 
analytical methods and equipments, the inhaler devices, a powder filling and packaging 
system and materials for formulation researches. Some important definitions and 
calculation methods are also introduced right after corresponding equipments. 
3.2 Analytical Method 
3.2.1 Physical property analysis 
3.2.1.1 Bulk and tapped density 
The bulk and tapped density was tested by FT-100A Powder Density Tester (Ningbo 
Haishu Instrument Ltd, China) as Fig.3.1b, which complied with USA/British/European 
pharmacopoeia. Because the quantity of powder sample was limited, 10ml cylinder was 
used. The tapping frequency was set to 100times/min, and the amplitude was 3mm. 
Firstly, m grams of powder was taken and poured into the cylinder freely and the volume 
of powder bed recorded as V0. Then the shaking strength was set. After 500 times of 
shaking, the powder volume V1 was recorded and compared with the value V2 of 1250 
times to ensure V1 equal to V2. 
Bulk density   
Tapped density    
Then compression index, e.g. Carr’s index was calculated. It could reflect powder 
flowability to some extent, since larger compression represented lower flowability and 
vice versa. 
Compression index  
0/VmB =r
1/VmT =r
TBTscarr rrr /)(' -=
 3.2.1.2 Angle of repose
The angle of repose was tested by 
suitable for a small amount 
repose tester. The angles of repose at four 
average value θ, representing 
Figure 3.1: Picture
In general, a smaller angle of repose indicates
Powders can be roughly categorized into the following 5 groups according to their angle 
of repose. 
 
 
equipment developed in our lab as Fig.3.1a, which was 
of powder. Its principle was the same as a common angle of 
directions were calculated and then get the 
the angle of repose for this powder.  
 
s of equipment for testing angle of repose (a) and 
powder density (b)  
 better flow property as listed
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 in Table 3.1. 
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Table 3.1: The relationship between Angle of reposes and flow properties 
Angle of repose Flow properties 
20°<θ<30° Very free-flowing 
30°<θ<38° Free-flowing 
38°<θ<45° Fair to passable flow 
45°<θ<55° Cohesive 
55°<θ<70° Very cohesive 
3.2.1.3 Solid state property 
To study the influence of jet mill on the solid state property of particles, 
Thermogravimetric Analysis (TGA, Netzsch tg 209 f1, German), Differential Scanning 
calorimeter (DSC, Netzsch dsc 204 f1, German) and X-Ray Polycrystaline 
Diffractometer (XRPD, D8 Advance, German) were used. TGA was a thermoanalytical 
technique by which a very small but accurate change of weight of samples was measured 
as a function of increasing temperature (with constant heating rate). Usually, TGA could 
effectively provide information on second-order phase transitions, including vaporization, 
sublimation, and absorption and desorption. During the development of DPI formulation, 
it was often applied to characterize moisture such as crystallization water and absorbed 
water[126]. During the DSC test, the difference of heat to increase the temperature of the 
sample and a reference was measured as a function of temperature. This technique could 
be applied to study polymorphs and content of amorphization during powder 
preparation[127; 128]. XRPD applied X-ray diffraction on powder or microcrystalline 
samples for structural characterization of materials. This technique could detect the 
change of polymorphs and content of amorphization during powder preparation[129; 130]. 
The TGA and DSC took about 2mg sample for each test, with the same temperature 
program from ambient to 300°C at 10K/10minutes rate, under N2 atmosphere protection. 
XRPD was carried out with a condition as: SCAN: 3.0/45.0046/0.01974/23.66 (Sec), Cu 
 (40kv, 40mA), I (max) =34988.
professional analytical center 
3.2.1.4 Scanning electron microscope
Scanning electron microscop
characterize the shape, surface, size 
of sample would be mounted rigidly on a 
specimens were coated first 
low-vacuum sputter coating.
Figure 3.2: 
3.2.1.5 Electrostatic charge 
As Fig.3.3, a combination of
unit (JCI-178, British) was used to measure 
package material. When the 
inner barrel and outside barrel would 
was used to calculate the quantity
The JCI-178 could detect the charge from
±10pC. Before a test, all cables were connected and JCI
sample was carefully transferred into 
caused by the transfer. The charge value was displayed on JCI
 Yet, those tests were not carried out by 
that provided a contracted research service. 
 
e (SEM, Hitachi S-2600, Japan, Fig.3.2) was applied to 
of particles and particle interaction. A small 
specimen stub. As a result of non
with an ultra-thin coating of electrically conducting 
 Then the pretreated sample would be analyzed by SEM.
 
A picture of SEM (Hitachi S-2600, Japan) 
test 
 Faraday peril (JCI-150, British) and a charge measurement 
the electrostatic charge of powder and 
charged powder was placed in the inner barrel, the surface of 
generate potential difference. Then, the difference 
 of charge. 
 0~±20nC and 0~±200nC with 
-178 was reset to 0.
the Faraday pail softly to avoid electrostatic 
-178 screen as Q
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us but by a 
amount 
-conductivity, 
gold by 
 
a resolution of 
 Then, m g 
charge 
. The most 
 important thing for this test was that all 
the JCI-178 should be grounded 
should be carried out in sta
but not repeatedly.  
The charge-to-mass ratio was calculated 
Figure 3.3: A picture of JCI
3.2.2 HPLC method for 
High-performance liquid chromatography
analytical equipment in pharmaceutical R&D
substance from others and accurately quantify its content even.
process, each analyte interact
hence the required elution 
same elution solvent-mobile phase. Its quanti
Beer law,  
When a beam of UV (Ultraviolet
absorbance (A) was proportional
length l and substance concentration
interference should be eliminated
well; tester wear anti-static clothing and gloves, and t
ble environment. All samples were tested 3 times in parallel 
as . 
 
-150 and JCI-178 (Chilworth Technology Ltd, 
content analysis 
 (HPLC) method was the most common 
. This method could effectively isolate a 
 During 
ed differently with the adsorbent material of the solid 
time for each substance might be different when using the 
tative principle was based on 
 
) light passed through the sample solution, 
 to absorption coefficient K of the substance
 C. The former two parameters were constant for the 
mQme // =
clKA ··=
33 
. For example, 
ests 
UK) 
an analytical 
phase; 
the Lambert–
the 
, light path 
 same substance and the instrument;
absorbance A by a calibration curve.
method had to be validated 
durability. 
The HPLC condition was listed 
Separation module-e2695 (Waters, USA)
UV detector 2487 (Waters, USA)
Solid phase: SUPELCO C18 15cm*4.6mm
Mobile phase: 0.08mol/L NaH
Detection wavelength: 276nm
Column temperature: 25°C; 
 Injection volume: 100µl; 
Flow rate: 1ml/min. 
Figure 3.4: A picture of HPLC e2695 and 2487
During a HPLC analysis, 
analyzed first for the peak area
like this: 
 hence the concentration c could be calculated
 Therefore, as a foundational work, the HPLC 
first for linearity, accuracy, precision, s
as follows: 
 as Fig.3.4; 
; 
，5um (Sigma-Aldrich, USA); 
2PO4*2H2O (pH3.11): methanol (HPLC grade)
; 
 
 (Waters, USA
reference samples with known concentration
 (A0), and then a Calibration Factors (CF) 
CF=A0/C0 
34 
 from 
pecificity and 
 = 85:15; 
) 
 (C0) were 
was calculated 
 Usually, 2 reference samples were injected twice and 4 CF would be obtained
content assay. It was required 
was less than 2% to make sure the HPLC system was stable.
When the peak area (A1) of 
quantity (m1) could be calculated, where V
3.2.3 In vitro method for p
3.2.3.1 Inertial impaction tests
Glass twin impinger (TI, also named
equipment for inhalers, especially
could be divided into three parts: throat (induction part), stage1 and stage2. 
Figure 3.5: A schematic diagram
The operations could refer 
2010. 1) 7ml receiving solvent 
vacuum, adjust flow rate to 60L/min and 
that the relative standard deviation (RSD) of 4 CF values
 
another sample was acquired, the concentration
1 stood for dilution volume. 
 
 
article Size characterization 
 
 as TSI) was a simple and convenient
 suitable for early R&D work. As Fig.3.
 and a picture of twin impinger (Copley
to European Pharmacopoeia 7.0 and China Pharmacopoeia 
was added into stage1 and 30ml to stage2.
turn off the solenoid valve. 3) Insert
11 * ACFC =
111 *VCm =
35 
 for each 
 
 (C1) and 
 impaction 
5, this device 
 
 
, UK) 
 2) turn on the 
 a inhaler 
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into the throat with a suitable adapter; 4) Release a dose and turn on the solenoid valve 
which would turn off automatically when a set time was over; 5) Repeat above 
procedures for required doses, 6) Turn off the vacuum, and use a receiving solvent to 
rinse each part to a set volume; 7) Analyze the drug content by the HPLC. It was 
noteworthy that the same sampling operation was applied in all in-vitro evaluation as 
following: the inhaler was actuated first according to its instruction, with the vacuum 
pump running and the solenoid valve closed; the powder is discharged into the sampling 
apparatus with the airflow, by activating the timer controlling the solenoid valve. 
There are several important definitions which have to be described clearly. The Total 
Recovery Mass (TRM) indicates all drugs recovered from inhaler device, throat, stage1 
and stage2. The Total Recovery Rate (TRR) is used to evaluate the recovery rate of 
impaction test, and usually the higher TRR represent a better operation. The Emitted 
Dose (ED) means that all drugs delivered out from the mouthpiece of the inhaler, 
including drug in adapter/throat, stage1 and stage2. By comparing TRM and ED, it could 
be calculated that how much drug is left in the inhaler device. The Fine Particle Dose 
(FPD) here refers to drug deposited in stage2 with aerodynamic diameter under 6.5µm. 
This FPD is proportional to the respirable dose. The Fine Particle Fraction (FPF) 
usually is defined as the ratio of FPD to ED. Similarly, the deposition fraction of each 
part could be calculated. The Blister remains indicates the fraction of powder remains in 
the blister after a test, which somewhat reflects the delivery efficiency.  
 
  
 
 
 
Fraction of blister remains=mblister remains/ (mblister remain+ED) 
21 stagestagethroatdevice mmmmTRM +++=
Labeldose
TRMTRR =
21 stagestagethroat mmmED ++=
2stagemFPD =
EDFPDFPF /=
 The twin impinger is useful to get 
two parts: the larger one (>
information on particle size distribution. Hence, the N
applied, as Fig.3.6. 
Figure 3.6: A picture of Next Generation Impac
and a schematic diagram of NGI connected with a flow controller and pump.
The NGI is mainly comprised of three parts: 
seal body holds the jets, and 
structure is shown in Fig.3.7
particles within a certain size range would 
particles would fly into the next stage
in collection stages, those particles a
collecting process. These collection stages
As a result of replaceable design, 
Meanwhile, as all collection
automatic rinse and sampling beco
Unlike NGI used for pMDI, 
stages for testing a DPI. Since
overload on collection stages
reentrainment into the airflow
a rough deposition profile by dividing particles into 
6.5µm) and smaller one. But it could not provide more 
ext Generation Impactor (NGI) i
 
tor with pre-separator
a bottom frame holds the impaction
a lid that contains the inter-stage passage
. Particles are blown out from jet nozzles with airflow, then 
deposit in corresponding stage
 as a result of smaller inertia. Since particles deposit
re difficult to fly away during the rinse and 
 could be moved and replaced as a whole set
the efficiency of instrument is significantly enhanced. 
 stages are placed on the same level without interference, 
me possible. 
an additional pre-separator is assembled before collection
 lots of carriers in a DPI formulation could resu
, a pre-separator is essential to avoid particles bounce or 
.  
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s 
 (Copley, UK) 
 
 stages, a 
. The inner 
s and smaller 
 
. 
an 
 
lt in 
 Figure 3.7: A picture of internal
The operations was described 
on vacuum and set flow rate
Connect a inhaler to induction port and release a dose, turn on solenoid valve to start flow 
for a set time; 3) Repeat above operation
Rinse each part including in
orifice collector (MOC) by suitable solvent
Similar as Twin Impinger, the 
Total Recovery Mass (TRM), 
particle dose (FPD), Fine particle Fraction (FPF) and Mass Fraction of 
= mTRM
ED
 
 structure of Next Generation Impactor 
separator (Copley, UK) 
as follows: 1) Assemble the equipment as instruction, turn 
 to a designated value and turn off the solenoid valve
s for designated doses and turn off vacuum; 
duction port, pre-separator, stage 1-7 and the last micro
; 5) Determine the drug content in each part.
in vitro deposition could be analyzed by following values: 
Total Recovery Rate (TRR), Emitted Dose (ED), 
 
 
å
=
- +++
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i
isepprectionindudevice stagemm
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Labeldose
TRMTRR =
å
=
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i
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and the pre-
; 2) 
4) 
-
 
Fine 
stage-i (MFi).  
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A major difference of calculation between TI and NGI is that the FPD would change with 
flow rate for NGI, since the cutoff diameter D50 of each cup would alter with flow rate. 
The cutoff diameter at Q flow rate D50, Q is calculated like following according to U.S 
pharmacopoeia 32: 
 
Table 3.2: Cutoff aerodynamic diameter for stages of NGI (US Pharmacopoeia 32) 
To calculate D50, Q for flow rate at Q within 30-100LPM 
Stage D50,60LPM(µm) χ 
1 8.06 0.54 
2 4.46 0.52 
3 2.82 0.50 
4 1.66 0.47 
5 0.94 0.53 
6 0.55 0.60 
7 0.34 0.67 
When flow rate is 60LPM, then the cutoff diameter of stage2 is 4.46µm. It means that 
stage2 would capture particles within 4.46~8.06µm and all particles above 4.46µm are 
captured before stage3. Consequently, the FPD (<4.46µm) under 60LPM is calculated 
like: 
 
 
TRMmMF ii /=
c)/60(*60,50,50 QDD LPMQ =
å
=
=<
moc
i
istageLPMmFPD
3
)60,46.4( m
EDstageLPMmFPF
moc
i
i /)60,46.4(
3
å
=
=< m
 3.2.3.2  Laser diffraction size test
Laser diffraction was utilized
laser diffraction sizing was employed
direct measurement of inhaler performance. Sympatec Helos
(Fig.3.8b) were combined to test dry powder samples. Helos
could measure particles within different size range
automatic lens changing system.
from 0.25µm to 87.5µm, 0.5
to measure fine particles, like API or fine additives
carrier. A Rodos® dispersion system
disperse particles by impaction and friction of 
claimed by the manufacturer 
as 0.1µm. 
Figure 3.8: Pictures of Sympatec Helos (a) and Rodos (b)
The operation parameter: 
Assume all particles were sphere and density
Quantity of sample: ~20mg;
Lens: R2 or R4; 
Trigger and termination condition: start when C.opt
0.5%); stop 4s after C.opt<=0.1% or 4s real time. 
Dispersion condition: 3~4bar
s 
 to characterize the particle size of carriers and 
 as a useful tool for formulation work but not 
® (Fig.3.8a)
® is a laser optical s
s by corresponding 
 The R2 and R4 lens were used to characterize
µm to 350µm respectively. Specifically, the R2 lens was used 
. And R4 was used to test lactose 
 with the Vibri feeding system was
particles in high speed airflow
that this system could effectively disperse particles as small 
 
 (Sympatec
 as unit; 
 
>=0.5% (optical concentration above 
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the API. The 
a 
 and Rodos® 
ystem. It 
lens with an 
 particle 
 employed to 
. It was 
, German) 
 Usually, three points on the 
and X90. For example, X10 represented a diameter that 10% of part
accumulation were smaller than it.
Figure 3.9: Pictures of Sympatec Helos and Rodos 
3.3 Dry Powder Inhaler Device
3.3.1 Evaluation of m
Several typical marketed dry powder inhale
comparison with the novel DPI device designed by us
uniformity was a major concern for 
Clickhaler® Asmasal®. Thereby
described later was carried out for these two inhalers
all devices was acquired. This resistance 
device, which would directly influence the feeling and effect when patients use it.
 
size distribution profile were taken for analysis: X10, X50 
icles by volume 
 
 
combination (Sympatec
 
arketed dry powder inhalers  
rs as Table.3.3 were evaluated, serving as 
. It was noteworthy that
reservoir-type device, e.g. Turbuhaler®
, a test of delivered dose content uniformity (DDCU) 
. Besides, the airflow resistance 
was an important parameter of 
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, German) 
a 
 dose 
 Oxis® and 
of 
the inhaler 
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Table 3.3: Evaluation items of typical marketed products  
Brand name API Test Items Types of 
device 
Aerolizer® 
Foradil® 
Fumarate formoterol 
12µg/dose TI 
NGI 
Air resistance 
Laser diffraction sizing 
Capsule 
Diskus® 
Seretide® 
Salmeterol&Fluticasone 
propionate 
50µg&250µg/dose 
Multiple 
blister 
Turbuhaler® 
Oxis® 
Fumarate formoterol 
6µg/dose 
TI 
NGI 
Air resistance 
DDCU 
Laser diffraction sizing 
Reservoir 
Clickhaler® 
Asmasal® 
Sulfate Salbutamol 
95µg/dose 
TI 
ACI 
Air resistance 
DDCU 
Reservoir 
The operation parameters for TI and NGI are summarized as Table 3.4. Both TI and NGI 
were carried out under the same flow rate of 60 LPM and same flow time of 4 seconds. 
A certain volume of rinsing solvent was added to each stage of cascade impactor, and the 
drug content was analyzed by HPLC.  
Table 3.4: Critical impaction test parameter for the marketed products 
Brand name Delivered dose for TI  Delivered dose for NGI Rinsing solvent 
Aerolizer® Foradil® 2 capsules 2 capsules Methanol:water=1:1 
Diskus® Seretide® 5 blisters 10 blisters Methanol:water=7:3 
Turbuhaler® Oxis® 10 doses 20 doses Methanol:water=1:1 
Clickhaler® Asmasal® 5 doses 10 doses for ACI Water 
Primary parameters of HPLC methods for above 4 products are listed as Table.3.5. The 
Foradil® and Oxis® had the same condition as a result of the same API—formoterol. 
The detection method was relatively complicated for Seretide® because of a combination 
of two APIs. The salmeterol was detected by fluorescence with an excitation wavelength 
of 225nm and emission wavelength at 305nm. 
 Table 3.5: Primary param
Brand 
name 
Mobile phase
Foradil® Acetonitrile-
PBS(3.10)=25:75
Seretide
® 
methanol-
Acetonitrile-
water=30:30:40
Oxis® 
Acetonitrile-
PBS(3.10)=25:75
Asmasal
® 
methanol-PBS 
3.10）=15:85 
Delivered dose content uniformity and 
Dose Uniformity Sampling A
Figure 3.10: A schema
apparatus connected with a flow controller and pump
DDCU test was carried out like that: 
4s; 2) Insert an inhaler into DUSA tube
which would turn off automatically; 
analyze the drug content. S
better to use the ratio of deliver
ratio could be calculated to evaluate the uniformity.
eters of HPLC methods for marketed products
 Column Detection 
wavelength 
 
ultimate XB-C18 
4.6*250mm 5µm 
UV 214 
 
Kromail C18 
150*4.6mm.5µm 
Fluorescence
225nm&305nm
UV 239 
 
Ultimate XB-C18 
4.6*250mm 5µm UV 214 
(pH 
Waters X-Bridge 
C18, 
150*4.6 mm，5µm 
UV276 
inhaler device air resistance evaluation 
pparatus (DUSA) shown as Fig.3.10.  
tic diagram and picture of Dose uniformity sampling 
(Copley
1) Adjust the flow rate to 60LPM and set the time to 
 and release a dose, then turn on solenoid valve 
3) Turn off vacuum pump, rinse DUSA tube and 
ince different inhalers had different amount of API, it was 
ed dose to the labeled dose. Then the RSD of 10 delivered 
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Injection 
100µl 
 
 100µl 
100µl 
50µl 
utilized the 
 
, UK) 
 Delievered Ratio=Delivered dose/Labled dose*100%
The test for air resistance was slightly 
value (20, 40, 60, 80 LPM); 
of releasing doses; 3) Record the pressure drop through the device, reflected by P1 value
4) Establish a linear regression of t
stood for device resistance. 
3.3.2 Design of a novel dry powder inhaler d
A novel dry powder inhaler device w
following characteristics: 1) 
delivery mode, no need for 
for 1~5mg powder; 4) blister package, precise dos
this device has been developed 
Inhaler-WU2011 for short. Its 
acupuncture pieces the drug package.
the inspiratory flow would
Simultaneously, the aerosols are
Figure 3.11: A schematic diagram of 
The appearance is shown in 
an inner functional part. Since the mouthpiece i
 
different: 1) Adjust the flow rate
2) Insert an inhaler into the DUSA tube, make it in the status 
he square root of P1 on the flow rat
 
evice 
as developed in our group. This device has
multiple unit doses, it can be used repeatedly; 
an operation-inhalation coordination; 3) micro
ing and better moisture proof.
by Western University from 2011, it 
basic principle is shown in Fig.3.1
 Then a patient inhales from the mouthpiece
 fluidize and entrain powder to form gas-
 delivered to patients’ lung with the inspiratory airflow
 
Inhaler-WU2011 working principle
Fig.3.12a, b. The inhaler is comprised of an 
s placed in the mouth when 
44 
 to a series of 
; 
e, where slope 
 
2) Passive 
-dose, suitable 
 Because 
was named as 
1: A hollow 
, and 
solid aerosols. 
. 
 
outer shell and 
a patient 
 using this device, a shell is necessary 
also provide protection against misuse, 
The basic dimensions are shown in Fig.
rather compact and portable.
Figure 3.12: Appearance and primary dimension
The functional parts of Inhaler
push button, puncture and mouthpiece are
Fig.3.13a. The center of the cover and central axi
hollowed out, where the push button and
only move up and down vertically without 
vertical motion ensures that the puncture pierce
accurately time by time. As shown in Fig.
for both children and adults. 
and lower cover, which can 
Fig.3.14 displays the inner structure of the inhaler 
blisters is placed on a circular tray with suitable pockets. 
to keep the mouthpiece clean. Besides, the shell can
e.g. pushing down the push button by accident. 
3.12c&d. The dimensions show that this device i
 
 of the novel inhaler
-WU2011 include an upper cover and lower cover. 
 integrated on the upper cover, as shown in 
s connected with mouthpiece are
 puncture could be placed. The puncture can
horizontal movement in a hole.
s the blister package 
3.13b, the mouthpiece is rather small, suitable 
Two hasps on the upper cover are used to assemble
be opened when replacing a drug disk.  
device; a drug disk containing 14 
The circular tray i
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s 
 
 
The 
 
 
 Hence, the 
in the center 
 upper 
s bound with a 
 ratchet underneath, which is
when moving the trigger clockwise, 
drug disk rotate for next blister.
ratchet would remain still as a result of 
Figure 3.13: A schematic diagram of Inhaler
 driven by a trigger unidirectionally. As shown in F
the ratchet rotates and makes the circular tray and 
 Meanwhile, when moving the trigger anti-
braking effect by the locator. 
-WU2011 upper and lower covers
upper cover; c&d, lower cover. 
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ig.3.14c, 
clockwise, the 
 
. a&b, 
 Figure 3.14: A schematic diagram of Inhal
b, disk tray; c, combination of 
As shown in Fig.3.15a&b, a sharp formed by two 
hollow puncture. When the punc
blister with a tearing effect. 
result of a spring, and brought the puncture to its original position. S
carved on the bottom surface of the puncture,
through the notches into a blister
effect. 
The air pathway is placed 
comprised of two parts, one 
the mouthpiece.  
er-WU2011 inner structure.
the ratchet, trigger and lower cover; 
d, dimensions of a blister. 
wedges is located at the 
ture moves downward, the sharp pierces the package of a 
After delivering a dose, the push button would go back as a 
ome notch
 which are designed to introduce airflow 
 and produce a better fluidization and 
inside the upper part of the puncture. This 
connected with push button and the other one c
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 a, drug disk; 
 
bottom of the 
es are 
entertainment 
air passage is 
onnected with 
 Figure 3.15: A schematic diagram of Inhaler
puncture; b, the shape of the p
combination of puncture, push button and upper cover
Table 3.6: The material for primary parts of the inhaler
Part 
Outside shell
Upper and lower cover
Mouthpiece
Ratchet
Puncture
Drug disk tray
Trigger
Push button
Locator
The operation of this new inhaler 
2) Push down the button and the puncture would pierce top sur
-WU2011.  a, cross-section diagram of 
uncture; c, puncture combined with push button; d, 
 
-WU2011
Material 
 Styrene acrylonirile copolymer (AS)
 AS 
 Polypropylene (PP) 
 Polyoxymethylene (POM) 
 Steel, SUS304 
 AS 
 Steel, SUS304 
 Steel, SUS304 
 Steel, SUS304 
device is described as follows: 1) Open the upper shell
face of a blister;
48 
 
 
 
; 
 3) Keep 
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the pressed status and put the mouthpiece into mouth and wrap it tightly, then take a deep 
breath and the inspiratory flow would fluidize particles and take them through the air 
passage and mouthpiece into the lung; 4) When an administration finished, release the 
button, then push button and puncture go back to the original position; 5) Move the 
trigger clockwise once, driving the ratchet and circular-tray rotate for next blister. 6) 
When a disk is finished, the device could be opened by unlocking the hasps and a new 
drug disk could be placed into the circular tray. Therefore this device can be used 
repeatedly.  
3.4 Dry Powder Inhaler Filing Device 
3.4.1 Design and implement of packaging system 
As mentioned before, the powder formulation, inhaler device and filling & package 
equipment constitute a whole system. Based on this principle, a small blister and 
puncture structure (dimension shown in Fig.3.14&3.15), plus a small amount of powder, 
determine that the filling technique has to meter and dispense several micrograms powder. 
Yet, there is no powder filling device on the market, which is able to dispense a small 
amount of powder into 14 blisters in one disk simultaneously. Consequently, a whole 
system including blister package formation, powder filling, hot sealing and final 
punching was established. 
 
Figure 3.16: A flow chart of filling and packaging. 
Polyvinyl chloride (PVC) is commonly used for drug package. During production of drug 
disks, the PVC is pre-heated (>150°C) to become soft first, then placed into a special 
designed mold where pressure air (0.56~0.74Mpa) blow against the soft PVC material to 
form desired blisters. After filling powder into blisters, the drug disk is sealed with 
aluminum foil by hot pressing. Following that, the sealed disk is punched to cut off 
 excessive PVC and foil. If this disk i
is used to wrap the disk for better anti
Figure 3.17:
Figure 3.18: The pictures of equipment for disk formation (a),
hot
s used for a stability test, one additional
-moisture. 
 The whole process of drug disk production 
 powder filling (b), 
-pressing sealing (c), punching (d). 
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 foil package 
 
 
 3.4.2 Design and implement of Powder Filling system
As shown in Fig.3.19, the principle of filling device i
quantitation. With or without assistance of vacuum, 
pockets as a result of mechanical stirring and form a loose powder 
metering plate is moved to the
blisters, the plate is vibrated to make 
of powder in each blister is determined by 
density. This filling device can
pockets in the plate.  
Figure 3.19: A schematic diagram of 
The device design is shown in Fig.
tube can be connected with vacuum. A 
slides in designated grooves. When it 
with powder in the powder chamber
metering pockets are vertically above empty blisters
falls out of the pockets into blisters. During the plate sliding process, 
the chamber wipes powder on the surface of the plate
ends of the metering plate help the metering pockets locate accurately.
 
s rather simple, using
the powder enters
“cake
 right position where the pockets were vertically above th
powder in the pockets fall into blister
the volume of a metering pocket and powder 
 fill 14 blisters simultaneously as there ar
the filling device working principle.
3.20. A motor provides the mechanical
steel plate with 14 metering pockets at its left end 
slides to the right end, metering pockets are
. When the metering plate slides to
. After mechanical vibration, powder 
a polymer blade in 
. Two steel bars (Fig.3
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 volumetric 
 into metering 
”. When the 
e 
s. The quantity 
e 14 metering 
 
 
 stirring and a 
 filled 
 the left end, 
.21) on both 
 Figure 3.20
Figure 3.21:
: A schematic diagram of filling device 
 A schematic diagram of the metering plate 
52 
 
 
53 
 
3.4.3 Evaluation of powder filling uniformity 
When the packaging and filling system is established, its function is validated first, 
especially for powder filling system. The validation work is focused on powder filling 
uniformity, which is a prerequisite for the following DPI inhaler evaluation and 
formulation work. 4 kinds of powder containing 0%, 5%, 10%, 20% fine additives 
(detailed information is presented in Section 7.4.2) are used in following experiments.  
To evaluate the uniformity, including filling weight per disk/blister, drug content per 
disk/blister, drug content of blend, delivered drug content, the RSD is usually employed 
to measure the uniformity. RSD can reflect the level of variance even for different 
average values. Generally, the SD is applied to make sure the inhaler performance is 
similar or not, such as FPF or blister remains.  
3.4.3.1 Filling weight uniformity among different disks 
Considering the weight of all powder from 14 blisters in a disk as a whole, the weight 
uniformity at the beginning, middle and end of the filling process was analyzed to 
evaluate the filling stability. After powder filling, a drug disk was sealed with aluminum 
foil and then weighed by a balance (AB135-S, Mettler Toledo, Swiss) to get Md, 0. Then 
each blister on this disk was opened carefully without foil loss, and all powder was 
cleaned away completely, then the weight Md,1 of the empty disk was obtained. The 
filling weight M for one disk was calculated as this, where x represented Disk-x and d for 
disk.  
 
The uniformity of filling weight among disks was evaluated by RSD of Mid. 
3.4.3.2 Filling weight uniformity among blisters in one disk 
The uniformity of powder weight among blisters was essential for the delivered dose 
uniformity. After the powder filling, the drug disk was sealed with aluminum foil and all 
blisters were numbered. Then a blister on this disk was cut off and weighed (Mxb,0). 
x
d
x
d
x
d MMM 1,0, -=
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Following that, this blister was opened carefully without foil loss, and the powder was 
rinsed by a solvent completely. After air drying of the blister, the weight of an empty 
blister was obtained (Mxb, 1). 
 
The uniformity of filling weight among blisters was evaluated by RSD of mx. 
3.4.3.3 Drug content uniformity among different disks 
When filling weight uniformity among disks and blisters were validated, we moved on to 
drug content uniformity. Similarly, the uniformity among different disks was evaluated 
first. After filling powder, a drug disk was sealed with aluminum foil. Then all blisters on 
this disk were opened carefully without foil loss, and the powder was rinsed into water of 
designated volume Vx. To ensure complete drug dissolution, the disk was immersed into 
water and sonicated for several minutes. Then the solution was analyzed by HPLC to get 
the drug concentration Cx. The drug content of the whole disk was calculated, where x 
represented disk x.  
 
The uniformity of drug content uniformity among disks was evaluated by RSD of MAPI
i. 
3.4.3.4 Drug content uniformity among blisters in one disk 
After powder filling, a drug disk was sealed with aluminum foil. All blisters of one disk 
were numbered sequentially first, then cut off and weighed separately. Thereby, we got 
the weight of each blister mb,0. Next, each blister was opened carefully without foil loss, 
and the powder was rinsed into water of volume Vi. To ensure complete drug dissolution, 
the blister was immersed into water and sonicated for several minutes. When the solution 
was analyzed by HPLC to get the drug concentration ci, the drug content for each blister 
was calculated, where i represented blister mi.  
x
b
x
b
x
b MMM 1,0, -=
xxX
API VCM *=
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After drug content analysis, all blisters were taken out and rinsed with ethanol. And those 
empty blisters were allowed for air-drying until solvent volatilize completely, then 
corresponding percentage of API for blister (i) could also be calculated based on weight 
mb,1 of empty blister.  
 
Likewise, the drug content and percentage uniformity among blisters in one disk were 
evaluated by RSD. 
In addition to 4 kinds of uniformity described above, the drug content uniformity of the 
bulk powder blend during filling was also evaluated. Samples were taken out from 
different positions in the powder chamber (Fig.3.20) to make sure the mechanical stirring 
and filling process would not cause heterogeneity.  
3.5 Dry Powder Inhaler Formulation 
3.5.1 Powder preparation 
3.5.1.1 API processing and lactose carrier 
The most common micronization method for the API is jet mill. A spiral jet mill (Alpine 
® 50 AS, Hosokawa, Japan) with an automatic feeder was applied to micronize API 
particles as Fig.3.22. Particles were drawn in by a pressure difference resulted from 
feeding pressure air. Then particles were accelerated to very high speed by grinding 
pressure air. Because the particles with various sizes exhibited different speeds, then they 
would impact on each other and walls to become smaller. Until particles were smaller 
than a cut size when the centripetal force was bigger than centrifugal, those particles 
would be collected in a filter-bag. Three primary parameters could be adjusted in the jet-
milling process: feeding rate, feeding pressure and grinding pressure. For example, 
decreasing feeding rate would produce smaller particles since a small amount of particles 
iii
API VCm *=
( )ibib
i
API
mm
mAPI
1,0,
%
-
=
 were accelerated more efficiently and exhibited higher speed and impaction 
During a jet-milling, the feeding pressure should be 
avoid flow field interference in
The feeder rate was set as 30rpm, 
7~8bar and P2 representing 
the times of micronization, 3 batches of API with different size distribution were obtained
Those batches were used to study the effect of API size on formulation performance.
Figure 3.22: A
The carriers used in this project 
commercial products are provided by suppliers.
 
smaller than the grinding pressure
 the grinding chamber. 
and P1 indicating the pressure for grinding
the pressure for material feeding was 5~6bar. 
 picture of a jet-mill and an automatic feeder
are listed in Table.3.7, where the size 
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Table 3.7: The information of lactose used  
Lactose Source  Size criterion(µm) 
Fine lactose Self-made D90: <200 
Lactose-120504 
Lactose-121218 
Lactose-121225 
Self-made from 
Lactose 
314WG(Kerry)  
38.5-74 
Inhalac 120 
Meggle 
excipient and 
technology 
D10:70-105, D50:110-155, D90: 160-215 
Inhalac 230 D10:30-60, D50:70-110, D90: 110-150 
Sorbolac 400 <32 
SV003 
DFE pharma 
D10:19-43, D50:53-66, D90: 75-106 
Lactohale LH100 D10:40-80, D50:125-145, D90: 200-250 
Lactohale LH200 D10:25-65, D50:80-120, D90: 130-190 
3.5.1.2 API and lactose mixing method 
The powder mixing is a key process of DPI formulation development, since the mixing 
process determines the uniformity of blend and affects the aerosol performance, like FPF 
and FPD. The mixing may be considered as energy input process, which not only 
provides energy to disperse API to bulk carriers, but also changes the interaction between 
particles, like electrostatic charge and mechanical locking. 
Consequently, the methods to mix API and lactose were studied and determined. 
After sieving the API by an 100-mesh sieve (147µm), the API particles and lactose 
carrier were added into a steel container as shown in Fig.3.23. The lactose carrier was 
divided into two layers, one above API particle and the other one under API. This 
mixture looked like a sandwich. The height of a powder bed should not be more than 1/3 
of the container. The empty space ensured that enough space existed for particle 
movement. Then the container was placed in a shaker-mixer (Turbula T2F, WAB, Swiss), 
 serving as a low shear force
10min respectively. 
Figure 3.23: A schematic diagram of 
After low shear mixing, all powder 
made by ourselves. This device
50g), whereas other commercial equipments usually required 200g powder
for high shear mixing. Large
waste of expensive API and lactose. 
experiment, the speed of which was 
direction of the blades were changed for better agitation effect
mixing speed and time, the effect of these two
was studied. 
Figure 3.24: Pictures of 
 mixer. The mixing speed and time was set as 72rpm and 
 
mixing bed and a picture of the shaker 
was transmitted to a high shear mixer
 was suitable for a small amount of powder mixing (40
-scale mixing in the primary R&D phase would
Consequently, a food mixer was altered 
controlled by a voltage transformer. The
 (Fig.3.24b)
 parameters on formulation performance 
 
the high shear mixer. a, a voltage transformer and the 
mixer; b, the altered blades. 
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At last, because ultrasonic vibration was believed to break agglomerates efficiently, an 
ultrasonic screen (UVS, Shanghai Xuanyi, China) was also applied in the powder mixing 
research. Its working parameter was set as follows: 60 watts of power, 200-mesh sieve 
and vibrating 10min with a 4s interval per 30s. 
3.5.2 Composition of powder formulation 
3.5.2.1 API size and proportion 
APIs with different size distribution were applied in the formulation research to 
investigate the effect of API size on formulation performance.  
The ratio of API to the formulation was also studied to understand its effect on 
formulation performance. In most formulation research, the strength of the drug was 
determined by clinical experiments and the content of API for one administration was 
fixed. Here, a high and low proportion of the API was studied. The result might expand 
the application range of Inhaler-WU2011, indicating that this device could deliver 
different doses suitable for various API.  
The API mixing sequence was also investigated. One method was to mix fine API 
particles with fine lactose in the pre-sieving and then this fine mixture with coarse lactose. 
Another method was to blend fine lactose with coarse carrier first and then carrier as a 
whole with the API. 
3.5.2.2 Lactose composition 
Most of the time, the proportion of the API in a specific formulation is fixed and the API 
particle size is difficult to decrease further by micronization. Hence, the only variable left 
for pharmaceutical scientists to regulate formulation performance is lactose, including the 
size distribution, concentration of fine lactose. Consequently, size distribution, the source 
of lactose, in addition to proportion of fine lactose was investigated. 
Using a vibratory sieve shaker (AS 200 control, Retsch, German) as Fig.3.25, the Inhalac 
230 was divided into 4 parts: <45µm, 45~75µm, 75~100µm and 100~150µm. The 
 vibratory amplitude was set as 
was mixed with these carrier
Similarly, the lactose within the same size range 45~75
(Inhalac230, LH200, SV003
of lactose source. 
When taking Inhalac230 as coarse lactose, the
5%, 10%, and 20% respectively to study aerosol performance 
formulations. 
Figure 3
3.6 Discussion 
This chapter can be divided into
the powder filling and packaging system, plus 
work. There are 3 aspects deserving attention
Firstly, the dry powder inhaler developed in this thes
an excellent idea. It combines
the multiple blisters on one disk
moisture resistance and convenience
since this device can be used repeatedly with 
it decreases the quantity of carrier and increase
1.3 mm/”g” and interval time was 10 second
s without additional fine lactose.  
µm but from different sources 
) were sieved and applied in formulation to study the effect 
 percentage of fine lactose 
and stability of 
 
.25: A picture of vibratory sieve shaker 
 4 parts, including the analytical tool, the inhaler device, 
materials and methods for
 especially. 
is is a completely novel design
 some advantages of other marketed products. F
 ensure a uniform delivery because of pre
. It also can relieve the economic burden for patients, 
replaceable disks. As a result of 
s lung delivery efficiency. 
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device, powder filling system and formulation constitutes a whole system. A new powder 
filling and packaging system is designed and developed, plus comprehensive formulation 
work is carried out to validate the performance of the novel inhaler. For this thesis, the 
research is divided into several parts to make it easier to understand, but actually it was 
impossible to separate those work completely. 
Secondly, all analytical methods serve as a tool to facilitate the R&D of inhaler device, 
powder filling and formulation work. It is difficult to use single equipment for this 
research. Among all these analytical methods, the most important and difficult one is the 
inertial impaction test for its key role in vitro evaluation and for its complexity. Besides, 
there are several important definitions and calculation for inertial impaction methods, 
which are accepted by pharmaceutical scientists and regulatory agencies in many 
countries.  
At last, the methods described in pharmacopoeia to measure delivered drug content and 
NGI are changed slightly here. According to a pharmacopoeia, the flow rate should be set 
to a specific value when producing a pressure drop of 4 kPa over the inhaler. When the 
flow rate is determined according to the pressure drop for a specific inhaler device, then 
the flow time has to be consistent with a withdrawal of 4L of air from the inhaler. 
However, all tests of the project are carried out under a flow rate of 60LPM and flow 
time of 4 s, which also withdraw 4L air from the mouthpiece. There are mainly two 
reasons to change the test parameters. First, when different inhalers are compared, it 
would be better to apply the same test parameters since it could eliminate the operation 
difference and focus on the performance difference between inhalers. For example, If 
different flow rates or flow time are used in the experiment, then it is difficult to 
determine the performance difference is caused by test parameters or inhalers. Second, 
although the 4kPa pressure drop is described in pharmacopoeias for testing a DPI, the 
60LPM flow rate is commonly used for many marketed products because of its simplicity. 
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Chapter 4  
4  Validation of Analytical Method 
4.1 Brief Introduction  
Validation is carried out to ensure accuracy and reproducibility of analytical methods. 
Firstly, the HPLC method for content assay is validated according to FDA (Food and 
Drug Administration) and SFDA (State Food and Drug Administration) requirements, as 
the HPLC provides a basic and reliable tool for other research. Secondly, a validation of 
laser diffraction size measurement is introduced briefly. At last, a validation of the NGI 
and TI, serving as the core of in vitro evaluation, are completed. Fortunately, this 
validation work demonstrates that all analytical methods are reliable and precise. 
4.2 Validation of HPLC Method for Content Analysis 
The HPLC method for sulfate Salbutamol content analysis was established on a method 
for sulfate Salbutamol tablet in China Pharmacopeia 2010. This work was carried out to 
validate the suitability of this HPLC method in the DPI formulation. 
According to requirements of ICH (International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use) and SFDA 
on validation of an assay method, the validation work was consisted of system suitability, 
specificity, sensitivity, linearity and linear range, precision, reproducibility, intermediate 
precision, solution stability, accuracy and durability. 
About 10mg sulfate Salbutamol was weighed into a 25ml volumetric flask and dissolved 
by water. Then, the 4µg/ml reference solution was ready. 
About 40mg sulfate Salbutamol and corresponding lactose were weighed and dissolved 
by water to obtain 4µg/ml test solution. 
The HPLC method is detailed in Section 3.2.2, and not repeated again. 
 4.2.1 Validation of suitability
Repeating 6 times of HPLC assay for reference solution, the 
shown in Fig.4.1. A photodiode array detector
inspect the peak purity. The 
threshold value, indicating a pure c
of the peak is fine without impurity interference. 
than 2.0% and retention time less than 1.0%, shown as Table
Figure 4.1: Pictures of 
Table 
Injection
1
2
3
4
5
6
Mean
RSD (
, specificity 
chromatogram
 (PAD2998, Waters, USA) 
results show that the purity angle is smaller
hromatogram peak of sulfate Salbutamol
In addition, the RSD of peak area
 4.1. 
typical salbutamol chromatogram and peak purity
4.1: The suitability results 
 Peak Area Retention time (min) 
 70002 4.207 
 68205 4.212 
 71563 4.224 
 70348 4.238 
 70887 4.239 
 71760 4.249 
 70461 4.228 
%) 1.84 0.39 
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was applied to 
 than the 
. The shape 
 is less 
 
 
 A blank solvent of deionized wate
0.12mg/ml) were injected for HPLC analysis. A
expicient do not affect the detection of sulfate salbutamol.
Figure 4.2: The chromatogram of reference solution, lactose solution, 
4.2.2 Validation of sensitivit
The reference solution was diluted 
Signal/Noise is closed to 3 (S/N>=3) and 10 (S/N>=10), the corresponding 
concentrations, 300ng/ml and 920ng/ml
quantitation (LOQ). Preparing 6 LOQ and 6 LOD 
retention time of main peak 
Table 4
LOQ 
LOQ1-1 
LOQ1-2 
LOQ2-1 
LOQ2-2 
LOQ3-1 
LOQ3-2 
RSD (%) 
r, a reference solution and lactose solution (about 
s shown in Fig.4.2, the blank solvent and 
 
and blank solvent. 
y and linearity 
gradually and analyzed by the 
 are the limit of detection (LOD)
solutions for HPLC, the RSD of 
is less than 2.0%/ as Table 4.2. 
.2: Signal-noise ratio of LOD and LOQ 
RT S/N LOD RT S/N 
4.135 11.5 LOD1-1 4.312 3.4 
4.105 9.6 LOD1-2 4.291 3.2 
4.149 10.2 LOD2-1 4.350 3.7 
4.144 10.4 LOD2-2 4.358 3.8 
4.154 12.5 LOD3-1 4.370 3.5 
4.194 11.6 LOD3-2 4.401 3.3 
0.70 
  
0.92 
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HPCL. When 
 and limit of 
 The anticipated linear range 
(samples from tests like blend uniformity, drug content uniformity among disks and 
blisters, DUSA, TI, and NGI)
the target range were prepared
established between the sample concentration
and the linear coefficient and range were investigated. 
concentration divided by corresponding peak area, were also calculated to 
system stability. 
An excellent linearity inferred by R
shown in Fig.4.3. Besides, the intercept on the Y
response and RSD of calibration factors smaller than 2.0%
conclusion, this HPLC method shows
Figure 4.3: The 
 
was set as 40%~ 300% concentrations of possible sample
. Corresponding solutions of 7 concentration poi
 and analyzed by the HPLC. Then a linear regression was 
 (µg/ml, X-axis) and peak area (
The calibration factors (CF
2=1 between sample concentration and peak area 
-axis is smaller than 2% of complete 
 as shown in Table
 a good linearity from 1.63 to 12.22µg/ml.
linearity between concentration and peak area.
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Table 4.3: The linear range of concentration and corresponding peak area 
Concentration 
µg/ml 
Peak area 1 
（AU） 
Peak area 2 
（AU） 
Averaged 
area（AU） 
 CF 
1.63 27865 28614 28239.5 5.76781E-05 
2.44 42692 43343 43017.5 5.67955E-05 
3.26 57328 55862 56595.0 5.75599E-05 
4.07 70959 70519 70739.0 5.75637E-05 
6.11 106590 106553 106571.5 5.73136E-05 
8.14 143384 142824 143104.0 5.69097E-05 
12.22 215144 214934 215039.0 5.68083E-05 
RSD (%)    0.68 
4.2.3 Validation of precision, reproducibility and intermediate 
precision 
The reference solution was injected 6 times repeatedly to calculate the RSD of peak area, 
and results showed that the RSD was less than 2.0%, indicating good precision.  
3 powder blends with similar composition as formulations were prepared, and then those 
blends were dissolved and analyzed by HPLC. The recovery rate was calculated by 
following formula, where mi, weighed stood for the quantity of the API in the blends, i for 
blend sample and r for reference sample. As shown in Table.13, the averaged recovery is 
99.66% with 0.71% RSD, indicating good reproducibility. 
                                 Recovery=  
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Table 4.4: The reproducibility results  
Sample name 
Concentration
（µg /ml） Peak area 
recovery
（%） 
reference1-1 3.95 68527  
reference1-2 3.95 68486  
reference2-1 4.07 70959  
reference2-2 4.07 70519  
Blend 1-1 3.94 67861 99.25 
Blend  1-2 3.94 68629 100.38 
Blend  2-1 4.07 70010 99.13 
Blend  2-2 4.07 70230 99.44 
Blend  3-1 4.00 69918 100.73 
Blend  3-2 4.00 68749 99.04 
Average   99.66 
RSD (%)   0.71 
Samples that were similar as reproducibility test were prepared and analyzed by different 
analysts and HPLC instruments. The total result of 18 tests shows that the average 
recovery is 99.82% with 0.37% RSD, indicating good intermediate precision. 
Table 4.5: The intermediate precision results 
 Analyst, A 
HPLC 1# 
Analyst, B 
HPLC 2# 
Analyst ,C 
HPLC 3# 
Recovery (%） 98.75 100.96  100.48 
 99.87 100.10  100.12 
 99.13 99.69  99.22 
 99.44 100.01  99.05 
 100.73 99.95  99.95 
 99.04 100.64  99.72 
Average（%） 99.49 100.22 99.75 
RSD（%） 0.72 0.47 0.54 
Average for all tests：99.82%                   RSD for all tests：0.37% 
4.2.4 Validation of solution stability, accuracy and durability 
The reference solution was stored in 4°C environment and detected at 0, 2, 4, 6, 8 hour 
and 15th day. Table 4.6 shows that the sample is rather stable under 4°C for 15 days. 
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Table 4.6: The solution stability result 
Time（h） Peak area 
0 67986 
2 68918 
4 67196 
6 66453 
8 69282 
15day 68812 
Average 68108 
RSD% 1.62 
9 samples were prepared by accurately weighing API and setting their concentration at 
80%, 100% and 120% level. Then the recovery was calculated in the similar way as 
reproducibility evaluation. As Table 4.7, the recovery is between 98.0~102.0% for three 
concentrations, exhibiting excellent accuracy.  
Table 4.7: The recovery rate result 
Sample 
Recovery 
（%） Average recovery（%） RSD（%） 
Lower concentration-1 100.66 
100.66 1.05 
Lower concentration-2 101.76 
Lower concentration-3 101.32 
Middle concentration-1 101.73 
Middle concentration-2 100.04 
Middle concentration-3 99.32 
Higher concentration-1 100.76 
Higher concentration-2 98.85 
Higher concentration-3 101.48 
To investigate the durability of HPLC method, different conditions were set: changing 
the proportion of mobile phase (±5%), pH of mobile phase (±0.2), column temperature 
(±5°C), and flow rate (±20%). Meanwhile, columns of different brands, different HPLC 
instrument were also studied.  
The results show that the tailing factor of primary peak is less than 1.5 and resolution 
between the API peak and impurity is acceptable. The RSD of concentration results 
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detected under different conditions is less than 2.0%. To sum up, this HPLC method is 
durable even if the detection conditions change slightly. 
4.3 Validation of Size Characterization Methods  
4.3.1 Validation of laser diffraction size measurement 
The operation parameters of laser diffraction size measurement are described in Section 
3.2.3. When particles are in the range of 0.25µm to 87.5µm, R2 lens should be used and 
R4 lens for particles from 0.5µm to 350µm. At the beginning of each laser sizing, a 
reference sample provided by the manufacturer should be measured as a calibration, to 
make sure that operating parameters are suitable and instrument is running well. 2 
standard references, Sic-F1200’03 and Sic-P600’06 are applied for R2 lens and R4 lens 
respectively.  
A typical size distribution result is shown in Fig.4.4. From the cumulative distribution, 
the percentage of particles under a certain size would be known. The type of particle 
distribution can be inferred from the density distribution graph. A monomodal 
distribution is exhibited in Fig.4.4, since there is only one peak. As we can see in Table 
4.8, the results of reference samples conform to the criteria very well, implying accurate 
and reliable results for following tests.   
q3(x)=dQ3(x)/dx 
X represents a diameter value, q 3 and Q3 represent volumetric density and cumulative 
distribution respectively. 
 Figure 4.4: The cumulative and density distribution results 
Table 4.8: The calibration criteria
R2 lens 
Criterion 
 Calibration test-1 
Calibration test-2 
R4 lens 
Criterion 
 Calibration test-1 
Calibration test-2 
4.3.2 Validation of 
4.3.2.1 Validation of NGI test method
The cascade impaction method i
a size distribution comparison between 
Consequently, to investigate the influence of coating stages on NGI
Impactor) results, about 50mg
of Sic-F1200’03 for R2 lens. 
 and results for laser diffraction sizing
X10(µm) X50(µm) X90(µm
1.79-1.98 3.76-3.96 6.30-6.63
1.63 3.84 6.53 
1.82 3.87 6.65 
X10 X50 X90 
15.03-16.62 25.41-26.72 39.23-41.25
15.39 26.31 39.99 
15.38 26.31 40.04 
inertial impaction size measurement 
 
s a little different for DPIs from pMDIs, which 
the coated and uncoated stages for DPI test first
 (Next Generation 
 surfactant mixture (Tween 80: Glycerin=1:
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) 
 
 
mandates 
. 
 4) was added 
 into each stage and then the liquid was smeared evenly
Oxis® inhaler was tested by
test parameters and data processing method 
The size distribution results a
dose) and FPF (fine particle fraction)
are coated, if the detailed particle
more particles depositing 
phenomenon implies that, if there is no coating,
experience reentrainment into stages which
difference of aerodynamic particle size distribution (APS
uncoated NGI, the coating method i
particle bounce and reentrainment.
Table 4.9: The calibration criterion and results for Laser
Turbuhaler® Oxis® 
Coated 
Uncoated 
Figure 4.5: The comparison of NGI r
 with a soft brush. A
 a coated NGI and an uncoated NGI simultaneously
are described in Section3.2.3 and 3.3.1.
re shown in Table 4.9, presenting similar FPD
 between the coated and uncoated NGI
 size distribution is investigated in Fig.4
on stage1-4 and less particles on stage5
 the large particles may bounce and 
 should catch small particles
D) between the coated and 
s used for all following NGI tests to avoid 
 
 diffraction sizing
TRM(µg) ED (µg) FPD(µg) FPF
105.9 89.7 51.8 57.8%
107.9 95.5 51.3 53.6%
esults for Turbuhaler® Oxis® with
and uncoated stages 
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4.3.2.2 Validation of TI test method 
The TI (Twin impinger) method is described in Section3.2.3 and 3.3.1 in detail. The TI 
method is used most in this project for its simplicity and convenience. Therefore, the 
operation parameters of TI test are validated carefully with a Clickhaler® to make sure 
that little operation error will not influence the final results. The performance of 
Clickhaler® is rather stable and suitable for TI method validation. What we have done for 
the validation is to adjust three critical testing parameters intentionally, and investigate 
the influence of the alterations on TRR (Total Recovery Rate) and FPF (Fine Particle 
Fraction). Both values are important for evaluating inhalers performance. In the research 
scheme as Table 4.10, the higher volume of receiving solvent is excluded, because the 
receiving solvent only confront the problem of solvent volatilization or solvent loss as a 
result of fast air flow. 
Table 4.10: The research scheme of TI test method validation 
Clickhaler® Lower (n=3) Normal (n=3) Higher (n=3) 
Flow rate (LPM) 58 60 62 
Volume of receiving solvent (ml) 25 30  
Flow time (second) 3 4 5 
Table 4.11: The TRM and FPF result of TI method validation 
TRR Lower (n=3) Normal (n=3) Higher (n=3) 
Flow rate 99.0% 99.9% 103.7% 
Volume of receiving solvent 106.3% 99.9%  
Flow time 101.9% 99.9% 106.6% 
FPF    
Flow rate 22.8% 22.2% 23.5% 
Volume of receiving solvent 24.9% 22.2%  
Flow time 24.3% 22.2% 24.3% 
The validation results are shown in Table 4.11. As we can see in this table, even if there 
is little alteration of operating parameters, the results are still constant, indicating a stable 
and reliable TI impaction method. 
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The electrostatic charge produced in the powder preparation and powder filling exerts a 
great influence on the inhaler performance, then it would disturb the judgement of 
researchers in the formulation studies. Consequently, the powders and drug disks should 
be allowed to stand for a period to dissipate electrostatic and reach a relative stable state.  
Hence, two kinds of powder were prepared by 0%w/w and 20%w/w fines with Inhalac 
230, representing powder with better and worse flowability respectively. The percentage 
of the API-sulfate salbutamol was set to 0.72%w/w for both powders and these powder 
were prepared by the same mixing process, including pre-sieving, low shear and high 
shear mixing as mentioned as Section 3.5.1. The device used here was Inhaler WU2011. 
After powder preparation, the drug powder was sealed and stored in a dryer to get rid of 
moisture. A certain amount of powder was taken out and filled into disks for TI tests 
instantly at proposed time points (Table 4.12). This study was used to determine the 
interval between powder preparation and TI tests required for stable data. After that, 
when we got the desired information from the above experiments, these two powders 
were prepared again and allowed to rest for a designated time. And then these powders 
were filled into drug disks and tested by TI at proposed time points (Table 4.12).  
Table 4.12: The research scheme of TI test time point validation 
Interval between powder 
preparation-TI test n=2 for each time point TI test 
0%fines-100%Inhalac®230 0day 3day 7day 14day 
20%fines-80%Inhalac®230 0day 3day 7day 14day 
Interval between powder 
filling-TI test 
    
0%fines-100%Inhalac®230 0day 3day 7day 14day 
20%fines-80%Inhalac®230 0day 3day 7day 14day 
The results of interval validation between powder preparation and TI test are shown in 
Fig.4.6. As we can see in Fig.4.6, the FPF and remains in blisters do not show any 
obvious trend from 0-day to 14-day for 0%-fines or 20%-fines formulation, implying that 
the electrostatic charge produced in powder preparation do not influence the aerosol 
performance.  
 The result of studies for interval
The FPF shows a small raise
the remains in blisters decrease
are more obvious for 0%-fines than 20%
As shown in these pictures
FPF and remains in blisters. 
0%-fines and also higher remains in blisters. 
performance is examined carefully in the formulation part.
As a conclusion for TI test me
into disk without intentional
powders are sealed well and kept from moisture, 
2 weeks. What is more important, the fresh drug disk should not 
and 1 week of rest time is recommended for TI test after filling disk
Figure 4.6: The in vitro
between powder preparation and TI test
 between powder filling and TI test are shown in Fig.
 with increasing rest time of the filled disk. O
 gradually when increasing the rest time. Both 
-fines formulation. 
, the composition of formulation has great influenc
The 20%-fines formulation exhibits a much higher FPF than 
The influence of fine particles on 
 
thod validation, when powder is prepared, it 
 rest for eliminating electrostatic charge. Meanwhile
its performance does not 
be tested
s. 
 performance of the new inhaler at different
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can be filled 
, if these 
change within 
 immediately, 
 
 intervals 
 Figure 4.7: The in vitro
between powder filling and TI test
4.4 Discussion 
This chapter is mainly focused on validation of analytical method
method, laser diffraction size measurement, and inertial impaction
The HPLC validation work 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use
the HPLC method used in this thesis i
The difference between testin
HPLC method should be very sensitive
small and is divided into many parts in 
be specific to distinguish 
challenge when the concentration of the API i
analytical work in cascade impaction 
easy and time saving. 
 performance of the new inhaler at different
s. 
s, including the HPLC 
 methods
is carried out according to requirements of ICH (
) and SFDA. The results have successfully proven
s simple, accurate, precise, durable and specific. 
g inhalers and other pharmaceutical dosages i
, since the quantity of the API per dose i
an impaction test. Meanwhile, this method should 
the API and impurity, excipients, which may become a 
s very low. Additionally
tests is labor-intensive, the HPLC method should be 
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The laser diffraction method should be calibrated before each test, to make sure the 
detected size results conform to the criteria of reference samples. 
The validation of inertial impaction method is the core of this chapter, not only for its 
importance but also for its susceptibility to the personnel, operation and equipment.  
The comparison between the coated and uncoated NGI clearly show that during a NGI 
test, the stages should be coated. Since scientists do not consider the particle bounce and 
reentrainment during the design of NGI or other cascade impactor[131], the particle bounce 
would produce false results. For example, particles with aerodynamic diameter above 
4.46µm should be caught on stage2 or even before stage2 at 60 LPM. However, as a 
result of bounce, these particles are reentrained into the flow and enter next stage. The 
result would show more fine particles and less large particles, in other words, the particle 
size distribution moves to the smaller end. Mitchell et al described the common coating 
material and quantity used in cascade impactor on behalf of members of European 
Pharmaceutical Aerosol Group[132]. Although there are lots of materials available for 
coating, it is essential that the coating material would affect the detection of the API. 
Rissler et al reported a methodology to study impactor particle reentrainment, and found 
that at higher flow rate, like >=60 LPM, the particle bounce became even more worse and 
proposed a soaked filter paper as coating material[133]. For high dose DPIs, the situation 
may become more complicated, because too much powder may result in overload of 
cascade impactor and make it easier for particle bounce. Consequently, when a high-dose 
DPI is tested, more attention should be paid to stages coating[134]. Nevertheless, for 
droplet aerosols, like nebulizer or solution-pMDI, the necessity of coating declined as 
droplets are not so easy to bounce[135].  
The validation of TI method is divided into two parts: the first one focuses on operation 
and parameters. Fortunately, the validation results indicate that even if there is a little 
error in operation, it does not affect the accuracy of final results. The validation work of a 
cascade impactor usually refer to validation of its cutoff diameter[120; 136], and there are 
few studies focusing on the reproducibility and durability of operation and parameters in 
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TI tests, although the operation and parameters are even more important for industry and 
formulation scientists.  
The second part of TI validation involves the formulation, powder processing and 
package. The results demonstrate that electrostatic charge produced in powder 
preparation would not affect the aerosol performance, but charge produced in powder 
filling and packaging would affect its performance. Adi et al also found that charge 
induced by different containers during tumbling does not play a significant role in 
mannitol powder aerosolisation[137]. It is recommended that all drug disks should be 
tested one week after filling. It is inferred that the electrostatic charge produced in 
particle-PVC interaction is much higher than particle-particle interaction. This 
assumption is supported by the experiment of Carter et al that PVC could acquired the 
highest charge compared with lactose and salbutamol and particles. The charge would 
take a longer time to dissipate charge[138]. Ament et al also reported that a coarser aerosol 
was delivered when the DPI was immediately tested after filling and further testing 
results confirmed that the particle size distribution would go up and keep stable over a 
period of 2-3weeks. The electrostatic charge results showed that relaxed blisters had 
lower and constant charge[139]. What is noteworthy, the longer time required for 
dissipating charge in that research is related to ultrasonic vibrating of blisters. This high-
energy vibration may produce lots of electrostatic charge. 
Interestingly, the electrostatic charge has various influences on powders with different 
fine additives. For 0%-fines formulation, the blisters remains decline but FPF goes up 
when increasing rest time. This result can be explained that the electrostatic force 
between particle and PVC decrease with time. As a comparison, the 20%-fines 
formulation does not show similar trends. It is inferred that since there exist more fine 
particles in 20%-fines formulation, the cohesive force between the fine API particles and 
PVC is diluted as a result of fine additives.  
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Chapter 5  
5  Evaluation Results of Dry Powder Inhalers  
5.1 Brief Introduction  
Several typical marketed inhalers are evaluated first, including airflow resistance, fine 
particle fraction (FPF) and delivered drug content uniformity. Secondly, an operational 
state of the inhaler-WU2011 is described. Furthermore, improvements of the inhaler 
design and corresponding results are presented. At last, the inhaler-WU2011 is compared 
to several marketed products using the same formulation. This experiment could reflect 
the performance of inhalers by excluding an interference of different powders. 
5.2 Evaluation of Marketed Dry Powder Inhaler Devices 
Four typical marketed DPI products are evaluated, including all three categories of DPI 
device: single unit dose-Aerolizer® Foradil®, multiple unit dose-Diskus® Seretide® and 
multiple doses (reservoir) -Turbuhaler® Oxis® and Clickhaler® Asmasal®. The tested 
items and operations are described in Section 3.3.1 in detail. 
5.2.1 The air resistance and delivered dose content uniformity 
The flow rates and corresponding pressure drop are listed in Table.5.1. A linear 
regression of the square root of pressure drop on the flow rate is established for each 
device as Fig.5.1. The air resistance of a device is represented by the slope of 
corresponding curve, as Fig.5.1. All devices show a good linearity between the square 
root of pressure drop and flow rate with linearity factors above 0.99. The result 
demonstrates that all airflow resistances are within the range of 0.02-0.04kPa0. 5*min/liter. 
The reservoir device, Clickhaler® Asmasal® show the highest resistance and capsule 
device Aerolizer® Foradil® has the lowest one. 
  
 Table 5.1: The pressure drop 
 
Flow rate (LPM) Turbuhaler®
20 
40 
60 
80 
Figure 5.1: The linearity between (pressure drop
Table 5.2: The
DPI device
Turbuhaler®
Aerolizer® 
Diskus® 
Clickhaler
Usually, the pre-metered device,
present a good delivered drug content uniformity
carried out for Aerolizer®
Clickhaler® Asmasal®. The DDCU results
in corresponding flow rate of marketed 
Pressure drop (kPa) 
 Aerolizer®  Diskus® 
0.80 0.32 0.53 
3.02 0.92 1.73 
5.80 1.99 3.19 
9.69 3.40 5.36 
) 0.5 and flow rate 
for marketed inhalers 
 airflow resistance of marketed inhalers 
 Resistance (kPa0. 5*min/liter) 
 0.036 
 0.021 
 0.026 
® 0.04 
 like single unit dose and multiple unit dose 
 (DDCU). Hence, the DDCU 
 and Diskus® Seretide® but for Turbuhaler®Oxis
 are shown in Fig.5.2 and Fig.5.3
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inhalers 
Clickhaler® 
0.90 
3.38 
6.70 
Too high 
 
 
inhalers 
test is not 
® and 
, from which 
 we can see the delivered dose fluctuating within a certain range.
Asmasal® is about 11.6%, much smaller than 22.9% of 
fluctuation of Clickhaler® Asmasal
Pharmacopeia, but the uniformity of 
pharmacopeia requirements
content of at least 9 of 10 doses collected from one inhale
of the target-delivered dose, and none is outside the range of 65% to 135% of the target
delivered dose. These requirements are
consideration of accidental e
follows: If the contents of not more than 3 doses are outside the range of 75% to 125%, 
but within the range of 65% to 135% of the target
are selected, and repeat the prescribed procedure for a
requirements are met if not mor
of 75% to 125% of the target
of the target-delivered dose.
Asmasal® meet the first tier, and 
second tier. 
Figure 5.2: The delivered dose content uniformity of 
 The RSD of 
the Turbuhaler®Oxis
® is still acceptable according to US and European 
Turbuhaler® Oxis® does not meet the 
. Since the pharmacopeias usually requires 
r should be between 75
 usually considered as the first tier. In 
rrors, the pharmacopeia also provides a second tier
-delivered dose, 2 additional inhalers
nalyzing 10 doses from each. The 
e than 3 results, out of the 30 values, lie outside the range 
-delivered dose, and none is outside the range of 65% to 135% 
 The results show that the uniformity of 
Turbuhaler® Oxis does not even comply with 
Clickhaler® Asmas
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%-125% 
-
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Clickhaler® 
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 Figure 5.3: The delivered dose content uniformity of 
5.2.2 The inertial impaction test
The results of in vitro particle size distribution of 
Seretide®, Turbuhaler® Oxis
(Twin Impinger) impaction 
according to the calculation method in Section 3.2.3
APIs, salmeterol and fluticasone in the formulation of 
salmeterol is analyzed for convenience.
The result is shown in Table
and multiple-unit device present
to different device designs, t
than Aerolizer® Foradil®. 
Asmasal® have a much higher FPF value
has a TRR more than 100%, 
Fig.5.4 and Fig.5.5, the Turbuhaler® Oxis
FPF and TRR. On the contrary, the 
exhibit the best consistency 
Turbuhaler® Oxis
 
Aerolizer® Foradil
® and Clickhaler® Asmasal® are first acquired 
detailed in Section 3.2.3 and 3.3.1. And all data ar
. It is noteworthy that t
Diskus® Seretide
 
.5.3 and Fig.5.4. The unit dose devices including single unit 
 similar a FPF (fine particle fraction) of about 26%.
he TRR (total recovery rate) of Diskus® Seretide
The reservoir devices, Turbuhaler® Oxis® and 
 above 40%. The Clickhaler® Asmasal
indicating excellent delivery efficiency. As we can
® shows the greatest variation in terms of both 
Diskus® Seretide® and Clickhaler® Asmasal
of FPF and TRR. 
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® 
®, Diskus® 
by a TI 
e processed 
here are two 
®, and the 
 Due 
® is higher 
Clickhaler® 
® even 
 see from 
® 
 Table 5.3: The FPF and TRR results of TI tests 
Device
Aerolizer® 
Foradil
Di
Turbuhaler® 
Clikchaler
Figure 5.4: The 
Figure 5.5: The TRR results of TI test for the marketed 
for the marketed 
 FPF(<6.5µm,n=2) TRR(n=2) 
 26.3% 75.0% 
skus®  26.5% 86.4% 
Oxis 41.9% 79.7% 
 47.8% 104.9% 
FPF results of TI test for the marketed inhalers
inhalers
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These devices are further investigated by cascade impactors with coated stages. The FPF 
and TRR results are shown in Table 5.4. Aerolizer® Foradil® and Clickhaler® 
Asmasal® almost have the same FPF values as TI tests. The increasing FPF of 
Turbuhaler® Oxis might be caused by an abrupt TRR rise. The descending FPF of 
Diskus® Seretide® might be related to the sensitivity of this device to air flow. Since the 
dead volume of NGI is larger than the TI, the flow rate would reach 60 LPM slower for 
NGI than TI. Hence, the flow time is not long enough to produce sufficient airflow 
through the NGI. Based on this assumption, the flow time is prolonged from 4s to 10s. 
This NGI test obtains a 30% FPF, being similar to the TI result. To keep test parameters 
the same for all devices, the result of 4s flow time is presented. 
The NGI presents a detailed aerodynamic particle size distribution (APSD) as shown in 
Fig.5.6. Above 50% of API particles deposit on induction port (throat) and pre-separator, 
but the Turbuhaler® Oxis® shows less deposition in these two parts. Generally, particles 
from the single unit dose and multiple unit dose inhalers are caught earlier than reservoir 
devices. Particularly, Aerolizer® Foradil® and Diskus® Seretide have more particles 
deposited before stage3 but fewer particles on last 5 stages. On the contrary, the APSD of 
reservoir devices tends to the smaller end, causing larger FPF values. 
Table 5.4: The FPF and TRR results of NGI tests for the marketed inhalers 
Device FPF(<4.46µm) TRR 
Aerolizer® 
Foradil 
25.2% 79.5% 
Diskus® 
Seretide 15.7% 86.1% 
Turbuhaler® 
Oxis 57.8% 99.6% 
Clikchaler 46.7% 101.1% 
 Figure 5.6: The 
5.3 Primary Evaluation and Design I
Novel Inhaler 
5.3.1 Primary evaluation
A description of the new Inhaler WU2011 i
designed functions. Nevertheless
chapter 7. 
The external shell can be close
contamination. When the outside shell is
any more to avoid a wrong operation.
When the external shell is op
puncture would pierce into the center of a blister. 
releasing the push button, the spring under the push button would help the
and puncture return to their original positions
aerodynamic particle size distribution (APSD) 
for the marketed inhalers 
mprovements
 
s provided to ensure the achievement of 
, detailed performance data is presented 
d tightly to protect inner structure and mouthpiece from 
 closed, the push button and trigger can
  
en, the push button can be pushed down smoothly and the 
After an administration
. 
84 
 
 
 of the 
mainly in 
 not move 
 or test, 
 push button 
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For next dose or blister, the trigger is turned clockwise once to drive the ratchet and 
circular-tray rotate for one blister, and then a new blister was available for the next 
administration. People could turn the trigger back immediately or until the next 
administration. When a disk is finished, the hasps can be unlocked to open the cover, and 
the exhausted disk can be replaced.  
5.3.2 Design improvement 
During the development of this inhaler device, it is continuously improved based on 
feedback from experts and testers. Firstly, the number of blisters on a disk is adjusted 
from 16 to 14, since it is believed that 14 blisters could be used for one or two weeks if 
two or one blister per day. Besides, decreasing the number of blisters on one disk allow 
more space between individual blisters, implying possibility of more tight sealing. 
The inhaler-WU2011 of initial design is evaluated for its air resistance, delivery 
uniformity and the proportion of remaining powder in a blister. Firstly, the air resistance 
is rather high, shown in Fig.5.8. Then the diameter of the puncture (Diameter A, Fig.5.7) 
was increased from 1.4mm to 2mm, and the diameter of the tube (Diameter B, Fig.5.7) 
connected to the push button was enhanced from 2.5mm to 3mm. These alterations allow 
more air to pass through the mouthpiece. Additionally, two very small air holes were 
placed on the both sides of the mouthpiece, also serving to decrease the resistance. 
As shown in Fig.5.8, the air resistance exhibits a significant decline from 0.22 to 0.06 
kPa0.5*min/L due to the design improvement. The lower resistance of the new design is 
much closer to marketed products. 
  Figure 5.7: The 
Figure 5.8: The linearity between (pressure drop
The improvements also exert 
As shown in Fig.5.9, the c
schematic of the improved puncture design
) 0. 5 and the flow rate
 the improved inhaler 
a beneficial effect on the delivery efficiency and uniformity
omparison clearly indicates that the new design not only 
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 of 
. 
 enhances the delivery rate and decrease
variability. 
Figure 5.9: The comparison of
the old design and new inhaler
The geometry of inhaler mouthpiece i
performance. Consequently, a series of mouthpiece 
their performance. The mouthpiece
shape are made as Fig.5.10 and
Figure 5.10
s the remains in blisters but also reduces
 delivered efficiency and content uniformity 
 (n=6) 
s believed to have great influence on the inhaler 
is designed and manufactured 
s of various interior diameters, length and 
 Table 5.5 and then tested by the NGI.  
 
: The airway structure of the mouthpiece 
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between 
to test 
airway 
 Table 5.5: The 
Devices Airway length (mm)
Mouthpiece-1 
(Original) 
Mouthpiece-2 
Mouthpiece-3 
Mouthpiece-4 
Mouthpiece-5 
In the first test, the influence of mouthpie
results are shown in Fig.5.11
the airway length almost do
decline of airway diameter greatly raises
spiral airway might be caused by increasing diameter 
Figure 5.11: The linearity between (pressure drop
 
dimensions of the investigated mouthpiece
 Airway diameter(mm) 
14 4.2 
7 4.2 
21 2.6 
14 2.6 
14 4.2 
ce geometry on air resistance is stud
 and Table.5.6. As we could see in Table.5.6
 not show any significant effect on air resistance
 the resistance. The decline of resistance for 
as a result of spiral design.
) 0.5 and flow rate 
for different mouthpieces 
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 Table 5.6: The air resistance
Devices
Mouthpiece-
Mouthpiece-
Mouthpiece-
Mouthpiece-
Mouthpiece-
To evaluate the influence of the mouthpiece on aerodynamic particle size 
(APSD), the drug disks containing the same formul
mouthpiece 1-5. The APSD result is
critical data are presented in Table.
the same except for one abnormal
test into account, the FPF values a
design of the mouthpiece and corresponding
great influence on the inhaler performance
Figure 5.12: The APSD of the 
 of the new inhaler with different mouthpiece
 Resistance (kPa0. 5*min/liter) 
1 (Original) 0.062 
2 0.060 
3 0.076 
4 0.079 
5 0.054 
ation are tested by NGI for 
 shown in Fig.5.12, Fig.5.13 and Fig.5.14
5.7. The APSD profiles of different mouthpiece
 point of mouthpiece-1. Taking the variation of NGI 
re the same as shown in Table.5.7. Consequently, the 
 slight alteration of air resistance 
. 
inhaler with different mouthpieces (mouthpiece 1
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 Figure 5.13: The APSD of the inhaler with different mouthpieces (mouthpie
Figure 5.14: The cumulative distribution
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Table 5.7: The FPF results of the inhaler with different mouthpieces 
Devices FPF values SD (n=3) 
Mouthpiece-1(Original) 42.7%  
Mouthpiece-2 41.6% 3.59% 
Mouthpiece-3 39.0% 5.30% 
Mouthpiece-4 43.2% 0.45% 
Mouthpiece-5 42.2% 3.34% 
During the evaluation and tests of the Inhaler-WU2011, the accurate position of the 
blister is very important for the drug delivery. In other words, it is required that the center 
of a blister should be where the puncture piece into. We compared a good inhaler to an 
inhaler with the ratchet and locator not working properly. The bad inhaler was tested 
repeatedly for 3 times using 10%-fines powder. As a comparison, the good inhaler was 
tested using three kinds of powders including 10%-fines. The results are shown in Table 
5.8 and Table 5.9. Although the FPF of both inhalers using 10%-fines powder are almost 
the same, huge difference of RSD in terms of blister remains and FPF indicates that right 
position of blisters and accurately puncturing greatly improve the uniformity of drug 
delivery. Therefore, it is concluded that materials of the ratchet and locator should be 
carefully studied in the future, and only those exhibiting excellent mechanical properties 
during a fatigue test are suitable. 
Table 5.8: The TI results of the inhaler when blister at wrong position 
Deposited mass/TRM 1st test 2nd test 3rd test AVG RSD 
Blister remains 4.1% 17.5% 6.7% 9.5% 75.2% 
FPF 54.3% 41.7% 29.6% 41.9% 29.4% 
Table 5.9: The TI results of the inhaler when blister at right position 
Deposited mass/TRM%（n=3）  0fines 5%fines 10%fines 
Blister remains 
AVG 27.1 % 16.6% 17.2% 
RSD 2.8% 7.3% 1.7% 
FPF 
AVG 15.8% 33.1% 40.0% 
RSD 5.8% 13.5% 1.3% 
 5.4 Parallel Comparison with the Marketed I
It is ideal to exclude the formu
inhaler devices. Yet, it is difficult
devices and reservoir devices. 
is sealed in an individual blister by special packaging
Diskus® is too complicated to
Turbuhaler® Oxis, its unique formulation
superb flowability. Only these sphere agglomerates
metering mechanism of Turbuhaler
Because the structure and powder filling i
Clickhaler®, they are employed as 
same powder. The powder was
and Inhalac 230. And it was
certain amount of powder was filled into 
and the reservoir of Clickhaler
impinger) method. 
Figure 5.15: The picture and schematic of twister® and 
nhalers
lation effect when we compare the performance of 
 to carry out such a research for multiple unit dose 
Take Diskus® Seretide® for an example, the drug powder 
 material. Besides, the structure
 disassemble and assemble. What is even worse for 
 is composed of sphere agglomerates with 
 are suitable for the powder filling and 
®, and other particles would not work properly
s relatively easier for Aerolizer®
a comparison with the inhaler-WU2011
 composed of 0.72% sulfate Salbutamol, 20% fine lactose 
 prepared by the method described in Section 3.5.1. Then a 
a 3# capsule for Aerolizer® and Twisthaler®, 
®. Then their performance was tested
Clickhaler®
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 Reservoir 
 The results shown in Fig.5.16
performance as Aerolizer® 
the Twister®. When considering the fraction of remains in inhaler devices, 
WU2011 has the same result
Clickhaler® do not show remains in the device after drug delivery.
Figure 5.16: The parallel comparison of FPF with marketed devices
Figure 5.17: The parallel comparison of 
 and Fig.5.17 indicate that the Inhaler-WU2011 ha
and Clickhaler®. Their FPFs are about 50% and higher than 
 as Twister® and similar variations as Aerolizer
 
using the same powder. 
remains fraction with marketed devices by 
using the same powder  
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5.5 Discussion  
Several marketed inhaler products are evaluated for in vitro performance. Then, the 
design improvement of Inhaler-WU2011 and enhanced performance is introduced. At last, 
the device performance is compared to several inhalers using the same powder 
formulation. The results indicate that the inhaler-WU2011 has better or similar 
performance as marketed products. 
Without consideration for formulation, the air flow resistance is a critical parameter for 
inhaler devices. Several marketed DPI device are tested here for resistance, and the 
results are similar as values mentioned in a review[140]. The single and multiple unit dose 
inhalers have smaller resistance and reservoir devices show higher one. The resistance of 
Inhaler-WU2011 after design improvement is close to the Inhalator®[140], higher than 
other marketed devices. As a result of descending resistance, the flow rate increases 
under the same pressure drop, resulting in a better delivery efficiency and uniformity. 
The passive DPI devices are greatly dependent on an inspiratory flow to disperse and 
deliver powder, and air flow resistance will influence the peak inspiratory flow (PIF) and 
maximal inspiratory capacity (MIC) directly. If the inspiratory effort is the same, then a 
bigger resistance results in a lower PIF and MIC[48; 141]. During an administration, the 
total air resistance is equal to the sum of the device (Rinhaler) and human airway (Rairway). 
For high resistance device (Rinhaler>> Rairway), the device resistance determines the whole 
resistance. But for low resistance device, both Rinhaler and Rairway would affect the whole 
resistance. It means that low resistance devices are more sensitive to the bronchi 
contraction and different patients may produce different aerosol performance.[142; 143] 
Moreover, a high-resistance device may reduce the velocity of the airflow and particles. 
Then impaction of particle on oropharyngeal would go down as a result of lower velocity 
and smaller inertia, and deposition of particle in lung would increase.  
Nevertheless, the high-resistance device may cause uncomfortable for the patient because 
it requires a greater effort. Furthermore, the flow rate of high-resistance device would be 
lower under the same pressure drop. The decline of flow rate might decrease the 
efficiency of API-carrier detachment as a result of lower airflow energy. For example, 
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Cegla et al reported that, compared to the patient who used Novolizers, patients had to 
invest a significantly higher inspiratory effort when they used a Turbuhaler as a result of 
its higher resistance. And patients had a worse inhalation performance when inhaling 
through the Turbuhaler than Novolizer[144]. On the contrary, Gac et al proposed that a 
noticeable increase of delivery efficiency and particle detachment was obtained at low 
airflow rates due to the use of turbulence, which suggested that an appropriate increase of 
flow resistance is acceptable[145]. 
As mentioned before, the delivery uniformity of reservoir device is a major concern by 
the regulatory agency. This problem is confirmed again by the results of this chapter. The 
uniformity of Clickhaler® Asmasal® is acceptable although there is a tail-off effect at the 
end of delivery. The tail-off effect is usually used to describe a content drop at the end of 
a pMDI. The Clickhaler® Asmasal® also experiences drug content decline for its last 3 
deliveries. This phenomenon is perhaps caused by its filling and metering mechanism. 
Particularly, the Clickhaler® must be shaken hard before administration. The shaking 
operation helps powder flow into a dimple from the reservoir. Then, the powder in that 
dimple is released when a patient inhaling through the device. Because the powder bed in 
the reservoir goes down gradually during usage, the density of powder in a dimple 
decreases and leads to a drug content drop. 
We believe that Turbuhaler® Oxis® can achieve its target delivery and meet the 
uniformity requirements, although the evaluation here shows a disappointing result. 
Nevertheless, it is doubtless that Turbuhaler® is difficult to operate for satisfying 
delivery uniformity. Chew et al also reported the problem of delivery efficiency and 
uniformity for Turbuhaler when they compared the Aerolizer® and Turbuhaler®[146]. It is 
inferred that the poor delivery performance is related to its formulation and 
filling/metering structure. Firstly, the Oxis® Turbuhaler® only contain 4.5 or 9µg API 
plus 450µg lactose, and Pulmicort® Turbuhaler® just contain 100 or 200µg API. The 
extremely small amount of powder makes it a huge challenge to fill and meter powder 
accurately. Secondly, the metering and filling mechanism of Turbuhaler® is greatly 
dependent on flowability of the formulation. A dose is loaded into a series of small holes 
in a dosing disc from the reservoir by twisting the base of the device backwards and 
 forwards, with a set of scrapers remov
of agglomerates, fragments 
the delivery uniformity. 
Figure 5.18:
When considering the FPF 
Clickhaler® Asmasal® have
Foradil® and Diskus® Seretide
described by Frijlink[140]. It i
to the formulation and inhaler device
powder prepared by ourselves, its FPF
Secondly, the particle size distribution 
sizing is carried out immediately after 
different FPF results. These
diffraction sizing, and the results a
particle size of Aerolizer® Foradil
Turbuhaler® Oxis®. Besides, the quantity of lactose would affect the FPF results. 
lactose used in Clickhaler® Asmasal
significantly less than single and multiple unit does inhaler
of a reservoir inhaler might make fine drug particles 
ing excess drug (Fig.5.18). Consequently, 
of agglomerates and remains in the dosing disk could affect 
 The schematic of air flow (blue arrow) and 
powder metering mechanism 
results, the reservoir devices, like Turbuhaler® Oxis
 a very high FPF (>40%) compared with 
® (~26%). The FPF results are similar 
s inferred that a high FPF of reservoir device i
s. First, when testing Aerolizer® 
 also reaches 50%, even higher than Clickhaler®.
from laser diffraction sizing. The laser diffraction 
inertial impaction tests to find the deeper reason of 
 four marketed DPI products are characterized by laser 
re shown in Fig.5.19, Fig.5.20 and Table
® and Diskus® Seretide® are much larger than 
®(~5mg) and Turbuhaler® Oxis
 (~30mg). Less lactose carrier 
easier to detach from lactose
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.5.10. The 
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® (450µg) is 
 carrier. 
 Figure 5.19: The 
Figure 5.20: The laser diffraction size result of Turbuhaler® Oxi
laser diffraction size result of Diskus® Seretide
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Table 5.10: The Laser diffraction size measurement results of  
the marketed products 
 X10 X50 X90 
Aerolizer® Foradil® 3 33 109 
Diskus® Seretide® 8 67 131 
Turbuhaler® Oxis® 0.6 2.1 5.0 
Clickhaler® Asmasal® 30 60 100 
The mouthpiece is the part connecting the inhaler to a patient, and it plays an important 
role in the device design. There are many researches about the influence of mouthpiece 
shape and geometry on inhaler performance[28; 31]. Coates et al studied the influence of 
mouthpiece geometry on the aerosol delivery performance of Aerolizer®. They found 
that the geometry had no effect on device retention or dispersion performance, but would 
affect the local deposition like throat deposition by changing the air flow velocity[147; 148]. 
It is not very common to compare the performance of inhaler device using the same 
powder. For one thing, it is difficult to fill and meter powder into the device like Diskus® 
and Turbuhaler®. On the other hand, the DPI product is usually considered as a whole 
system including device, formulation and filling system. The result of this chapter 
demonstrates that the Inhaler-WU2011 has better or similar performance as other 
marketed products using the same formulation. This conclusion lays a solid foundation 
for future R&D work in terms of both technology and confidence. 
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Chapter 6  
6  Evaluation of Dry Powder Filling Device 
6.1 Brief Introduction  
This chapter mainly focuses on the powder filling process. As shown in Fig.6.1, the 
uniformity of the filling is studied in the following sequence: A) the filling weight 
uniformity among disks, B) filling weight uniformity among blisters in a given disk, C) 
drug content uniformity among disks and D) drug content among blisters in a given disk. 
During the evaluation process, the filling operation and testing methods are improved 
continually. A vacuum-assisted filling and reduction of vibration strength are applied in 
the optimization of filling process, which are expected to improve drug content 
uniformity among blisters. 
 
Figure 6.1: A schematic diagram of the filling uniformity research 
 
 6.2 Uniformity of Dry Powder 
The powder filling techniques and 
uniformity experiment and method a
uniformity testing method i
helpful for future work. 
6.2.1 Filling weight uniformity among different disks
In Trial A-1, the quantity of 
subtracting the weight of a
uniformity was measured by the RSD of filling weight of several disks.
prepared by 10% fine sulfate 
Table 6.1 and Fig.6.2. An RSD of a
Table 6.1: The filling weight and uniformity of disks
 Filling weight mg
disk1 47.9
disk2 44.7
disk3 54.4
disk4 39.9
disk5 70 
disk6 32.3
Figure 6.2: The filling weight uniformity 
Filling Device 
equipment is detailed in Section 3.4.2, 
re introduced in Section 3.4.3. The deve
s not described before but in this chapter, and
  
all powder in 14 blisters in a disk was c
n empty disk from the disk filled with powder.
 The powder was 
Salbutamol and 90% Inhalac 230. The results a
bout 27% indicates a huge variance of filling weight.
 in Trial A
 AVG(mg) SD 
 
48.2 13.0 
 
 
 
 
between disks in Trial A
100 
and the filling 
lopment of 
 it is greatly 
alculated by 
 Then, the 
re shown in 
 
-1 
RSD 
27.0% 
 
-1 
 In Trial A-2, the filling process was improved by 
pockets every time before filling the next disk
6.2. As we can see, the filling uniformity is
weight can be explained by that the powde
variance becomes smaller. W
metering plate and is complicated 
samples, a downward trend i
is inferred that this problem is due to the testing method rather than filling device. 
the evaluating method for the uniformity of filling weight need to be 
Table 6.2: The improved uniformity of filling weight 
 M/mg
disk1 25.7
disk2 25.1
disk3 25.1
disk4 25.6
disk5 25.0
disk6 27.9
disk7 25.8
disk8 26.2
disk9 25.6
disk10 25.6
Figure 6.3: The improved uniformity of filling weight 
cleaning the metering plates and 
. The results are shown in Fig
 significantly improved. The decline of filling 
r with smaller density is applied and the 
hereas, this filling method would waste some powd
because of the cleaning procedure. When
s found despite of an acceptable RSD at 3.73%
further
between disks in Trial A
 AVG/mg SD/mg RSD% 
 
25.76 0.8369 3.25% 
 
 
 
 
 
 
 
 
 
between disks 
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.6.3 and Table 
er on the 
 testing more 
 as Fig.6.4. It 
Hence, 
 improved. 
-2 
 
in Trial A-2 
 Figure 6.4: The descending trend of fil
In Trial A-3, the drug disk was 
powder. Then each blister 
powder was cleaned away completely. 
the weight of a cleaned disk
3.4.3. Then, the number of 
analyzed at intervals. The results a
demonstrate excellent uniformity.
 
ling weight for 20disks in Trial A
immediately sealed with aluminum foil
in this disk was opened carefully without foil loss, and all 
The powder weight was calculated 
 through the disk filled with powder, as mentioned in Section 
the filled disks was increased to 100, and 17 disks were 
re shown in Table 6.3 and Fig.
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 after filling 
by subtracting 
6.5, and both 
 Table 6.3: The filling weight uniformity for 100 disks
Disk 
1 
2 
3 
11 
12 
13 
20 
30 
49 
50 
51 
52 
70 
90 
98 
99 
100 
Figure 6.5: The filling weight uniformity 
 in Trial A
M/mg AVG/mg SD/mg RSD% 
25.8  
27.8  0.726  2.61  
28.2  
28.5  
29.0  
28.3  
28.3  
27.7  
27.3  
28.3  
27.1  
28.0  
27.6  
27.7  
27.2  
28.3  
28.2  
27.7  
among 100 disks in Trial A
103 
-3 
 
-3 
 To evaluate the weight uniformity among disks when 
powders containing 0%, 5%, 10%, 20% fine lactose and corresponding Inhalac 230 were 
applied in Trial A-4. The result
the filling weight uniformity among
Moreover, the filling weight per disk 
more condense packing. 
Table 6.4: The filling weight uniformity of disks 
n＝50 
Filling weight 
per disk 
AVG（mg）
RSD％ 
Figure 6.6: The filling weight uniformity of disks 
6.2.2 Filling weight uniformity among blisters
The powder weight uniformity among 
uniformity. All blisters on a disk 
to the pockets on the metering pl
various powders were used, the 
s shown in Table 6.4 and Fig.6.6 clearly demonstrate
 disks for different powders is quite excellent. 
goes up with increasing fine lactose, as a result of 
using different powders
in Trial A-4 
0%-fines 5%-fines 10%-fines
 25.6 29.4 30.3 
3.18 1.28 1.23 
using different 
powders in Trial A-4 
 on one disk
blisters was a prerequisite for the 
were numbered sequentially according to 
ates. Thereby, it was possible to find out 
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 that 
  
 20%-fines 
30.4 
1.81 
 
 
 
delivered dose 
their position 
a pattern of 
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filling weight for blisters. Initially, the quantity of powder in a blister was calculated by 
subtracting the weight of the disk through its original one after emptying a specific blister. 
The powder comprising 10% sulfate Salbutamol and 90% Inhalace 230 were prepared for 
this filling uniformity test. 
After filling powder, a drug disk was weighed to get M14, where 14 represented 14 
blisters. After that, a blister on this disk was opened carefully without foil loss, and the 
powder was cleaned away completely, and then the weight of the disk M14-1 was obtained. 
The filling weight m1 for this blister (1) was calculated. Similarly, filling weight for other 
blisters (i) was acquired in the same way. 
 
The result of Trial B-1 is shown in Fig.6.7 and Table 6.5. At the first glance, the 
fluctuation of filling weight for the blisters 1-14 seem to be still acceptable in Fig.6.7 
with a SD of about 0.2 mg. Yet, its variation is rather significant actually since the target 
filling weight is very small. Then, if we consider the uniformity of all blisters from 5 
disks, the RSD of 17.8% indicates a unsatisfactory uniformity. As we can see in Table 
6.5, the RSD of disk1-5 is from 9.6% to 25%. Those results demonstrate that the 
uniformity among blisters in single disk also need to be improved. Additionally, if we 
look at the rows of the table, the quantity of powder metered by the same pocket also 
exhibit great variance. 
  
)141(1415 ££-= -- iMMM iixb
 Table 6.5: The initial filling weight uniformity of blisters
 disk1/mg disk2/mg
blister1 2.1 
blister2 1.7 
blister3 1.6 
blister4 2 
blister5 1.8 
blister6 1.9 
blister7 2.2 
blister8 1.2 
blister9 1.6 
blister10 1.8 
blister11 2 
blister12 1.8 
blister13 1.4 
blister14 1.5 
AVG/mg 1.81 
RSD% 9.6% 
Figure 6.7: The initial filling weight uniformity of 
 Trial B
 disk3/mg disk4/mg disk5/mg 
1.9 1.9 2.1 1.8 
1.8 1.3 2.2 2.2 
1.6 1.9 1.9 1.6 
1.9 1 2 2 
2.1 2.7 1.9 2.1 
1.8 1.9 2 1.8 
1.7 2.1 1.9 1.8 
1.6 1.6 2.1 2.7 
1.9 1.4 1.5 1.3 
1.7 2 2.2 2.3 
1.6 1.4 1.9 1.9 
2 1.8 1.5 1.5 
2.1 2.4 2.4 2.3 
1.7 1.4 1.6 1.4 
1.76 1.77 1.94 1.91 
15.9% 25.9% 13.7% 20.5% 
sequentially numbered 
blisters in Trial B-1 
106 
-1 
Avg RSD 
1.96 6.9% 
1.84 20.6% 
1.72 9.6% 
1.78 24.6% 
2.12 16.5% 
1.88 4.5% 
1.94 10.7% 
1.84 31.4% 
1.54 15.0% 
2 12.8% 
1.76 14.3% 
1.72 12.6% 
2.12 19.8% 
1.52 8.6% 
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In Trial B-2, we tried to change the powder based on an assumption that the improvement 
of powder flowability would be helpful for the filling uniformity. Hence, the powder was 
prepared by 5% fine sulfate Salbutamol and 95% Inhalac 230. 
The result presented in Table 6.6 and Fig.6.8 shows a slight improvement when 
compared with Trial B-1. The RSD for 42 blisters from 3disks is 15%, a little lower than 
the former result. The maximum RSD for single disk is 17%, which is a little better. Yet, 
the uniformity is not satisfactory. It is guessed that the variance is also from testing, and 
the evaluating method is improved in Trial B-3. 
Table 6.6: The filling weight uniformity among blisters for the powder with 
improved flowability in Trial B-2 
 disk1/mg disk2/mg disk3/mg AVG/mg RSD% 
blister1 1.95 1.74 1.27 1.65 21.06% 
blister2 1.64 1.63 1.65 1.64 0.61% 
blister3 1.44 1.71 1.43 1.53 10.41% 
blister4 1.4 2.01 1.63 1.68 18.34% 
blister5 1.51 1.46 1.57 1.51 3.64% 
blister6 1.26 1.53 1.3 1.36 10.69% 
blister7 1.3 1.3 1.56 1.39 10.83% 
blister8 1.33 1.28 1.08 1.23 10.76% 
blister9 1.05 1.48 1.49 1.34 18.75% 
blister10 1.48 1.69 1.32 1.50 12.40% 
blister11 1.45 1.2 1.31 1.32 9.49% 
blister12 1.49 1.2 1.2 1.30 12.91% 
blister13 1.22 1.24 1.19 1.22 2.07% 
blister14 1.23 1.17 1.64 1.35 19.00% 
AVG/mg 1.41 1.47 1.40   
RSD% 15.3% 17.4% 13.5%   
 Figure 6.8: The filling weight uniformity among
improved flowability
In Trial B-3, empty PVC disks 
filling. When filled with powder, the disks 
Then, the blisters were opened 
weighed. 
The results are shown in Table
while rows stand for corresponding blisters
electricity and sealing greatly 
RSD for 84 blisters from 6 
The maximum RSD for one disk i
enhanced uniformity. 
 
 blisters for the powder with
 in Trial B-2. 
were treated by an antistatic fan for 10min before powder 
were sealed with alumina foil by hot
sequentially and cleaned by vacuum pump, and were 
 6.7. The columns represent all 14 blisters on one disk, 
 from different disks. The eliminat
increase the uniformity of filling weight per 
disks is 7.5%, nearly half of the value of the above research
s 9%. The obvious decline of RSD indicate
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-pressing. 
ion of static 
blister. The 
. 
s an 
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Table 6.7: The improved filling weight uniformity of blisters in Trial B-3 
  1st/mg 2nd/mg 3rd/mg 4th/mg 5th/mg 6th/mg AVG/mg RSD% 
blister1 1.84 1.72 1.9 1.79 1.91 1.5 1.78 8.6% 
blister2 1.66 1.52 1.41 1.66 1.43 1.55 1.54 7.0% 
blister3 1.84 1.97 1.73 1.62 1.72 1.49 1.73 9.7% 
blister4 1.67 1.75 1.59 1.63 1.89 1.73 1.71 6.2% 
blister5 1.83 1.65 1.81 1.96 1.63 1.83 1.79 7.0% 
blister6 1.8 1.64 1.52 1.75 1.78 1.74 1.7 6.2% 
blister7 1.63 1.67 1.8 1.69 1.65 1.68 1.69 3.5% 
blister8 1.64 1.9 1.88 1.71 1.68 1.62 1.74 7.0% 
blister9 1.57 1.68 1.9 1.78 1.72 1.76 1.73 6.3% 
blister10 1.61 1.73 1.62 1.72 1.73 1.58 1.67 4.1% 
blister11 1.71 1.56 1.5 1.6 1.56 1.67 1.6 4.9% 
blister12 1.31 2 1.75 1.75 1.79 1.65 1.71 13.3% 
blister13 1.72 1.88 1.79 1.74 1.72 1.77 1.77 3.4% 
blister14 1.82 1.68 1.8 1.69 1.66 1.63 1.71 4.6% 
AVG/mg 1.69 1.74 1.71 1.72 1.71 1.66 1.7 1.7% 
SD/mg 0.14 0.15 0.16 0.09 0.12 0.1     
RSD% 8.5% 8.4% 9.3% 5.3% 7.2% 6.2%     
Finally, the test method in Trial B-4 was determined as the final version: After filling 
powder, the drug disk was sealed with aluminum foil and all blisters were numbered. 
Then a blister was cut off and weighed. Next, this blister was opened carefully without 
foil loss, and the powder was rinsed by solvent completely. After air dry, the weight of 
the empty blister was obtained. The quantity of powder was calculated by subtracting the 
weight of an empty blister from its original weight.  
The result of Trial B-4 is presented in Table 6.8. The RSD of total 42 blisters is 7.5% and 
maximum RSD of blisters in single disk is 8.1%, which exhibit a further RSD decline and 
improved uniformity. As shown in Fig.6.9, the filling weight for the sequentially 
numbered blisters show a very similar trend for all the 3 disks. This result indicates that 
the filling weight from the same metering pocket is similar, which is also reflected by the 
relatively lower RSD of each row in Table 6.8. The “consistent” variation of the filling 
 weight is possible due to a variance of the metering pockets size. In the future, the 
metering plate will be drilled by
Table 6.8: The final
 1st/mg
blister1 2.28 
blister2 2.16 
blister3 1.97 
blister4 2.33 
blister5 2.06 
blister6 2.14 
blister7 2.22 
blister8 2.25 
blister9 2.13 
blister10 2.03 
blister11 2.08 
blister12 1.88 
blister13 1.91 
blister14 2.22 
Avg 2.12 
RSD 6.5% 
Figure 6.9: The final filling weight uniformity of blisters
 laser, and such variance may be reduced. 
 filling weight uniformity of blisters in Trial B
 2nd/mg 3rd/mg Avg
2.39 2.19 2.29
2.06 1.91 2.04
2 1.86 1.94
1.99 1.98 2.10
1.88 1.94 1.96
1.92 2.29 2.12
2.21 2.14 2.19
2.15 2.18 2.19
2.02 2.18 2.11
1.79 1.94 1.92
1.9 1.91 1.96
1.87 1.8 1.85
2.05 1.87 1.94
2.22 2.11 2.18
2.03 2.02 
 
8.1% 7.6%  
 in Trial B
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 RSD 
 4.4% 
 6.2% 
 3.8% 
 9.5% 
 4.7% 
 8.8% 
 2.0% 
 2.3% 
 3.9% 
 6.3% 
 5.2% 
 2.4% 
 4.9% 
 2.9% 
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6.2.3 Drug content uniformity among different disks  
After powder filling, the drug content of single disk was measured In Trial C-1 by rinsing 
the powder of all blisters into a certain volume of solvent first, and then analyzed by 
HPLC. The uniformity was evaluated by the RSD of drug content. Disk1, Disk5, Disk10, 
Disk15, Disk20 and Disk25 were sampled from a series of disks. The powder was 
prepared by 0.74% sulfate Salbutamol, 10% fine lactose as additives and ~90% Inhalac 
230.  
The result is shown in Table 6.9 and Fig.6.10. As we can see in Table 6.9, the RSD of 
filling weight is quite small but the RSD of drug content and percentage of API per disk 
are obviously larger. This table clearly shows that the drug content uniformity is worse 
than weight uniformity.  
Table 6.9: The drug content uniformity among disks in Trial C-1 
Disk No Filling weight (mg) Drug content (ug) API percentage% 
disk1 28.7 251.2 0.88% 
disk5 29 220.9 0.76% 
disk10 29.1 200.7 0.69% 
disk15 28 195.6 0.70% 
disk20 29 199.0 0.69% 
disk25 29.2 226.0 0.77% 
AVG 28.8 215.6 0.75% 
RSD 1.5% 6.69% 9.79% 
 Figure 6.10: The filling drug content uniformity among disks
To investigate the reasons for the 
carried out. First, the filling weight 
variation was the cause of content deviation or not.
The filling weight of those 25 disks is
excludes the possibility that the drug content variation 
the uniformity of the bulk powder blend was evaluated by
The results are shown in Table
is quite uniform, implying 
heterogeneous bulk blend. 
Table 6.10: The blend content uniformity of the tested powder 
 
Blend 1 
Blend 2 
Blend 3 
Blend 4 
Blend 5 
Blend 6 
Blend 7 
Blend 8 
 in Trial C
high RSD of drug content, two experiment
of Disk 1-25 was measured to ascertain
 The results are shown 
 rather uniform with an RSD at 1.85%, which 
is caused by filling weight. 
 analyzing 8 random samples. 
 6.10. The RSD of 1.77% demonstrate that 
that variation of drug content per disk is not 
in Trial C
API percentage AVG% RSD%
0.73% 
0.74% 1.77%
0.72% 
0.76% 
0.74% 
0.74% 
0.74% 
0.75% 
0.74% 
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s were 
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in Fig.6.11. 
Second, 
the bulk blend 
resulted from 
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 Figure 6.11: The filling weight uniformity of the disks fo
In Trial C-2, 100 disks are analyzed and the uniformity is
uniformity declined as shown in 
for 25 disks, the uniformity 
6.7% to 18%. As shown in Fig.
average. Similarly, the percentage of 
17%. Nevertheless, if disre
uniformity would reach about 10%. 
beginning of the filling process, because the filling device 
working state immediately at the beginning.
 
r content uniformity 
evaluation in Trial C-1. 
 evaluated every 10 disks, 
Table 6.11. Compared with the drug content uniformity 
of API content exhibits a disappointing drop from 
6.12, two content points are even outside the 
API also shows a strange variation with 
garding the first point, then the RSD of drug content 
This result suggests us to give up several disks at the 
may not achieve a stable 
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the 
an RSD of 
±25% of the 
an RSD of 
 Table 6.11: The drug content uniformity for 100 disks
Disk No Filling
Disk1 
Disk 11 
Disk 20  
Disk 30  
Disk 50  
Disk 70  
Disk 90  
Disk 100  
AVG 
RSD 
Figure 6.12: The drug content uniformity 
Similarly, the reason for the 
aspects. The filling weight uniformity of disks 
result demonstrates an excellent uniformity of filling weight with
3%. Therefore, this result excludes
in the large RSD of drug content. 
It also shows a good uniformity of the 
 in Trial C
 weight (mg) API content (µg) API percentage%
25.8 105.61 0.41% 
29 177.15 0.61% 
27.7 166.93 0.60% 
27.3 172.04 0.63% 
27.1 173.75 0.64% 
27.7 221.44 0.80% 
27.2 166.93 0.61% 
27.7 172.04 0.62% 
27.4 169.5 0.62% 
3.2% 18.5% 17.1% 
between 100 disks in Trial C
less satisfactory uniformity is also investigated 
is shown in Fig.6.5 and Table
 an RSD smaller than 
 the possibility that variation of filling weight results 
The blend content uniformity is presented in Table
bulk powder blend, implying 
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 6.3. The 
 6.12. 
that the 
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unsatisfactory drug content uniformity among disks is not caused by heterogeneity of this 
blend. 
Table 6.12: The blend content uniformity of the tested powder in Trial C-2 
 Drug percentage% AVG RSD% 
Blend 1 0.71 
0.69% 1.19 
Blend 2 0.7 
Blend 3 0.69 
Blend 4 0.69 
Blend 5 0.7 
Blend 6 0.69 
Blend 7 0.7 
Blend 8 0.68 
Finally, the measurement method of drug content uniformity was determined in Trial C-3 
as follows: After filling powder, a drug disk was sealed with aluminum foil. Then all 
blisters on this disk were opened carefully without foil loss, and the powder was rinsed 
into waters of designated volume. After complete drug dissolution, the solution was 
analyzed by HPLC to obtain the drug concentration. Similar as mentioned above, 4 kinds 
of powder containing 0%, 5%, 10%, 20% fine lactose and corresponding Inhalac 230 
were prepared and 50 disks were filled with those powders.  
The result is shown in Table 6.13. The drug content uniformity among disks is improved 
significantly, since all RSD values of drug content for 4 powder compositions are near or 
smaller than 5%. With increasing fine lactose, the drug content also shows an obviously 
ascending trend as Fig.6.13. The growth of drug content per disk is directly attributed to 
an increase of filling weight per disk. As shown in Fig.6.14, the coefficient of regression 
between drug content and powder weight is close to 0.95, indicating a strong linear 
relation. 
Table 6.13: The drug content per disk for different powders in Trial C-3 
 0%-fines 5%-fines 10%-fines 20%-fines 
Drug content per 
disk (n＝6) 
AVG (µg) 139.3 175.1 194.7 200.6 
RSD 5.66% 2.74% 3.54% 2.87% 
 Figure 6.13: The drug content per disk
Figure 6.14: The linear relationship between drug content and 
 (n=6) for different powders in Trial C
filling powder 
per disk in Trial C-3 
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6.2.4 Drug content uniformity among blisters on one disk 
After evaluating uniformity for filling weight per disk, filling weight per blister, drug 
content per disk as discussed above, the uniformity work is then focused on the core part 
and the most difficult one — the uniformity of drug content among blisters. 
In Trial D-1, a drug disk was sealed with aluminum foil after powder filling. Each blister 
was cut off from the disk and weighed separately. Next, each blister was opened carefully 
without foil loss, and the powder was rinsed into water of a designated volume. Then the 
solution was analyzed by HPLC to get the drug concentration, and the drug content for 
each blister was calculated from concentration and the solvent volume. At first, the 
powder containing 10% fine lactose and 90% Inhalac230 was prepared and applied for 
this uniformity test. 6 blisters were taken from each disk randomly, and 3 disks were 
analyzed.  
The result of Trial D-1 is shown in Table.6.14. The RSD of drug content in blisters is 
from 14.1% to 17.7%. Meanwhile, the total RSD for all 18 blisters is 15%, but the RSD 
of filling weight between blisters is only 4.63%. It is noteworthy that the number of 
blister here is not related to the sequence in the disk but a random order. 
Table 6.14: The drug content uniformity among blisters 
 disk1 disk2 disk3 
blister1 11.1 15.3 16.2 
blister2 16.1 15.4 15.8 
blister3 16.4 15.1 10.6 
blister4 13.8 11.7 15.0 
blister5 15.9 17.4 11.0 
blister6 16.2 11.6 14.7 
AVG 14.9 14.4 13.9 
RSD 14.1% 15.8% 17.7% 
Then, in Trial D-2, powders with different ratios of fine lactose were tested to investigate 
the influence of powder composition on drug content uniformity among blisters. 6 
blisters were taken from one disk randomly, and 3 disks were analyzed for each powder.  
 The result is summarized in Table
blisters for all powders are ab
Table 6.15: The 
 
Drug content per 
blister（n＝18） 
AVG（
RSD
Figure 6.15: The drug content 
disks)
If the drug content per blister for 
shown in Fig.6.16 and Fig.6.1
per blister for 0%- and 5%-fines powder a
powder shows a smaller RSD than 
upper and lower boundary.
presented in Fig.6.17, the 10%
on or even outside the boundary
boundary than 10%-fines. 
would have an influence on the drug content uniformity among blisters.
 6.15 and Fig.6.15. The RSD of drug content 
ove 10%, and the 10%-fines shows the worst uniformity. 
drug content uniformity among blisters for 
different powders in Trial D-2 
0%-fines 5%-fines 10%-fines 
ug） 9.84 12.54 13.17 
％ 10.07 12.48 17.48 
per blisters (6 random blisters from each of the
 for different powders in Trial D-2. 
the 4 powders is investigated in detail, the results a
7. As we can see from these two figures, the drug content 
re in the range of average±25%
5%-fines as Table.6.15, but it has two
 Consequently, the 5%-fines is better than 0%
-fines shows the most obvious variance with several 
. The 20%-fines powder has fewer points
From these results, it is inferred that the powder property 
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20%-fines 
14.29 
14.83 
 
 3 
re 
. The 0%-fines 
 points on the 
-fines. As 
points 
 on the 
 Figure 6.16: The drug content per blister 
for 0%-
Figure 6.17: The drug content per blister
for 10%-
 
(6 random blisters from each of the 
fines and 5%-fines powder in Trial D-2 
 (6 random blisters from each of the 
fines and 20%-fines powder in Trial D-2 
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3 disks) 
 
3 disks) 
 The emitted dose from Inhaler
uniformity (DDCU) for those 4 powders
When comparing RSD of emit
blisters, the RSD of emitted dose increase
result means that the vari
nonhomogeneity in filling process and t
According to US or European pharmacopeias, it is
of at least 9 of 10 doses collected from one inhale
target-delivered dose. Theref
Fig.6.19, we might conclude
fail because 1 of 6 doses is outside the 
boundaries. Meanwhile, 5%
only several points approaching 
Table 6.16: The delivered drug
  
Delivered drug 
content per blister 
（n＝6） 
AVG
RSD
Figure 6.18: The delivered drug content uniformity for 0%
-WU2011 is studied for the delivered 
.  
ted dose with corresponding RSD of drug content 
s by 1~2% except for 0%-fines powder
ance of delivered drug content is mainly due to the 
he inhaler does not greatly increase this variance.
 usually required that the drug content 
r should be within 75%
ore, according to the results presented in Fig.
 that the 0%-fines and 10%-fines powder are very likely to 
acceptable range and several points approach
 and 20%-fines powder are a little better, because 
the limits and no point outside of the range
 content uniformity for different powd
0%-fines 5%-fines 10%-fines
（ug） 7.25 10.23 12.01
％ 17.02 14.76 18.85
-fines 
and 5%-fines powder 
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drug content 
among 
. This 
 
- 125% of the 
6.18 and 
 the 
there are 
.  
ers  
 20%-fines 
 10.02 
 15.92 
 
 
 Figure 6.19: The delivered drug content uniformity for 10%
In order to further investigate the reason for 
an experiment (Trial D-3) wa
each blister was numbered according 
sequentially for corresponding 
rinsing and HPLC analysis. 
blisters was obtained and recorded
calculated from the API content and 
sulfate Salbutamol, 10% fine lactose 
And 42 blisters from 3 disks w
As shown in Fig.6.20, the first blister usually has
and Blister 10-13 experience
blisters is studied to find out the reason for
for those blisters is presented in Fig.
filling weight happens for Blister 10
content is not due to filling weight change. 
blister is calculated and presented in Fig.
-
and 20%-fines powder 
less satisfactory uniformity among blisters, 
s carried out as follows: After powder filling and sealing, 
to their position and the number was fixed
position. Similarly, the drug content was 
At the same time, the filling powder weight of corresponding 
. And the API percentage of each blister was also 
powder weight. The powder comprised of
plus ~90% Inhalac 230 was used in this experiment. 
ere analyzed. 
 more drug content than other blisters 
 a strange and sudden drop. Then the filling weight for th
 the sudden content drop. The fill
6.21. As we can see in Fig.6.9, no ob
-13. This result indicates the abrupt decline
Following that, the drug percentage of each 
6.21, which also shows a drop for Blister 10
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Figure 6.21: The drug percentage for the sequentially numbered blisters in each of 
Then a picture of filling powder i
content and percentage, as shown in Fig.
corresponding to Blister 1-
for the sequentially numbered blisters in each of the 3 
disks of Trial D-3.  
the 3 disks of Trial D-3. 
s taken to study the reason for the abrupt drop
6.22. As we can see from Fig.6.2
8 and 14 form a cone on the paper, but the pow
122 
 
 
 of drug 
2, the powders 
ders from 
 Blister 9-13 are dispersive, especially for 
the drop of drug content and percentage for those blisters
Blister 10-12 are rather dispersive, 
result in a lower content. More discussion is presented in Section 6.3.2 and Section 6.3.3.
Figure 6.22: The 
6.2.5 Drug content uniformity of blen
During the filling process, it i
uniform. Because of mechanical stirring or other operation, 
experience stratification to 
uniformity was validated by taking samples from the top, middle and bottom of 
powder chamber for HPLC analysis when 10, 30 and 50 disks were filled.
The result is shown in Table
positions but the same time 
points. As we can see, the u
points. The uniformity in terms of sampling position
uniformity in the filling process does
uniformity among disks and blisters.
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Table 6.17: The blend content uniformity during filling process 
API percentage After 10disks After 30disks After 50disks AVG RSD 
Top 0.58% 0.59% 0.60% 0.59% 1.69% 
Middle-1 0.60% 0.59% 0.58% 
0.59% 3.03% 
Middle-2 0.62% 0.58% 0.57% 
Bottom-1 0.60% 0.60% 0.57% 
0.59% 2.81% 
Bottom-2 0.57% 0.57% 0.60% 
AVG 0.59% 0.59% 0.58% 
 RSD 3.3% 1.9% 2.6% 
6.3 Optimization of Dry Powder Filling process 
6.3.1 Minimization of electrostatic charge  
The quantity of electricity on a PVC disk is determined by a Faraday pail. After treatment 
of a PVC disk with an anti-static fan, the quantity of static electricity decreases from -
20nc to -0.4nc. Meanwhile, the charge-mass ratio is 0.4~0.8nc/g for powders, which is 
rather small for several milligrams of powder. 
A comparison of filling using antistatic and normal PVC is presented in Fig.6.23. The 
result clearly shows the necessity to minimize static electricity before filling. A careful 
observation on the particles dispersing on the disk surface reveals that all particles first 
fall into the blisters but then “jump out” if the disks are not treated by the antistatic fan. 
As we can see from the picture, the elimination of electrostatic charge significantly 
reduce the particles outside of the blisters. It is helpful to improve the drug content 
uniformity among blisters, since small particles like drug particles are more likely to 
“jump out” the blisters. Consequently, all PVC disks are treated by the antistatic fan for 
10min before powder filling. 
 Figure 6.23:
The electrostatic charge not only influences
delivery performance, although this effect was much smaller. The TI
tests are carried out by using disks with/wit
in Fig.6.24. Although the FPF
antistatic disks, the blister remains result
the untreated disks represents 
be explained by that when particles a
performance would not be influenced by the electrical property of 
the PVC package with a high electrostatic charge
between particles and package.
Generally, the higher blister remains result than other results in this chapter is caused by 
lower flow rate (30LPM) used here. 
 The comparison of filling disks with (a) or  
without antistatic treatment (b) 
 the powder filling, but also affect
 (Twin impinger)
hout an antistatic process. The result is
 (fine particle fraction) values are the same for
 shows difference. The higher blister remains
more API particles left in the blisters. The phenomenon 
re delivered out from the inhaler, its aerosol 
the package
 would increase the adhesion forc
 Hence, the fraction of the API left in blister goes up
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6.3.2 The role of vacuum in 
As described in Section 3.4.2
metering pockets. Consequently, vacuum wa
results. During the mechanical st
pressure through a tube under the powder chamber. Th
metering pockets as a result of stirring and neg
turned off and the metering plate 
rate of vacuum pump was set to 30
The result of drug content uni
see, the fluctuation of drug conten
Especially for the Blister 1 and Blister 14
level. The good news is that the drug cont
obvious as filling without vacuum. 
Similarly, the drop of API percentage 
 The influence of electrostatic charge on the 
TI performance of the inhaler 
the powder filling 
, vacuum can be applied to help powder flow into 
s applied to study its influence on filling 
irring, a vacuum pump was turned on to form a
e powder would flow into the 
ative pressure. After that, the vacuum was 
slid out to transfer the powder to drug disks. The 
 LPM. 
formity among blisters is presented in Fig.6.2
t among blisters is similar to the results of no vacuum
, the drug content is higher than 
ent drop of Blister 10-12 seems
The drug percentage result is shown
for Blister 10-12 is also reduced. 
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 not to be as 
 in Fig.6.26. 
 Figure 6.25: The 
Figure 6.26: The drug percentage per
A picture of filling powder 
in Fig.6.27, the dispersive state of powder in Blister10
improvement. 
drug content per blister by filling with vacuum
 blister by filling with vacuum
is compared with the filling without vacuum. 
-12 does not show
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As we can see 
 any obvious 
 Figure 6.27: The comparison of filling powder w
Table 6.18 is a summary of comparison between filling with and without vacuum. 
uniformity results, including filling weight, dru
improved when compared with filling without va
that the powders in the metering pockets beco
Therefore, the possibility of 
particles during the powder transfer fr
Table 6.18: The 
  Filling weight (
  
dis
Without vacuum 
AVG 2.12
RSD% 6.50
With vacuum 
AVG 2.26
RSD% 5.76
The application of vacuum in the powder filling also affect
Inhaler-WU2011. The drug disks fil
Impinger) impaction and the results
in Table 6.19, the FPF of filling with 
ith (a) without vacuum
 and (b) with vacuum 
g content and drug percentage a
cuum. The higher filling weight implies 
me tighter as a result of negative
fine particles flying out decrease, and the loss of fine 
om metering pockets to blisters declin
summary of the comparison results for filling 
with or without vacuum 
mg) Drug content (ug) Drug percentage (
k1 disk2 disk3 disk1 disk2 disk3 disk1 
 2.03 2.02 13.57 13.01 13.06 0.64 
 8.09 7.65 12.06 15.48 12.21 7.29 
 2.29 2.19 16.37 16.27 14.33 0.72 
 5.83 5.37 11.85 10.78 11.68 6.50 
s the FPF performance of the 
led with/without vacuum are tested by the TI
 are shown in Fig.6.28 and Table 6.19.
the vacuum is slightly lower than filling without 
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 As we can see 
 vacuum. It is easy to understand that the particles 
compact and therefore somewhat more 
Figure 6.28: The FPF and blister remains
Table 6.19: The FPF and blister remains 
 
FPF-AVG 
SD 
Remains-AVG 
SD 
6.3.3 The role of reducing vibration intensity
The research results reported 
related to the powder dispersion or f
reasonable assumption that reducing the undesired dispersion would 
uniformity. For example, increasing the tightness 
proven useful. Hence, a reduction of
applied to verify this assumption.
filled with vacuum would become more 
difficult to disperse during aerosolization
 of filling powder with or without vacuum.
results of filling powder
 with or without vacuum. 
Vacuum No-
25.4% 27.6%
0.4% 1.7%
9.5% 8.8%
0.6% 0.2%
 in the powder filling
above demonstrate that the drug content uniformity i
light during the filling process. Therefore
of powder in metering pockets 
 vibration intensity during the powder transfer
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 The filling powders with reduced vibration intensity 
improvement in the powder dispers
each metering pocket form a cone rather than 
Figure 6.29: The picture of the filling powder for each blister wit
The results of drug content uniformit
Fig.6.31 respectively. As we can
10, 12 are still a little lower 
Figure 6.30: The drug content per blister of filling with reduced vibration intensity 
are shown in Fig.
ion of Blister 10-12 is observed, since
a dispersed state.  
 
 reduced vibration intensity 
y and drug percentage are shown in Fig.
 see, although the drug content and percentage 
than other blisters, the gap is reduced.  
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 Figure 6.31: The drug percentage
The RSD of filling with normal vibrat
results are presented in Table
content and percentage per blister for 
than normal filling. The results indicate the uniformity beco
abrupt drop of drug content and percentage for Blister 10
powder filling is carried out b
following formulation research
Table 6.20: The 
 
Filling weight per 
blister(
disk1 dis
Normal 
vibration 
RSD
% 5.8 
Reduced 
vibration 
RSD
% 10.1 
 per blister of filling with 
reduced vibration intensity 
ion and the reduced vibration are compared and the 
 6.20. As we can see, the RSD of filling weight, drug 
filling with the reduced vibration are much higher 
me even worse, a
-12 is improved
y normal vibration rather than the reduced vibration
. 
summary of RSD results for filling with 
normal or reduced vibration 
mg) 
Drug content per blister 
(ug) Drug percentage (
k2 disk3 disk1 disk2 disk3 disk1 
5.8 5.4 11.9 10.8 11.7 6.5 
8.0 12.8 17.5 15.0 15.3 10.6 
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6.3.4 The flowability range suitable for the powder filling 
In the filling experiment, the flowability of powder is important to the powder filling and 
has to be within a certain range. Specifically, if the flowability is so good, the powder in 
the metering pockets might fall out easily during the sliding of metering plate. On the 
contrary, if the flowability is too bad to flow into the metering pockets, it may result in 
poor uniformity. Meanwhile, the powder might be too cohesive to fall from metering 
pockets into the blisters by a normal vibration. If a stronger vibration is applied, the 
particle dispersion and flying away might be more serious. Consequently, a series of 
blends with different flowability (shown in Table 6.21) are prepared and filled by the 
filling machine. Then the upper and lower limit of flowability suitable for filling are 
established.  
Table 6.21: The composition and flowability of Blends for filling tests 
samples composition Compression index 
Blend-1 0.72%API+LH200(<45µm)+30% fine lactose 49.07% 
Blend-2 0.72%API+Inhalac230(<45µm) 44.33% 
Blend-3 0.72%API+Inhalac230(45-75µm) 22.06% 
Blend-4 0.72%API+Inhalac230(75-100µm) 19.23% 
Blend-5 0.72%API+Inhalac230(100-150µm) 18.28% 
Based on a careful observation on the filling process, the Blend-1 is difficult to fall into 
blisters in a drug disk and Blend-4 tends to fall out prematurely during the sliding of the 
metering plate. Therefore, an approximate flowability range suitable for filling might be 
20% to 45% (presented as Compression index). 
6.4 Discussion  
An accurate and reproducible powder filling is a prerequisite for formulation research. 
Therefore, a powder filling system and uniformity evaluating method are established and 
developed step by step. The principle of filling is volumetric metering, which is faster 
than metering by weight. There is no direct displaying of filling weight or automatic 
feedback system to control filling quantity and the micro-dose filling is a big challenge 
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for pharmaceutical industry. Consequently, the accuracy and precision of this new filling 
system require to be validated.  
There is an inherent logic in the evaluation of filling uniformity where each step is the 
prerequisite for the next. Thereby, the uniformity test is carried out by the following 
sequence: 1) filling weight per disk, 2) filling weight per blister, 3) drug content per disk 
and 4) drug content per blister. The most important uniformity is the last one, drug 
content uniformity among blisters which is directly related to treatment effect for the 
patients. The other three kinds of uniformity not only serve to ensure the last uniformity, 
but also provide an insight for good or poor drug uniformity among blisters. As these 
results demonstrate, although the drug content per blister is not very uniform, the possible 
reasons such as variances of filling weight and blend content are excluded. Theoretically, 
the drug content per blister should be calculated as 
Drug content per blister=Filling weight per blister* Drug percentage 
According to an error calculation method, the relative error of drug content can be 
calculated as,  
The E stands for relative Error which is represented by the RSD. The results show that 
the RSD of drug content per blister is higher than a theoretical calculation from the above 
equation. Consequently, it is inferred that other unknown factors would greatly affect the 
drug content per blister. The most likely reason is later inferred as a dispersion or flying 
away during the powder falling out from the metering pockets. 
The filling weight uniformity can serve as an intermediate quality control, since the 
analysis of drug content is rather complicated. This result suggests us to carry out much 
easier and convenient filling weight tests first. In the section 6.2.1 and 6.2.2, the filling 
and test methods are modified gradually to the final version. There are many 
improvements during the method development, and the elimination of electrostatic 
charge is an impressive one. The electrostatic charge would result in the powder 
“jumping out” the blisters or flying away. Even worse, it may cause instability of the 
222
percentageweightfillingcontentdrug EEE += ××
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weighing balances. The weight of an empty PVC disk is tested by two balances (AB135-S 
and AL104).  
The results are shown in Table 6.22. As we can see, a SD value of about 4mg seems to be 
rather small to the weight of a disk. Yet, the 4mg of SD value can not be neglected when 
we calculate a filling weight, because the filling weight is 20-30mg per disk and 2-3mg 
per blister. At first, we acquire the filling weight by subtracting an empty disk from a 
filled disk. But this result fluctuates randomly as a result of balance instability. 
Consequently, this easy method is discarded but a complex test procedure is set up which 
includes sealing the disks with aluminum foil before the following operations. The 
sealing of aluminum foil not only protects powder from dispersing, but also stabilizes the 
weight reading on a balance. 
Table 6.22: The weight variance of a PVC disk  
 AB135-S AVG (g) SD (g) 
1 2.99796 
3.0020 0.0041 2 3.00184 
3 3.00612 
 
AL104 AVG (g) SD (g) 
1 2.9790 
2.9824 0.0041 2 2.9811 
3 2.9870 
The antistatic fan whose principle is shown in Fig.6.32, is used to reduce the electrostatic 
effect during filling process. The experiment result shows that the antistatic treatment is 
important for the filling uniformity as Fig.6.23. The particles deposit on the surface rather 
than in blisters may influence the sealing effect. The bumps as a result of particles on the 
surface would provide passage for air and moisture. The electrostatic measurement shows 
that the charge of powder is much smaller than the charge of PVC disk. It also explains 
why the particle-PVC interaction is more significant than particle-particle in the TI (Twin 
Impinger) test. Commonly, there are several methods to control the electrostatic charge of 
powder. The first one and most effective one is to increase environment humidity, but it 
is not suitable for DPIs since moisture may bring about stability problems. The second 
one is to keep the powder still for some time and allow electrostatic charge to dissipate. 
 Other methods such as additives would not be considered 
Consequently, it is very essential 
much as possible. Besides, 
each experiment and allow the freshly prepared powder to rest for some time.
Figure 6.32: The 
Although the uniformity of drug content per blister does
RSD<5%, some useful information 
applying a vacuum in the filling p
can be explained by that powder
keeps fine particles from “jump
metering pockets to blisters.
within a reasonable range. 
vibration is required for the powder transfer. The intensive vibration
undesirable dispersion of fine particles during transfer
Research result also shows that
powder become better than before
powder transfer is reduced. 
and other uniformity results 
result might be explained by 
to metering pockets.  
because of safety concern. 
to eliminate the electrostatic charge of PVC disk
it is recommended to monitor the environment
 
schematic of principle of an antistatic fan
 not achieve our target value as 
is obtained from the optimization research
rocess, the filling uniformity is improved
s in the metering pockets become tighter. 
ing out” blisters or flying away during the transfer from
 The tight extent of powder in the metering pockets 
When the powder is too tight to fall out, a more intensive 
 
 and worse uniformity
 when reducing the vibration intensity, the shape
. It is inferred that the undesired dispersion
Unfortunately, the uniformity of drug content 
become worse when decreasing the vibration intensity
that the less intensive vibration cause adherence
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When considering the drug content uniformity, all delivered drug content should be 
within the range of average ± 25% according to US or European pharmacopoeia. This 
requirement seems to be satisfied by the results of this chapter. However, this criterion is 
rather lax since it takes account of possible changes during stability tests or shelf-life. 
Usually, when a commercial inhaler is produced, its release criterion or internal control in 
the manufacturer is more stringent than the pharmacopoeia requirements. Consequently, 
it is difficult to conclude that our filling uniformity is acceptable or not. Even though the 
drug content uniformity between blisters still needs to be improved, it would not affect 
the following formulation work at all. The following evaluation of formulations utilizes 
one disk as a whole to analyze the in vitro performance. The results of this chapter show 
that the drug content uniformity among disks is excellent; hence the formulation work 
would not be affected. The filling research has validated the content uniformity among 
disks, which is a solid basis for the following formulation work. 
As a conclusion, this chapter provides an effective powder filling system for development 
of Inhaler-WU2011 and its primary function are validated.  
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Chapter 7  
7  Research on the formulation for Dry Powder Inhaler  
7.1 Brief Introduction  
The outline of the formulation study is shown in Fig. 7.1. First of all, the compatibility 
between the API (active pharmaceutical ingredient) and micronization, the API and 
excipient, formulation and package material is investigated. Then the micronized API and 
self-made lactose carrier are prepared and evaluated. The mixing process is studied in 
detail, including the mixing method, mixing speed and time, and mixing sequence. The 
results demonstrate that all the factors in mixing have an influence on the blend 
uniformity and the FPF (fine particle fraction). Then, the composition of formulations, 
like the ratio of fine lactose to powders, size and source of coarse lactose, percentage and 
size of the API, is investigated. At last, a performance stability test is carried out to study 
the influence of package, formulation and flow rate of the TI (Twin Impinger) test on the 
FPF stability. 
 
Figure 7.1: A schematic diagram of formulation study 
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7.2 The Compatibility Evaluation  
Usually, a compatibility evaluation of process, excipient and package materials is the first 
step in a formulation study. Only if this result demonstrates the compatibility of API with 
the preparation process, excipient and package materials, the following formulation work 
will be meaningful. Since no solvent, no heating or other dramatic physical operation is 
applied in this formulation study, the risk of chemical degradation is minimized. The 
compatibility test is focused on the micronization, excipient and package material. 
Firstly, solid properties of the micronized particles were studied by TGA, DSC and 
XRPD, as mentioned in Section 3.2.1. The TGA and DSC results are shown in Fig.7.2. 
As we can see from Fig.7.2b, the TGA curve clearly exhibits a dramatic decline at about 
100°C, standing for a weight loss of crystal water evaporation for the API. Because the 
percentage of API in the micronized mixture is very small, this characteristic peak is not 
reflected in Fig.7.2c. Additionally, there is no obvious peak of dehydration for lactose 
and micronized API+lactose, indicating the impossibility to measure the moisture of a 
formulation by the TGA. As we can see from the DSC results, the peak of micronized 
API+lactose is the same as lactose. This result demonstrates that there is no significant 
solid-property alteration during micronization, such as amorphous component increasing 
The XRPD results further prove this conclusion. The API+lacotse mixture and 
micronized API+lactose show almost the same diffraction intensity. The diffraction 
profiles of both are dominated by the lactose as shown in Fig.7.3. When comparing the 
XRPD results of the mixture and the API, a characteristic peak at 4-5°for the API 
disappears. It can be explained by that the API only accounted for a very small part of the 
mixture. Although a violent collision of particles is applied in the jet-mill, the amorphous 
content only occupy a very small part of the total. Consequently, XRPD, one of the most 
used methods for quantifying crystallinity, is not sensitive adequately to distinguish the 
micronized and unmicronized samples[149]. 
 Figure 7.2: The TGA and DSC results
Figure 7.3: The XRPD results of lactose, API+lactose, micronized API+lactose, API.
. a, lactose. b, the API. c, micronized 
lactose+API 
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An influence of jet-milling on the API chemical stability is also studied. The impurities 
of the unprocessed API and micronized API are analyzed by the HPLC. The result shows 
that the impurity content is 0.50% and 0.41% for the unprocessed API and the micronized 
API respectively. Hence, the almost same impurity level indicates no degradation of the 
API caused by micronization.  
After that, the compatibility of the API with excipient and packaging material is studied. 
The API is mixed with lactose for API-excipient compatibility, and then the powder 
blend is mixed with pieces of PVC and aluminum foil to study the packaging material 
compatibility. To accelerate a possible degradation, all samples are placed under stress 
conditions (high temperature, high humidity and intensive light) for 10 days.  
The research scheme and result are presented in Table 7.1. As we can see, the lactose and 
PVC do not significantly accelerate the degradation, since the impurity does not increase 
obviously even under high humidity (RH92.5%) and high temperature (60°C). The 
intense light (4500lx) has a larger influence for API+lactose and mixture+PVC. There 
were two reasons. First, the API is more sensitive to light. The fewer impurity of 
mixture+foil shows that the foil can prevent light and reduce degradation. Second, when 
API particles are dispersed in the mixture or mixture+PVC, the total exposure surface is 
increased and the possibility of degradation goes up. It is noteworthy that the attachment 
of API to the PVC because of electrostatic charge may enhance the degradation risk. The 
degradation results of the stress test under intense light imply that the protection of 
powder from light is necessary.  
Table 7.1: The impurity content of compatibility tests 
Impurity % Initial 
10day 
RH92.5％ 60°C Intense light (4500lx) 
API+lactose 
0.58 
0.58 0.69 0.90 
mixture＋PVC 0.57 0.48 1.02 
mixture＋foil 0.37 0.54 0.63 
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7.3 Powder Preparation for Dry Powder Inhaler  
When all the results demonstrate good compatibility of the API with micronization, 
excipient and the packaging materials, the research then shift to the powder preparation 
and formulation study. 
7.3.1 Preparation of the API particles and lactose 
The sulfate Salbutamol is micronized to several microns, which is a prerequisite for 
respiratory delivery. The equipment and parameters of the jet-mill is introduced in 
Section 3.5.1. To study the effect of multiple micronizations, the API particles are 
micronized for 1-3 times.  
The particle size distribution is measured by laser diffraction sizing, and the results are 
shown in Fig.7.4 and Table 7.2 As we can see, the particle size decrease gradually with 
more times of micronization, and the distribution becomes narrower. The reduction of 
particle size is especially obvious from 1st to 2nd jet-milling. Although more processing 
times produce smaller particles, the API loss on the wall of equipment increases, causing 
a problem of low production efficiency. Increasing times of jet-milling may also result in 
dramatical augment of electrostatic charge. Too much charge is difficult to dissipate and 
harmful for formulation performance. More importantly, the X90 is under 5µm after 2nd 
micronization, implying that most particles have been already suitable for inhalation 
delivery. Consequently, the API particles micronized twice are employed in the following 
experiments unless otherwise specified. 
 Figure 7.4: The laser diffraction size distribution of micronized API
Table 7
Micronization
Once 
Twice 
Three times 
The particles are also characterized by the SEM as
Fig.7.5, the particles are very small
tendency. As a result of extra 
as diluents and carrier become essential
.2: The size results of micronized API 
 X10 (µm) X50(µm) X90(µm) X99
0.75 2.24 7.55 21.3
0.57 1.57 3.89 7.23
0.51 1.33 3.4 7.02
 shown in Fig.7.5. As we can 
 strips or sheets, which exhibit a very strong cohesive 
small size and strong cohesive force, the addition of lactose 
. 
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(µm) 
 
 
 
see in 
 Figure 7.5: The SEM pictures of th
b, cohesive property of the micronized API.
At first, the coarse lactose 
exhibit an interesting surface and binding with the 
the surface of the carrier is rather coarse with lots of caves and crevices. 
carriers are mixed with the extra fine API par
surface of the carrier as shown in Fig
anticipated by formulation researchers
Figure 7.6: The SE
e micronized API. a, shape of the micronized API; 
 
as the carrier is prepared by wet granulation. 
fine API. As we can see from Fig.
ticles, the fine particles attach to the coarse 
.7.6b. This attachment is an ideal situation 
 sometimes. 
M pictures of self-made lactose (a) and the 
API + lactose mixture (b). 
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Yet, since those carriers are produced manually on a small scale, the size distribution and 
flowability are not very stable, as shown in Table 7.3 and Table 7.4. The particle size of 
lactose in terms of X10, X50 and X90 show an obvious difference among three batches. 
Besides, the angle of repose and compression index also indicate various flowability. It is 
interesting to notice that the flowability is closely correlated with the particle size. With 
the decreasing size from Batch 120504 to 121225, especially for X50 and X90, the 
flowability also exhibit a descending trend reflected by the increasing angle of repose and 
compression index. 
Table 7.3: The size results of self-made lactose carriers 
Batch No. Test X10 /µm X50 /µm X90 /µm 
120504 1st 18.14  69.89  151.52  
2nd 18.42  70.48  152.90  
121218 1st 22.65  61.87  138.11  
2nd 22.75  62.78  140.79  
121225 1st 12.58  56.49  138.94  
2nd 12.19  53.88  127.25  
Table 7.4: The flowability of self-made lactose carriers 
Batch No. Angle of repose Compression index 
120504 37 15.7% 
121218 41 26.3% 
121225 43 34.3% 
Consequently, commercial lactose rather than self-made lactose are used in the following 
experiments. However, as a result of smooth surface and regular shape, the adhesion of 
fine API particles to the carrier is much less than self-made lactose as shown in Fig.7.7. 
 Figure 7.7: The SE
The fine lactose as additives 
(Kerry, New Zealand). The particle size distribution i
The fine lactose particles are
lactose carriers. 
Figure 7.8: The cumulative and density 
M pictures of the commercial lactose and the 
API-lactose mixture. 
is micronized in this lab from a common lactose
s shown in Fig.7.8 and Table
 bigger than the API particles, but much smaller
volumetric distribution of micronized 
lactose as fine additives. 
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 Table 7.5: 
Sample 
Fine lactose 
7.3.2 Mixing method of the API and lactose
When the API and lactose are ready, the mixing method i
optimized process and knowledge of the 
performance. In the uniformity tests, taking samples from the bulk
job since these samples have
powder is just 40-50g, a simple met
Figure 7.9: A schematic of sampling method for blend content uniformity
At the beginning, the API and lactose particles are mixed by sieving
addition. This method is common
formulations, like tablets and capsules. 
mixed 1g API with m g lactose, 
the mixture is sieved by an
added into former blend and sieved again.
mixed. 
The uniformity result of the bulk blend
percentage since the weight may
The size results of the micronized lactose. 
Test X10 /µm X50 /µm X90 /
1st 0.89 4.43 
2nd 0.90 4.40 
 
s studied to 
influence on the content uniformity and FPF 
 powder 
 to represent all powder. Here, because 
hod is used to sample powders shown as Fig.
 
 with equivalent 
ly used to prepare a uniform blend in oral solid 
Its procedure is as follows: when we
1g carrier is weighed and mixed with the API 
 80-mesh screen (178µm). After that, 2g lactose carrier 
 This process is repeated until all powders 
 shown in Table 7.6 is expressed
 vary time to time. As we can see from the RSD, the 
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µm 
16.79 
16.91 
acquire an 
is a difficult 
the amount of 
7.9. 
. 
 plan to 
first, then 
is 
are 
 by the drug 
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drug content uniformity of the blend is excellent, implying that the drug particles are 
evenly distributed in the carriers. Nevertheless, this method is rather complicated and 
time-consuming. And manual procedures are not suitable for industrial production.  
Table 7.6: The blend content uniformity of screening method  
 
sample
1 
sample
2 
sample
3 
sample
4 
sample
5 
sample
6 
AVG RSD 
Drug 
percentage 0.61% 0.61% 0.62% 0.61% 0.61% 0.62% 
0.61
% 
0.81
% 
The mixing method of a common mechanical stirring after shaking the powder in a 
container is also used. This method shows poor uniformity performance, for RSD above 
10%. Similarly, the uniformity of mixing by low-shear Turbula is terrible. 
Then the mixing method is established as Section 3.5.1, including a pre-sieving, low 
shear mixing by Turbula and high shear mixing. The RSD result shown in Table 7.7 
indicates excellent uniformity. Although the final mixing method produces a little higher 
RSD than the sieving method, it is more mature and can be scaled up for industrial 
production. 
Table 7.7: The blend content uniformity of final mixing method 
 
sample
1 
sample
2 
sample
3 
sample
4 
sample
5 
sample
6 AVG RSD 
Drug 
percentage 
0.69% 0.69% 0.70% 0.69% 0.70% 0.68% 0.69
% 
1.09
% 
According to previous experiences, an ultrasonic sieving is able to effectively break 
agglomerates of extra-fine particles and prepare a homogeneous blend. Hence, the 
ultrasonic sieving is also applied in the mixing. The fine API particles and part of fine 
lactose are sieved by ultrasonic vibration through a 200-mesh screen, and then mixed 
with coarse carriers. However, the results are not good as we expected, shown in Table 
7.8. It is inferred that the agglomerates formed in the ultrasonic sieving are too solid to 
break up. Therefore, the agglomerates of the API and fine lactose are difficult to disperse 
into the bulk coarse carriers evenly. Consequently, the mixing method is established as 3-
steps method without ultrasonic sieving. 
 Table 7.8: The content uniformity of 
 
sample
1 
sample
Drug 
percentage 
0.68% 
When the mixing method i
studied for their influence on blend uniformity and FPF performance. 
sieving, serving to break API agglomerates. 
Two screens with different diameters, 100
in the pre-sieving, and the uniformity and FPF 
blend pre-sieved by 200-mesh also shows a good resu
does not show an obvious difference
concluded that there is no need to replace 100
increases the time. 
Table 7.9: The 
 
sample
1 
sample
Drug 
percentage 0.56% 
Figure 7.10: The 
blend mixed by ultrasonic
2 
sample
3 
sample
4 
sample
5 
sample
6 
0.83% 0.73% 0.67% 0.67% 0.70% 
s established, two critical steps of the mixing
O
The other one is the high shear mixing.
-mesh (147µm) and 200-mesh (75
are compared. The content RSD of 
lts as Table 7.9. The
 between 100-mesh and 200-mesh. Therefore
-mesh with 200-mesh, since the latter
content uniformity of blend by 200-mesh 
2 
sample
3 
sample
4 
sample
5 
sample
6 
0.59% 0.60% 0.59% 0.60% 0.59% 
comparison of FPF values for powder pre-sieved
by different meshes. 
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-sieve  
AVG RSD 
0.71
% 
8.63
% 
 are further 
ne is the pre-
  
µm) are used 
the 
 FPF result 
, it is 
 
AVG RSD 
0.59
% 
2.32
% 
 
  
 Then, the research is moving
the higher shear blender is revised by 
no visual display for the mixing
The speeds at 60v and 120v are
result in double speed. 
Since the speed is quite high when 
particles are not micronized by the 
10min under high speed (120v) and low speed (60v). The 
Fig.7.11 and Table 7.10. The
mixing is the same as low-speed
mixing. As Fig.7.11, the size distribution 
mixing nearly overlap. 
Figure 7.11: The laser diffraction sizing results for low and high
Table 7.10: The laser diffraction size results
 
60V
120v
 on to the high shear mixing. As mentioned in Section 3
us for mixing a small amount of powder.
 speed but the speed can be adjusted by the input voltage. 
 compared, with an assumption that double voltage may
using 120v voltage, it is necessary to ensure the 
mixing. The same Kerry 200 lactose is
particle size 
 result demonstrates that the particle size 
, and particles are not micronized during the high shear 
profiles of low-speed and high
-speed mixing
 of high and low-speed 
X10 X50 X90 
 2.70 21.03 47.04 
 1.54 20.26 47.36 
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Then the high-speed and low-speed mixing is used to prepare a blend composed of 0.72% 
sulfate Salbutamol, plus 5% fine lactose and about 94.3% Inhalac 230 respectively. The 
mixing time is set as 10min. As Table 7.11, the drug percentage and uniformity are 
almost the same for low-speed and high-speed. This result demonstrates that the speed of 
mixing do not affect the uniformity of the blend. 
Table 7.11: The comparison of blend content uniformity  
using different-speed mixing 
Drug 
percentage 
sample
1 
sample
2 
sample
3 
sample
4 
sample
5 
sample
6 
AVG RSD 
Low-speed 0.58% 0.56% 0.58% 0.59% 0.58% 0.58% 0.58
% 
1.70
% 
High-speed 0.58% 0.56% 0.57% 0.57% 0.57% 0.56% 0.57
% 
1.36
% 
Then these two powders are filled into blisters and used for TI (Twin impinger) tests to 
evaluate the influence of mixing speed on FPF. The result is shown in Fig.7.12. The FPF 
and blister remains are lower for high-speed mixing. This can be explained by that the 
interaction between API-API and API-carrier are much stronger as a result of high energy 
input. The strong adhesion force such as electrostatic force or mechanical interlocking 
makes it difficult to disaggregate agglomerates. Meanwhile, because the interaction 
between particles increases, the adhesion of particles to the blister wall become smaller 
accordingly and the blister remains decline. Nevertheless, constant blister remains is 
acceptable and less important than the FPF. Consequently, a lower mixing speed is 
selected for following research.  
It is reported that high shear mixing increased the FPF values when compared with low 
shear mixing[150]. The different results are caused by an in-situ generation of fine lactose, 
which is detected during the high-shear mixing in that reference. 
 Figure 7.12: The comparison of FPF and blister remains by different
When the mixing speed is determined, the mixing time is
powder composed of 0.72% sulfate 
Inhalac 230 was mixed at low speed (60v). Then samples were taken out at 5min, 10min 
and 20min for content analysis.
significant difference of uniformity 
mixing is enough to acquire a homogenous blend.
increasing mixing time although the decline i
mixing time is applied to ensure the uniformity.
Table 7.12: The influence of mixing time on blend drug uniformity 
Drug 
percentage 
sample
1 
sample
5min 0.70% 
10min 0.66% 
20min 0.66% 
The powders sampled at different tim
study the effect of mixing time on the FPF. 
-speed mixing
 optimized as the next step. 
Salbutamol, 10% fine lactose and about 89.3% 
 The results are shown in Table 7.12
between these time points indicates
 The drug percentages show
s not obvious. Despite all that
 
2 
sample
3 
sample
4 
sample
5 
sample
6 
0.67% 0.68% 0.64% 0.67% 0.66% 
0.64% 0.67% 0.67% 0.68% 0.64% 
0.66% 0.63% 0.63% 0.61% 0.64% 
e points are tested by the TI (Twin impinger)
Additionally, the powder at 0min 
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. 
A 
. Actually, no 
 that 5min of 
 a drop with 
, 10min 
 
AVG RSD 
0.67
% 
2.99
% 
0.66
% 
2.54
% 
0.64
% 
3.04
% 
 to 
representing 
 no high shear mixing is also studied. 
When increasing the mixing time, the FPF declines
0min to 5min. Meanwhile, the blisters remain
0min. The drop of FPF can be explained by 
fine particles with more mixing time
Figure 7.13: The influence of mixing 
Table 7.13: The FPF and blister remains results of different mixing time
 
FPF-AVG 
SD 
Remains-AVG 
SD 
7.4 Composition Research
The composition of a formulation
their talents, when a specific DPI device is given
excipients for inhalation drug delivery a
dose is determined by clinical requirements
challenging. 
The result is presented in Fig.7.13 and Tabl
 gradually with a dramatic drop from 
s do not show obvious changes
the higher energy input and increasing
.  
time on FPF and blister remains
0min 5min 10min 
34.4% 27.6% 25.0% 
6.6% 1.7% 4.2% 
12.1% 8.8% 9.1% 
0.9% 0.2% 0.6% 
 of Dry Powder Formulation
 is a field where the pharmaceutical scientists
 most of the time. Although 
re limited and the amount of the API for each 
, the formulation composition 
152 
e 7.13. 
 except for 
 loss of 
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20min 
22.2% 
4.5% 
8.4% 
0.1% 
 
 display 
the available 
is still 
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There are several ways to adjust the performance of a DPI formulation, like API size, 
ratio of fine lactose as additives to the powder, size of coarse lactose carrier and other 
factors.  All those factors are studied in the following experiments. 
7.4.1 The formulation with similar FPF as marketed products 
Several hopeful formulations are obtained after lots of formulation work. The 
composition of these formulations is listed in Table 7.14. The powder is mixed by the 
method mentioned in Section 3.5.1. 
Table 7.14: The composition of these formulations with similar FPF  
as marketed products 
No. Lactose-Carrier Fine lactose Sulfate Salbutamol 
Rx4 SV003 5% 0.72% 
Rx5 LH200 0 0.72% 
Rx6 Inhalac120 20% 0.72% 
Rx17 Inhalac230(<45µm) 0 0.72% 
The FPF results are shown in Fig.7.14 and Fig.7.15. As shown in these two figures, the 
Rx4 and Rx5 have similar or a little higher FPF than Aerolizer® Foradil® and Diskus® 
Seretide®. And Rx6 and Rx17 have similar or even little higher FPF than Turbuhaler® 
Oxis® and Clickhaler® Asmatha®. A little higher FPF is acceptable, since the marketed 
products have been dispersed out for some time and our formulations are freshly prepared. 
The newly preparation may experience a slight a drop of FPF after storage. Consequently, 
the FPF of the novel inhaler could match several marketed products by adjusting the 
composition of a formulation. 
 Figure 7.14: The similar FPF of formulation Rx4/5 as Aerolizer
Figure 7.15: The similar FPF of formulation Rx6/17 as Turbuhaler
It is noteworthy that the percentages of
0.72%, delivering about 12µ
® Foradi
Diskus® Seretide® 
®
Clickhaler® Asmatha®. 
 API for those 4 formulations are
g API by each blister. The dosage is the same as Aerolizer
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 Oxis® and 
 the same as 
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Foradil® and Turbuhaler® Oxis®, both of which deliver 12µg fumarate formoterol. But 
for clickhaler® Asmasal® and Diskus® Seretide®, their delivery dose are at least 
100µg/dose. Hence, a capacity to deliver high dose should be validated to evaluate the 
inhaler performance. This test is carried out in Section 7.4.3 and the result demonstrates 
the ratio of the API to the total power does not affect the FPF significantly. 
7.4.2 The influence of the lactose on formulation performance 
Although several formulations with similar FPF as marketed products are acquired, it is 
necessary to further investigate influences of formulation variables on the inhaler 
performance.  
Firstly, an influence of fine lactose as additives is studied. The blends containing 0%, 5%, 
10% and 20% fine lactose are prepared respectively. The percentage of sulfate 
Salbutamol is set at 0.72% and the Inhalac 230 as coarse lactose. The flowability is 
evaluated in terms of angle of repose and compression index. The results shown in Table 
7.15 and Table 7.16. demonstrate that the flowability decreases gradually with increasing 
fine lactose. During these tests, it is found that the angle of repose is difficult to measure 
accurately when the flowability is too bad, thereby the compression index could be used 
to evaluate the flowability of powders.  
Table 7.15: The angle of repose of blends with different ratio of fine lactose 
Angle of repose 
Fraction of fine lactose 
0% 5% 10% 20% 
test1 35.55 42.28 49.64 54.25 
test2 34.98 40.54 51.03 53.15 
test3 35.94 41.05 47.71 53.15 
AVG 35.49 41.29 49.46 53.52 
 
  
 Table 7.16: The compression index of blends with diff
Compression 
index 
test1 
test2 
test3 
AVG 
Table 7.17: The blend drug content uniformity for formulations containing 
API 
percentage 
AVG 
RSD 
As the first step of formulation evaluation
Table 7.17. This result clearly demonstrates
4 powders. As we can see from this table, 
the loss of the API particles decreases
(Twin impinger) results are shown in Fig.
Figure 7.16: The FPF and blister remains of
erent ratio of fine lactose
Fraction of fine lactose 
0% 5% 10% 20% 
18.28% 26.37% 34.83% 47.31% 
19.32% 25.56% 35.35% 45.16% 
17.39% 27.47% 34.07% 46.74% 
18.33% 26.47% 34.75% 46.40% 
different fine lactose 
Fraction of fine lactose 
0 5% 10% 20% 
0.53% 0.58% 0.63% 0.63% 
1.89% 0.62% 1.72% 2.03% 
, the drug content and uniformity 
 the excellent drug content uniformity for all 
when increasing the percentage 
 slightly. After a uniformity evaluation
7.16 and Table 7.18. 
 formulations containing 
different fine lactose. 
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As we can see from Fig.7.18, the FPF goes up gradually with the ascending ratio of fine 
lactose but experiences a slight drop when the fines is increased from 10% to 20%. There 
are several hypotheses which can explain this phenomenon. For example, the fine lactose 
would compete against the API for “active or high energy” site on the larger carrier, or 
the fine lactose act as a diluent to reduce the API-API interaction. Both mechanisms can 
increase the FPF with more fines. However, there is a critical point between 10% and 20% 
fines, indicating a turning point or platform for the increasing effect of FPF. 
The blister remains also shows a slightly ascending trend with increasing fine lactose. 
The effect might be explained by the descending flowability as a result of a higher 
proportion of fine particles. Or it is correlated with an augment of adhesiveness because 
of the increased contact area[151; 152]. 
Table 7.18: The FPF and blister remains results of different fine lactose 
 Fraction of fine lactose 
 0% 5% 10% 20% 
FPF-AVG 30.0% 39.7% 48.3% 44.2% 
SD 2.2% 4.8% 0.8% 7.3% 
Remains-AVG 12.5% 15.7% 16.7% 24.5% 
SD 3.6% 2.1% 0.4% 3.9% 
The influence of coarse lactose is also studied. The Inhalac 230 is sieved into 4 parts 
(<45µm, 45-75µm, 75-100µm, 100-150µm) by a vibratory sieve shaker. Then the size 
distribution of those sieved powders is validated by laser diffraction sizing. For particle 
smaller than 45µm, the sample is tested by R2 lens and R4 lens for other powders.  
The laser diffraction size measurement results are shown in Table 7.19. It is interesting 
that the laser diffraction size results are not completely consistent with sieving results. As 
we can see in this table, the X10 standing for small particles is close to the lower limit of 
sieving, but X90 representing large particles is larger than the upper limit of sieving, 
especially for particles in 45-75µm and 75-100µm. It is inferred that the shape of the 
particles caused the size difference. Since the laser diffraction test might take an axial 
length as particle size for those long-strip particles, it overestimated the particle size. 
However, those long-strip particles can penetrate the pores of a screen vertically, 
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exhibiting a smaller diameter. The X90 of 100-150 particles is less than 150µm and this 
can be explained by that the original size distribution of Inhalac230 is less than 150µm as 
Table 3.7. Generally, the Inhalac 230 lactose is divided into several parts with a desired 
size range. 
Table 7.19: The vibration sieving size and laser diffraction size of the sieved lactose 
Vibrating sieve 
Laser diffraction size 
X10(µm) X50(µm) X90(µm) 
<45µm 4.5 27.1 53.4 
 4.4 27.0 54.2 
45-75µm 42.4 71.5 98.4 
 
43.2 72.9 100.2 
75-100µm 72.6 105.1 137.2 
 
71.0 104.4 135.7 
100-150µm 78.4 116.3 141.7 
 77.8 114.0 139.5 
Then, the API (0.72%) is mixed with the lactose without fine lactose, avoiding an 
influence of fines on FPF. The blend drug content uniformity is tested at first. The result 
shown in Table 7.20 also indicates a good uniformity. 
Table 7.20: The blend drug content uniformity of formulation with  
different-size lactose 
API 
percentage(n=6) 
The size of lactose 
<45µm 45-75µm 75-100µm 100-150µm 
AVG％ 0.68% 0.66% 0.69% 0.67% 
RSD％ 1.4% 1.4% 2.6% 0.9% 
The TI (Twin Impinger) result is shown in Fig.7.17 and Table 7.21. As we can see from 
this figure, the small carriers (<45µm) exhibit the highest FPF and lowest blister remains. 
And other 3 carriers show a trend that the FPF increase with the decline of carrier size, 
however this trend is not as obvious as carriers <45µm. Guenette et al studied an effect of 
lactose size on the FPF of DPI formulations, and proposed that the fraction of fine lactose 
was the reason for the difference of FPF[84]. Steckel et al used different-size lactose from 
sieving to study the effect of lactose size on the inhaler performance. Their results also 
 demonstrated that a smaller lactose (<32
larger lactose (125-180µm). 
agglomerates, but the API particle adhere
also demonstrated that smaller lactose carrier
emitted dose than larger carriers
The blisters remains seems to be more complicated.
more blister remains. 
Figure 7.17: The FPF and blister remains of formulation with different
Table 7.21: The FPF and blister remains results 
TI test (n=2 ) 
<45
FPF-AVG 46.8%
SD 0.3%
Remains-AVG 15.9%
SD 0.6%
Obviously, the size of lactose carrier exert
Then, an influence of lactose source on the formulation performance 
µm) produced much higher FPF (37%) than 
It was suggested that small particles formed redisper
d to the larger carrier tightly[82]. 
 (<32µm) exhibited better FPF but less 
(~100µm)[82]. 
 Generally, the larger carrier result in 
of formulation with 
different-size lactose 
The size of lactose carrier 
µm 45-75µm 75-100µm 
 23.4% 22.8% 
 1.4% 0.5% 
 27.4% 29.6% 
 0.5% 1.1% 
s a great influence on the inhaler 
was 
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sible 
Another study 
 
-size lactose. 
 
100-150µm 
19.4% 
2.8% 
28.3% 
0.1% 
performance. 
also studied. 
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The lactose within the 45-75µm was sieved by vibratory sieving respectively from 
Inhalac 230, SV003 and LH200 (milled). The size distribution of those lactose carriers 
was first validated by laser diffraction size measurement. 
As we can see from Table 7.22, the particle size is similar for Inhalac230 and SV003. 
The LH200 (milled) showed a little larger size than the other two. Again, the X90 is 
higher than the vibration sieving results, which are explained above. 
Table 7.22: The sieving size and laser diffraction size of lactose  
from different sources 
 
Vibrating sieve 
Laser diffraction size 
X10(µm) X50(µm) X90(µm) 
Inhalac230 45-75µm 
42.4 71.5 98.4 
43.2 72.9 100.2 
SV003 45-75µm 
43.4 67.7 97.2 
43.1 67.1 95.6 
LH200 milled 45-75µm 
50.2 81.9 119.0 
49.0 81.9 119.4 
After that, those powders are tested by the TI impaction method. And the results are 
shown in Fig.7.18 and Table.7.23. The FFP and blister remains result demonstrate no 
great difference between Inhalac 230 and SV003. The FPF and blister remains of LH200 
(milled) are a little higher than the former two. The result of higher blister remains for 
LH200 is consistent with an observation above, which shows that larger lactose result in 
more blister remains when studying different-size lactose. However, the research on 
lactose size shows that larger lactose may decrease the FPF. That result is contrary to the 
results of lactose source study. It is infer that the source of lactose outweigh the effect of 
lactose size on the inhaler FPF. Since the LH200 is prepared by a mill and other two are 
prepared by sieving, the LH200 may contain more fine particles. And these fines are 
attached to surface of large particles so tight to be detached during the vibration 
sieving[153]. Another explanation is that the fines in the sieved LH200 are too tiny to be 
reflected by the Sympatec, but those fines play an important role in the FPF. The 
microscope observation in Fig.7.19 proves the above inference to some extent, which 
shows more fines for the LH200 than SV003. Larhrib et al reported that the different 
 grades of lactose were likely to produce varying de
FPF difference mainly stemmed from fraction
Table 7.23: The blend drug content uniformity of formulation with 
API percentage (n=6) 
AVG％ 
RSD％ 
Figure 7.18: The FPF and blister remains of formulation with 
Table 7.24: The FPF and blister remains results of different
TI test (n=2) 
FPF-AVG 
SD 
Remains-AVG 
SD 
livery profiles of inhaled drug, and
 of fines or the carrier size[154]
different-source lactose 
Lactose (45-75µm) 
Inhalac230 SV003 LH200 milled
0.63 0.68 
2.0% 1.0% 
different-source lactose. 
-source
Lactose (45-75µm) 
Inhalac230 SV003 LH200 milled
22.8% 20.2% 25.1%
1.4% 0.8% 
24.6% 23.5% 28.0%
0.5% 0.5% 
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 Figure 7.19: The
7.4.3 The influence of API on formulation performance
The percentage of sulfate Salb
deliver 12µg drug per dose. 
or even more per dose. Consequently, it i
percentage on the formulation performance. 
one of which contained 0.72% fine sul
additives, and the other contained
lactose to keep the percentage
sulfate Salbutamol would deliver about 120
shown in Table 7.25, indicating uniform blends.
Table 7.25: The blend drug content uniformity of formulation
API percentage(n=6) 
AVG％ 
RSD％ 
The TI performance result is
results, the percentage of API does
 microscope images of different-source lactose
a, SV003; b, LH200 (milled) 
 
utamol in the blend is set at 0.72% for most experiments
Nevertheless, many commercial products deliver
s necessary to study the influence 
Two powder formulations were prepared, 
fate Salbutamol and about 20% fine lactose as 
 7.2% fine sulfate Salbutamol and about 13
 of fine particles constant. The formulation containing 7.2% 
µg drug per dose. The content uniformity is 
 
s with different
percentage API. 
API=0.72% API=7.2%
0.62 5.74
2.9% 4.4%
 shown in Fig.7.20 and Table 7.26. As we can
 not affect the FPP values but the blister remains 
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 100µg API 
of the API 
% fine 
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 see from the 
 slightly. The high percentage
blister remains, because more API particles mean more 
More fine drug particles do 
fine particle from carriers. T
since it greatly expands device 
only the fumarate formoterol inhalers. 
higher than low-API formulation
constant during storage and transportation.
Figure 7.20: The FPF and blister remains of formula
Table 7.26: The FPF and blist
TI test (n=2)
 of the API in formulation results in a larger
adherences to the blister wall.
not affect a disaggregation of agglomerates or 
his result is especially meaningful for the Inhaler
application to match different marketed products but
Although the fraction of blister remains
, it is still acceptable as long as the value remain 
 
tion with 
different-percentage API. 
er remains results of the different - percentage API
 Percentage of API 
 0.72% 7.20% 
FPF-AVG 48.6% 49.0% 
SD 0.1% 0.8% 
Remains-
AVG 
29.5% 36.8% 
SD 4.5% 0.8% 
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The influence of API size on formulation performance is studied. The sulfate Salbutamol 
particle is micronized by a jet-mill to produce API with different size distribution. The 
size distribution results are shown in Table 7.2. Then formulations containing 0.72% of 
these API, about 5% fine lactose and 94% Inhalac 230 were prepared. The drug content 
uniformity result shown in Table 7.27 demonstrates an excellent uniformity. 
Table 7.27: The blend drug content uniformity of formulation with  
different-size API 
 API size (µm) 
API percentage(n=6) X50=1.33 X50=1.57 X50=2.24 
AVG％ 0.61 0.60 0.59 
RSD％ 1.5% 0.8% 0.8% 
As shown in Fig.7.21 and Table 7.28, the FPF and blister remains are not sensitive to the 
API particle size. This result not only provides an investigation into the influence of API 
size on the formulation performance, but also demonstrates that even if the size of API 
fluctuates within a certain range, the performance does not change obviously. This 
conclusion is greatly useful for large-scale production. Usually, some critical parameters 
of commercial production should be set in a range rather than a specific value. A lot of 
work should be carried out to validate the acceptable range for the critical parameters. 
This is a core viewpoint in the Common Technical Document (CTD) by the International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH). 
There is some literature focusing on the influence of the API particle size on the inhaler 
performance. Yet, most of the API particles are prepared by spray-drying; hence they can 
not provide plenty of useful information for jet-milled particles. For instance, Chew 
reported that the spray-dried disodium cromoglycate with 2.3µm of MMD exhibited 
lower FPF then particles with 3.7 or 5.2µm of MMD[155]. When considering the jet-milled 
API particles, it was reported that the larger size would decrease the FPF and 
performance stability in pMDI[156]. 
 Figure 7.21: The FPF and blister remains of formula
Table 7.28: The FPF and blister remain
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Figure 7.22: The FPF and blister 
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Table 7.30: The FPF and blister remains results of different  
API mixing sequences  
 API mixing sequence 
TI test (n=2) (API+fines)+coarse API+(fines+coarse) 
FPF-AVG 27.2% 21.6% 
SD 4.6% 1.0% 
Remains-
AVG 
14.3% 21.0% 
SD 1.0% 2.3% 
7.5 Orthogonal Experimental Design and Results 
Many factors in the DPI formulation process and composition have been studied by the 
single-factor method. However, when considering all those factors at the same time, 
orthogonal experimental design is a wise choice to decrease the times of experiment, 
obtain evenly distributed data and more reliable conclusion. 
As shown in Table 7.31, four factors with mixed level are studied, including the ratio of 
fine lactose, mixing time, mixing speed and mixing sequence. Since there are only two 
levels for mixing speed and sequence, a Taguchi design of L16 (4^2*2^2) is obtained 
from Minitab 16 software. The orthogonal experiment design is shown in Table 7.32 
Table 7.31: The factors and levels in the orthogonal experiments 
Level A B C D 
 Percentage of fines Mixing time Mixing speed Mixing sequence 
1 20% 2min 60V (F-lac+API) +Inhalac230 
2 10% 5min 100V (F-lac+Inhalac 230) +API 
3 8% 8min   
4 5% 10min   
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Table 7.32: The factors and levels in the orthogonal experiments 
Formulation No. A B C D 
1 1 1 1 1 
2 1 2 2 2 
3 1 3 1 1 
4 1 4 2 2 
5 2 1 2 1 
6 2 2 1 2 
7 2 3 2 1 
8 2 4 1 2 
9 3 1 1 2 
10 3 2 2 1 
11 3 3 1 2 
12 3 4 2 1 
13 4 1 2 2 
14 4 2 1 1 
15 4 3 2 2 
16 4 4 1 1 
16 formulations are prepared and content uniformity of these blends is evaluated first. 
The result indicates that all blends are uniform with RSD of the API percentage around 2-
3%. Then, each formulation is tested by the TI (Twin impinger) twice and FPF (fine 
particle fraction) result is calculated as shown in Table 7.33.  
Table 7.33: The FPF results of the orthogonal experiments 
Formulati
on No. 
Averaged 
FPF % (n=2) 
Percentage of 
blister remains % 
Formulati
on No. 
Averaged 
FPF% (n=2) 
Percentage of 
blister remains % 
1 51.4 29.4 9 39.7 20.3 
2 46.0 33.3 10 18.8 16.0 
3 42.8 32.6 11 23.9 20.4 
4 32.0 15.1 12 16.5 12.5 
5 32.4 20.4 13 25.7 15.4 
6 39.4 21.0 14 22.5 21.4 
7 20.7 18.6 15 12.8 15.7 
8 30.0 20.6 16 13.9 18.2 
169 
 
After that, the FPF is set as “response data” and the signal-to-noise ratio as “large 
expectation” by the Taguchi analysis using Minitab 16. The results are shown in Fig.7.23 
and Table 7.34. As we can see in Fig.7.23, the FPF increases with more fine lactose, less 
mixing time and lower mixing speed. All these results are perfectly consistent with 
former results of single-factor experiments. The results of mixing sequence are opposite 
the previous study. The orthogonal experiment indicates that mixing fine and coarse 
lactose first and then with the API is better for higher FPF results, which is more reliable 
than the previous study. And the contradiction with former result might be explained by 
the lowest ratio of signal to noise for the mixing sequence presented in Table 7.34. The 
smaller ratio of signal to noise implies that this factor would be more vulnerable to 
interference. To sum up, the optimized parameters for the best FPF are 20%-fines, 2min 
of mixing time, 65v of mixing speed and (fine lactose+Inhalac 230)+API of mixing 
sequence. 
When considering the ratio of signal to noise presented in Table 7.34, the percentage of 
fine lactose exhibits the largest ratio and mixing time presents the second largest one. 
This result implies that the percentage of fines has the greatest and most definite 
influence on the FPF and the mixing time occupies the second place. Consequently, when 
carrying out a formulation project, the percentage of fines and mixing time should be 
considered and adjusted first. 
 Figure 7.23: The averaged 
Table 7.34: 
Level Percentage of fines
1 32.56 
2 29.50 
3 27.35 
4 25.07 
Delta 7.48 
Ranking 1 
The blister remain results of
7.35. As we can see in Fig.
with less fines, longer mixing time and higher mixing speed. 
factors result in a decline of fines in t
remains. This inference is consistent with the results of single
mixing sequence shows a negligible
FPF response and various levels of the studied factors.
The signal-to-noise ratios of FPF response 
 Mixing time Mixing speed Mixing sequence
31.16 29.73 27.90
29.43 27.52 29.34
27.17  
26.73  
4.43 2.21 1.44
2 3 
 this orthogonal experiment are shown in Fig.
7.24, the percentage of blister remains experiences
It is inferred that these three 
he formulation and then the decrease of blister 
-factor results a
 effect on the blister remains. 
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 Figure 7.24: The averaged blister remains response 
The signal to noise ratios of blister remains a
ranking of factors as FPF response. 
greatest and most definite influence on the blister
smallest effect on the blister remains. 
remains, the percentage of fines and mixing time 
Table 7.35: The signal
Level Percentage of fines
1 28.41 
2 26.07 
3 24.6 
4 24.86 
Delta 3.81 
Ranking 1 
and various levels of 
the studied factors. 
re listed as Table 7.35, presenting the same 
This result implies that the percentage of fines has
 remains and mixing sequence exert
Consequently, when we want to adjust the blister 
should be considered first
-to-noise ratios of blister remain responsive
 Mixing time Mixing speed Mixing sequence
26.36 27.06 26.12
26.9 24.91 25.85
26.45 
 
24.24  
2.66 2.15 0.28
2 3 
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7.6 Stability Evaluation of Dry Powder Inhaler Formulation 
7.6.1 The influence of package on performance stability 
As mentioned above, four kinds of powder containing 0%, 5%, 10% and 20% fine lactose 
were prepared, and the percentage of the API was 0.72% for all 4 powders. Then the 
powders were filled into PVC disks and sealed with aluminum foil, and those drug disks 
were divided into two groups: one was wrapped by foil outside the disks and the other 
was treated without additional package. Both groups were placed under 40°C, RH75% for 
1 month. Then the FPF performance and blister remains were compared. 
The results are shown in Fig 7.25, Fig.7.26 and Table 7.36. First of all, the external foil 
package is very useful to maintain the FPF performance. The packaged disks show 
similar or a little lower FPF than the initial value after 1 month. The disks without an 
additional foil package experience a dramatic decline of the FPF when compared to 
initial values. Besides, the foil package is helpful to decrease the blister remains. When 
comparing the blister remains, the results of disks with the external foil package are less 
than disks without external package, except for powder containing 20% fines. It is 
believed that the external foil package can provide better protection against moisture. 
Under high humidity environment, a capillary force plays a dominating role in the 
particle interactions and it will greatly affect the dispersibility of API particles. What is 
worse, if a liquid bridge forms between particles, then the dispersibility would decrease 
to a very low level. The descending dispersibility of particles not only reduce the FPF, 
but also is unfavourable for the fluidization and entrainment of particles into the flow. 
Consequently, the drop of the dispersibility would increase blister remains. It is also 
inferred that the moisture would raise the interaction force between particle and PVC 
wall. 
 
 Figure 7.25: The FPF and blister remains 
with/without external foil packages.
Figure 7.26: The FPF and blister remains of initial and accelerated test for 1 month 
with/without external foil packages.
 
of initial and accelerated test for 1 month 
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Table 7.36: The FPF and blister remains results of the initial and accelerated test 
for 1 month with/without external foil packages 
TI test (n=2) 
 
 40°C,RH75%, 1month 
0day Without packaging With package 
0% 
FPF-AVG 30.0% 5.5% 30.2% 
SD 2.2% 0.2% 0.2% 
Remains-AVG 12.5% 26.5% 9.9% 
SD 3.6% 11.2% 0.8% 
5% 
FPF-AVG 39.7% 15.0% 41.2% 
SD 4.8% 2.3% 2.7% 
Remains-AVG 15.7% 22.2% 10.7% 
SD 2.1% 0.3% 0.8% 
10% 
FPF-AVG 48.3% 22.6% 25.9% 
SD 0.8% 2.9% 2.0% 
Remains-AVG 16.7% 18.6% 7.0% 
SD 0.4% 1.5% 1.4% 
20% 
FPF-AVG 44.2% 33.0% 43.9% 
SD 7.3% 3.2% 3.5% 
Remains-AVG 24.5% 11.0% 8.3% 
SD 3.9% 0.2% 0.7% 
It is interesting to find that various powders show different anti-moisture performance, 
since these 4 powders without external package experience dissimilar FPF declines from 
the initial value. The powder containing 20% fines exhibits the best stability without 
external package, and 0%-fines powder shows the worst stability by contrary. 
Consequently, the stability performance is speculated to be related to the percentage of 
fine lactose in a formulation. The formulation would be more stable with more fine 
lactose. As a conclusion of this experiment, an external foil package is essential to ensure 
product stability.  
Following that, the influence of desiccant on the FPF performance was also investigated. 
One group of disks was wrapped by an external foil package with a certain amount of 
desiccant in it and the other group was wrapped by foil without desiccant. Here, the 
representative powders containing 0% and 20% fines were tested under 25°C，RH92.5% 
for 5/10 days which was a typical humidity condition for a stress test. 
 Figure 7.27: The FPF and blister remains of stress test for 0/5/10 days with/without 
desiccant
Figure 7.28: The FPF and blister remains of stress test for 0/5/10 days with/without 
desiccant
. 0%-fines formulation. 
. 20%-fines formulation. 
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Table 7.37: The FPF and blister remains results of stress test for 0/5/10 days 
with/without desiccant 
TI test (n=2) 
 0day 
25°C, RH92.5% 
5day 10day 
Without 
desiccant 
With 
desiccant 
Without 
desiccant 
With 
desiccant 
0% 
FPF-AVG 18.0% 20.6% 23.2% 19.0% 17.3% 
SD 3.9% 1.8% 3.3% 0.2% 1.0% 
Remains-
AVG 
15.9% 16.7% 13.7% 16.6% 15.0% 
SD 2.9% 4.1% 1.9% 2.4% 0.8% 
20
% 
FPF-AVG 49.2% 54.8% 54.5% 52.0% 50.3% 
SD 1.0% 1.7% 3.2% 0.7% 3.1% 
Remains-
AVG 
25.1% 21% 26% 28.3% 26.2% 
SD 1.5% 2.7% 0.5% 0.1% 3.4% 
As we can see from Fig.7.27, Fig.7.28 and Table 7.37, the FPF is relatively stable under 
the high humidity environment for both 0%- and 20%-fines formulation. Besides, the 
desiccant seems to be useless, since the samples without desiccant also show good 
stability of FPF. Consequently, this experiment does not display desiccant’s influence on 
keeping DPI stability. As mentioned above, the humidity exert a great influence on the 
FPF performance of a DPI, therefore the extreme humidity (RH92%) is expected to affect 
the FPF significantly. Yet, the results do not comply with the expectation. Firstly, it is 
inferred that the external foil package provides good protection against humidity. 
Secondly, the time for this stress test is not long enough to allow ingression of moisture 
into packages. Or, the influence of moisture on interactions between particles may require 
a longer time than 10 days. Similar results are obtained during the development of other 
DPI inhaler products in our group. When the inhalers are exposed to RH92% for 10 days, 
the FPF performance does not show any decline but experiences an obvious decrease 
when exposed to RH75% for 1 month. Therefore, it is inferred that not only the relative 
humidity but also the equilibrium time influence the stability of FPF performance. The 
invasion of moisture into the foil package, the absorption of moisture on the particle 
surface, and capillary force working require a relatively long time. Consequently, the FPF 
 performance stability need 
example, the result of a high humidity test may
7.6.2 The accelerated stability of 
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to study which factor may greatly inf
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 Figure 7.30: The FPF and blister remains of accelerated tests 
Figure 7.31: The
for 0%
for 5%-fines formulation. 
 uniformity of delivered dose of accelerated tests 
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The delivered dose uniformity of 0% and 5%-fines formulation is presented in Fig.7.31. 
Most delivered doses are within the acceptable range except for the 4th point where the 
delivered dose is higher than the upper limit.  
The trends of blister remains for 10%-fines and 20%-fines are similar as 5% and 10%-
fines. The ratio of the blister remains experiences a decline at the first month and then a 
rise. Nevertheless, the blister remains for 10% and 20%-fines formulation are relatively 
constant when comparing the 3month values to the initial values. The phenomenon of 
blister remains going down first and then up is rather confusing. Above all, an accidental 
error should be excluded, since all samples tested at 1st month show a decline and the 
results of two repeated tests present a very small variation. Then, an assumption is 
proposed. After the first month, the electrostatic force between particle and PVC disk 
decrease a lot. The descending electrostatic force results in less adhesion and smaller 
blister remains. But for next 2 months, the adhesion caused by capillary force becomes 
the dominant and results in the growth of blister remains.  
When considering the FPF performance, the 10% and 20%-fines formulation show a 
completely opposite trend as Fig.7.32 and Fig.7.33. The FPF of 10%-fines formulation 
presents an abrupt drop at first month, and then is almost stable for next 2 months. The 
FPF of 20%-fines is stable at first month and then shows a gradually rising trend for 
following months. The results are rather confusing, which require further research and 
more stability data. However, it is conclusive that the ratio of fine lactose exert a great 
influence on the performance stability.  
 Figure 7.32: The FPF and blister remains of accelerated tests 
Figure 7.33: The FPF and blister remains of accelerated tests 
for 10%-fines formulation. 
for 20%-fines formulation. 
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 Figure 7.34: The uniformity of delivered dose of accelerated tests 
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Table 7.38: The FPF and blister remains results of accelerated tests for 4 powders 
TI test (n=2) 
 
Accelerated test, 40°C RH75% 
0d 1month 2month 3month 
0%fines 
FPF-AVG 30.0% 30.2% 23.1% 26.8% 
SD 2.2% 0.2% 1.9% 1.7% 
Avg-remains 12.5% 9.9% 20.5% 22.6% 
SD 3.6% 0.8% 3.3% 5.6% 
5%fines 
FPF-AVG 39.7% 41.2% 34.8% 40.4% 
SD 4.8% 2.7% 4.0% 0.8% 
Avg-remains 15.7% 10.7% 24.5% 21.8% 
SD 2.1% 0.8% 1.1% 1.3% 
10%fines 
FPF-AVG 48.3% 25.9% 28.7% 27.7% 
SD 0.8% 2.0% 1.1% 1.0% 
Avg-remains 16.7% 7.0% 12.8% 19.4% 
SD 0.4% 1.4% 0.1% 5.8% 
20%fines 
FPF-AVG 44.2% 43.9% 56.4% 57.9% 
SD 7.3% 3.5% 2.4% 2.3% 
Avg-remains 24.5% 8.3% 22.6% 27.7% 
SD 3.9% 0.7% 0.1% 5.9% 
As a conclusion of these stability experiments, the 0% and 5%-fines formulation show 
the FPF stability after 3 month in the accelerated tests. The 20%-fines powder 
experiences a slow rise during accelerated test, which is also observed in other stability 
tests for powders with more fine particles. The 10%-fines formulation is also acceptable, 
because accelerated results are quite stable after 1st month. This phenomenon provides a 
possible solution to the dramatic decline at first month, which is to place the products 
under a certain environment for some time. When the FPF becomes stable, those products 
can be tested or dispersed to patients. 
In addition to the influence of fine-lactose percentage on stability, the size of carrier 
lactose is studied preliminarily. The sieved lactose from Inhalac 230 with 4 different sizes 
(<45µm, 45-75µm, 75-100µm, 100-150µm) is further studied for stability. These samples 
are placed under 40°C, RH75% for 1 month. 
 Figure 7.35: The FPF and blister remains of 
lactose <45
Figure 7.36: The FPF and blister remains of accelerated tests for lactose within 
The results are shown in Fig.
that different-size lactose exhibit
accelerated tests
µm and within 45~75µm. 
75~100µm and 100~150µm. 
7.35, Fig.7.36 and Table 7.39. These results demonstr
 various stabilities. Specifically, the FPF of smallest 
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lactose (<45µm) experiences a little rise after 1 month whereas the largest lactose 
(100~150µm) shows a slight decline after 1 month. Meanwhile, the FPF of lactose within 
45~75µm and 75~100µm almost do not show any alteration. It is relatively easy to 
explain the FPF decline or constant FPF values, but it is difficult to guess the reason for 
FPF raise. Here, the ascending of FPF after 1 month is explained by that fine particles 
formed tight agglomerates initially as a result of electrostatic force or other forces, and 
those interaction forces become weaker after a month. Yet, this assumption is difficult to 
validate. The increasing FPF for lactose <45µm is consistent with stability results of 
20%-fines formulation, which has the most fine particles. The latter one also shows an 
upward trend during the accelerated test. The decline of FPF for lactose within 
100~150µm is similar as the FPF drop of formulations without fines. Different-size 
lactose present different FPF stability, which may be helpful to understand the confusing 
stability results of formulations with different amount of fine lactose. 
Table 7.39: The FPF and blister remains results of accelerated tests for  
different-size lactose 
TI test (n=2) 
 
<45µm 45-75µm 75-100µm 100-150µm 
0d 1month 0d 1month 0d 1month 0d 1month 
FPF-AVG 46.8% 53.6% 23.4% 23.4% 22.8% 24.2% 19.4% 15.6% 
SD 0.3% 3.5% 1.4% 1.6% 0.5% 1.0% 2.8% 3.6% 
Avg-remains 15.9% 24.3% 27.4% 27.0% 29.6% 32.1% 28.3% 33.6% 
SD 0.6% 4.6% 0.5% 2.9% 1.1% 1.8% 0.1% 7.0% 
7.6.3 The performance stability of under different flow rates 
One important characteristic of an ideal DPI is to exhibit similar FPF performance under 
different flow rates. The formulation including 0.72% sulfate Salbutamol and about 99% 
lactose (45~75µm) was tested for TI (Twin Impinger) impaction under 30LPM and 
60LPM respectively. 
The result is shown in Fig.7.37. It is reasonable that the larger flow rate produces a better 
fluidization and entrainment effect. As a result, more particles are taken into the air flow, 
and the blister remains decrease correspondingly. The FPF values of high and low flow 
rate are similar, implying that the inhaler can be operated under high or low flow rate. 
 This result is an attractive characteristic 
flow rate can be explained by 
more serious under high flow rate. When tested at high flow rate, the particles acquire 
higher initial speed and larger inertia when 
larger inertia, the particles cannot
part. This assumption is proven
is 20% for low flow rate and 30%
effectively dispersed under 30
Figure 7.37: The FPF and blister remains of
7.7 Discussion  
In recent years, the particle engineering i
scientists to develop dry powder formulation for macromolecules. 
engineering technologies include
fluid (SCF). The spray drying
marketed products, such as Nektar
There are some impressive advantages for 
size and density of particles can
for a DPI. The lower FPF produced by the 
that impaction of particles on the throat part of TI bec
particle size does not change. 
 change direction immediately and impact on the throat 
 by the fraction of API deposited on the throat part, which 
 for the high one. This result implies the particles a
 LPM as a sign for an excellent inhaler. 
 high and low flow rate
s increasingly popular among pharmaceutical 
The common
 a spray drying, spray freeze-drying and supercrit
 is studied most extensively and has been applied 
’s Pulmosol®. [103] 
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inlet/outlet temperature, feeding rate. Mostly important, sphere and hollow particles 
produced by the spray-drying present smaller aerodynamic diameter as a result of less 
density. These engineered particles can penetrate into the deep lung and keep good 
flowability at the same time [157; 158]. Additionally, the porous and hollow particles exhibit 
low inter-patient variability and flow rate independence[109].  
Nevertheless, the application of particle engineering is still limited for its stability 
problems. The instability may be caused by a transient exposure of API to high 
temperature and high flow jet, or a physical alteration like a transformation of crystalline 
phase. Due to a rapid precipitation process in the spray-drying or SCF, there is not 
enough time for the nucleation of API. Therefore, the spray-dried substance exist mainly 
in amorphous state, making it a big challenge for physical stability. First of all, the 
amorphous state is metastable with excess entropy and free energy which may experience 
“annealing” or “aging” during storage. The amorphous particles are transformed slowly 
to crystalline and the surface change from smooth to rough during storage[159]. Secondly, 
an amorphous material is more sensitive to moisture for its larger surface area. And a 
small amount of moisture may decrease the glass transition temperature (Tg) greatly, 
resulting in a dramatic drop of stability[160]. To improve the Tg of an amorphous 
formulation, other glass-forming agents are required. However, these agents may increase 
the complexity of formulation research as a result of safety and compatibility concerns[161; 
162]. At last, small molecules with smaller configurational entropy are much easier to 
transform from amorphous to crystallization[163]. Consequently, a jet-mill micronization 
is still the most common method to prepare the API particles for respiratory drug delivery, 
especially for small molecules.  
The API particles are micronized for several times. The results show that the particle size 
decrease with increasing times of jet-milling. Despite of various API sizes, the FPF 
performance does not show a great difference. Hence, the twice of jet-milling is applied 
for economic and stability consideration. As Fig.7.38, after a micronization, surface 
layers of particles become disrupted, leaving a small amount amorphous area. That 
amorphous content may go up with more times of micronization. Then, when these 
particles are exposed to water vapor and/or heat, the amorphous part may experience a 
 conversion to crystalline which result in inter
Fig.7.38. The formation of tight co
FPF performance[149; 164]. 
Figure 7.38: The schematic of disorder and recrystallization on the surfac
The intentional addition of a small amoun
a well developed technique to impro
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and coarse lactose first showed higher FPF[165], or the mixing sequence would affect the 
FPF[166]. However, there is also some literature reporting that the mixing sequence would 
not influence the final FPF results. The second hythe fine lactose  
Lucas et al reported that when fine particle lactose was increased from 2.5% to 10%, the 
FPF showed a gradually but obvious increase. They also found that the improvement in 
performance was independent of the addition order of fine particle lactose[167]. Louery et 
al proposed a novel hypothesis involving competitive and multilayer adhesion when they 
found that a higher FPF obtained from the addition of fines. This improvement was 
independent of the mixing order[168]. On the other hand, it was reported that more API 
and fine lactose increased the API dispersion in carrier-based system. And the 
agglomeration as a result of high fine-particle load coincided with increased dispersion, 
which directly supported the second hypothesis.[169; 170].  
When considering the effect of flow rate on the in vitro performance, the inertia of the 
particles determines their deposition. Usually, the inertia of a particle can be evaluated by 
a stop distance shown as the following formula. ρ、v、d represented the density, 
velocity and diameter of a moving particle respectively and η for viscosity. This equation 
is able to explain why larger particles impact on the earlier stages of cascade impactors. It 
also provides an interpretation why more particles deposit in the throat part of TI under a 
higher flow rate as we find. When the particle velocity is similar, the stop distance is 
proportional to the square of diameter. Hence, the difference of particle size is amplified 
and then distinguished by the stop distance. Meanwhile, when the particles size and 
density are similar, the higher flow rate makes the particle exhibit higher velocity, then 
the stop distance is increased and particles impact on the corner of the throat part[171]. 
h
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The influence of flow rate on the blister remains can be explained by particle entrainment 
in a laminar wall boundary layer as Fig.7.39. The drag force (Fdrag) can be calculated by 
following formula, where CD is drag coefficient, ρ for fluid density, Af for cross area of a 
particle, U for fluid velocity. Based on an approximation that the CD is constant, the 
 higher fluid velocity may produce 
force. Consequently, the increase of
effect and reduce the blister remains
Figure 7.39: The schematic
 
a larger drag force. The lift force is similar as drag 
 drag force and lift force result in a better entrainment 
[171; 172].  
 
 particle entrainment in a laminar wall boundary layer
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Chapter 8  
8  Conclusions and Future Directions 
8.1 Major Conclusions 
A new dry powder inhaler device is designed, manufactured and evaluated. This device is 
characterized by micro-dose, passive drug delivery and multiple doses in one replaceable 
disk with each dose individually packaged. The evaluation results show that this device 
can deliver 2-3mg powder each time, disperse the powder effectively and obtain ideal in 
vitro depositions with suitable drug formulations.  
A novel powder filling and packaging system is established specifically for this inhaler. 
This system can dispense a small amount of drug powder into blisters of a drug disk 
quickly and accurately. The uniformity evaluation demonstrates that the filling is rather 
uniform among disks and blisters, except for drug content among blisters of a disk. This 
uniformity problem does not affect the evaluation of inhaler at present and should be 
solved in the future. 
Through a formulation study, it is found that the in vitro performance of this new inhaler 
can match different marketed products. Furthermore, the influence of various factors on 
the inhaler performance is clarified by a comprehensive and systemic formulation 
research. 
The novel dry powder inhaler is the core part of this project, and the powder filling & 
packaging system and formulation research are designed and carried out based on the 
inhaler. Specifically, because the delivered dose is rather small for each blister, the filling 
system should be able to meter a small amount of powder accurately. Additionally, the 
arrangement of 14 blisters in one disk determines the mode of powder metering and 
filling. Meanwhile, the formulation has to be consistent with the inhaler and filling 
system. For example, the quantity of formulation is also small and flowability of the 
powder is suitable for filling. Most importantly, the formulation should be dispersed 
effectively by this novel inhaler device when administered.  
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Although the novel inhaler device is the key to the project, its performance is greatly 
dependent on other two components. For instance, the powder filling system would 
greatly affect the delivered drug uniformity, and packaging system would determine the 
performance stability. The drug delivery efficiency and uniformity are also determined by 
the formulation process and composition. Moreover, the formulation is the easiest 
variable and most convenient one to adjust to acquire a desired fine particle dose. 
8.2 Summary of Key Results  
During the establishment and validation of analytical methods, the HPLC method is 
validated according to the ICH requirements. All validation results demonstrate that the 
HPLC method is accurate, precise, sensitive, durable and reproducible. In addition, the 
methods of Twin Impinger (TI) and Next Generation Impactor (NGI) are also validated. 
The validation data show that the TI is accurate and durable. Besides, the stages of NGI 
need to be coated before an NGI test according to pharmacopoeias, since the APSD 
(Aerodynamic particle size distribution) of coated and uncoated NGI present a difference. 
Therefore, the impaction tests provide a reliable and widely accepted tool to study inhaler 
performance. Following that, the calibration of laser diffraction size measurement is also 
mentioned. This sizing method is applied as a fast, convenient and reliable method to 
analyze the formulation powder. 
 In chapter 5, typical marketed products including unit-dose inhaler (Aerolizer®), 
multiple unit-dose inhaler (Diskus®) and reservoir inhalers (Turbuhaler® and 
Clickhaler®) are evaluated first. The results of air flow resistance, DDCU (delivered drug 
content uniformity) and the FPF (fine particle fraction) of those marketed products are 
obtained and provide a comparison to the new inhaler designed by us. 
When considering the novel inhaler of this project, the designated and mechanical 
functions are confirmed first. After design improvement, a dramatic drop of resistance 
from 0.218 to 0.062 kPa0.5*min/l is observed. Meanwhile, the delivery efficiency is 
increased as the blister remains experience an obvious decline from 20% to 10%. 
Mouthpieces with different geometries are manufactured and tested. The result shows 
that air resistance is negatively correlated with the diameter of airway, but the APSD and 
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FPF are the same for 5 mouthpieces. Consequently, the original geometry of the 
mouthpiece is adopted. Through a parallel comparison with the marketed inhalers using 
the same formulation, the novel inhaler shows similar FPF as Aerolizer® and 
Clickhaler®, and better performance than Twister®. 
The powder filling system is established and validated. The filling uniformity is studied 
in following sequence: 1) the filling weight uniformity among the disks, 2) filling weight 
uniformity among blisters of a disk, 3) drug content uniformity among disks and 4) drug 
content uniformity among blisters of a disk. During the uniformity evaluation, not only 
the filling operation but also the test methods influence the results. The RSD of filling 
weight and drug content among disks is about 1~3% and 3~5% respectively even for 
different powders. The RSD of filling weight among blisters of a disk is 6~8%, but the 
RSD is 10%~17% for drug content among blisters. Through a detailed investigation of 
drug content of each blister in one disk, it is suggested that dispersion of fine API 
particles during the powder transfer from metering pockets to blisters is the main reason 
for the slightly higher RSD of drug content among blisters. This assumption is verified by 
the experiment of vacuum-assisted filling and reduction of vibration strength in the 
powder transfer. As mentioned in the discussion part of chapter 6, the drug content 
uniformity among blisters do not affect the following research at present, since one disk 
is tested as a whole for inhaler evaluation. At last, a sketchy flowability range suitable for 
powder filling is set up, represented by compression indices from 20-45%.  
When the novel inhaler device and filling system are ready, the formulation work is 
carried out thoroughly. The compatibility between powders and processing, the API and 
excipient, formulations and package is confirmed.  
The API is micronized in our laboratory and the size distribution is acquired by laser 
diffraction sizing. The API particles are suitable for inhalation drug delivery since all 
X90 values are under 5µm. Following that, a mixing method including pre-sieving at first, 
then low shear and high shear mixing is established. This mixing method can obtain a 
powder with RSD<2% of drug content. Then, several critical parameters of the mixing 
are investigated. With increasing mixing speed and mixing time, the blend uniformity 
193 
 
does not show obvious improvement but the FPF experiences a decline. Specifically, 
when the mixing speed is doubled, the FPF decreases from 22% to 14%. The study of 
mixing time shows that, when the mixing time is increased from 0 to 20min, the FPF 
exhibit a decline from 34% to 22%. 
During a composition research, the formulations containing SV003 and LH200 show 
similar FPF as Aerolizer® Foradil® and Diskus® Seretide®. The formulations 
containing Inhalac120 and Inhalac230 (<45µm) exhibit similar FPF as Turbuhaler® 
Oxis® and Clickhaler® Asmatha® respectively. The ratio of fine lactose and the API to 
the total powder, size and source of the coarse lactose, and size of the API particles are 
all studied. Different ratios of fine lactose to the whole powder exert a great influence on 
the FPF and the following performance stability. An exciting result is that the ratio of 
API to the powder does not affect the FPF, implying that the novel inhaler can be used to 
deliver various APIs for different delivered doses. Additionally, the FPF is rather stable 
for different-size API, indicating the durability and reproducibility of the inhaler 
performance. 
An orthogonal experiment is completed after a series of sing-factor experiments. This 
statical result further proves the conclusion of single-factor tests. Meanwhile, because of 
the ratios of signal to noise obtained in this experiment, it is found that the percentage of 
fine lactose has the most significant effect on both FPF and blister remains. Consequently, 
the percentage of fines should be considered first in the future formulation work.  
Through a stress test and accelerated test, the package form is determined. The drug disk 
should be wrapped with an aluminum foil as an external package without desiccant. Then, 
some formulations show satisfying stability under an accelerated condition for several 
months. The performance stability under different flow rates also demonstrates good FPF 
consistency. 
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8.3 Future Directions 
Since the target of this project is to develop an inhaler product which can be 
commercialized some day, there will be some industrialization research required in the 
future. 
For the inhaler device: 
A fatigue test would be necessary to study and validate the mechanical property, such as 
how many times the device can be used without influence on drug delivery. 
The materials of the device have to be chosen carefully. The ideal materials should 
exhibit a good mechanical property, lightweight and an acceptable price. Most 
importantly, the material should be approved by the regulatory agency for application in 
medical devices or health products.  
Some volunteers and clinicians should be called together to use this device, and 
suggestions from them will be important for further improvement of device design. 
For the powder filling: 
First of all, the drug content uniformity among blisters should be enhanced by improving 
the design of filling machine. This filling uniformity is the prerequisite for the delivered 
drug content uniformity. If possible, the filling quantity should be adjusted conveniently.  
Secondly, the operation of filling should be automated as much as possible; hence it can 
satisfy the requirements of a pilot-scale production. More importantly, an automated 
filling process is easier to comply with Good Manufacture Practice (GMP), and will 
minimize the possibility of contamination and operational errors. 
At last, if possible, a monitoring system should be applied to monitor the filling weight 
online, which could detect the wrong filling and discard it immediately. To achieve those 
functions, it will be a complicated system requiring cooperation between pharmaceutical 
scientists and engineers. 
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For the powder formulation: 
Most formulation research is carried out on a small scale here, and it should be scaled up 
to a pilot production. Then, the optimized formulation should be repeated for 3 batches. 
The performance and stability of 3 batch sample will be studied carefully for application 
documents of a drug product. A systematic evaluation should be carried out, including 
appearance, delivered drug content uniformity, FPF, moisture, degradation impurities and 
so on. 
After formulation work, an acute toxicity and irritating experiment should be carried out 
on animals to demonstrate the safety of the inhaler. Both the API and excipient are quite 
safe since they have been applied in the commercial products for a long time. When the 
safety is established, a bioequivalence or clinical trial is required to demonstrate its 
efficacy, serving as an ultimate evaluation of the inhaler performance. 
From a viewpoint of basic research, there are also some interesting topics deserving 
further investigations. 
The computational fluid dynamic has been increasingly popular in the design of inhaler 
device. The entrainment of powder into airflow, dispersion of aerosol in the device could 
be treated as an air-solid interaction. The kinetic energy of turbulence, energy and times 
of particle impaction could be calculated and analyzed to find the relationship between 
the disaggregation of agglomerates and the aerodynamic design of the inhaler device. 
The electrostatic property of powder and packaging material could be studied deeply, 
since there are few reports in that field. If possible, the unexpected dispersion of particles 
during powder transfer in the filling process could be related to the quantity of electricity 
of particles and PVC disks. Furthermore, the generation and dissipation of electrostatic 
charge of powder in the PVC blister could be studied, and it might explain why the 
freshly filled drug disk should be kept still for some time before tests. 
During this research, commercial lactose is used as carriers, although the self-made 
lactose show interesting adhesion of fine particles. If possible, the effect of this adhesion 
on formulation performance should be studied. Most literature on the mixing process 
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utilize low shear mixing equipment to study the influence of mixing speed or time. If an 
appropriate high shear mixer is available which could process a small amount of powder 
and adjust/display the mixing speed, the relation between speed/time of high shear 
mixing and formulation performance can be studied in detail. 
The novel inhaler device also provides a good platform to deliver other inhaled powders. 
Consequently, engineering powders like spray-drying particles could also be applied in 
this device. Then, the application range of the inhaler device may be expanded greatly. 
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